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Abstract 
Drug-resistant infections are a global health crisis and drastically hinder the treatment 
options to effectively combat disease. Today, natural products remain an important 
source of novel drug candidates. Micro-organisms, in addition to being a source of 
bioactive natural products, represent a sustainable source of these compounds. As the 
marine environment is largely underexplored, the oceans represent a potential source of 
novel NPs.  
This study aimed at the discovery of novel NPs from bacteria associated with novel 
marine invertebrate species endemic to the South African coast, including a sponge 
Spongia (Spongia) sp. 001RSASPN and a tunicate, Pseudodistoma africanum Millar, 
1954. The methodology comprised of culture-dependent and culture-independent 
strategies. The former involved the isolation of bacteria associated with the invertebrate 
species and subsequent screening for anti-microbial activity against a panel of indicator 
strains including a multi-drug resistant E. coli strain. Anti-bacterial activity was detected 
in 6.1% and 4% of bacterial isolates from the sponge and tunicate isolates respectively.  
The culture-independent strategy involved the use of PCR to select bioactive strains 
likely to contain novel NRPS or PKS secondary metabolite pathways. An NRPS A-
domain exhibiting low sequence identity (65%) to reference sequences in the NCBI 
database was amplified from isolate PE8-15, a strain belonging to the genus Bacillus. 
This predicted a novel NRPS pathway within this strain. In addition, this isolate exhibited 
the most diverse anti-microbial profile including anti-bacterial and anti-fungal activity (A. 
fumigatus ATCC 46645). Therefore, as the most promising candidate, the genome of 
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PE8-15 was sequenced following which 10 secondary metabolite pathways including 
bacteriocins (5), NRPS (3), siderophore (1) and a terpene pathway were identified. The 
A-domain amplified from PE8-15 originated from Cluster 4, and NRPS pathway 
predicted to encode a lipopeptide. Lipopeptides are an important class of compounds 
with a range of industrial applications in the pharmaceutical, cosmetic as well as food 
industry.  
The identification of potentially novel secondary metabolite pathways from even well-
studied groups of organisms demonstrates the importance of sequence-based methods 
in natural product discovery. Furthermore, this study highlights the South African coast 
as a rich source of microbial natural products and should be exploited further for drug 
discovery.  
Key words: drug-resistance, natural products, marine invertebrates, micro-organisms, 
whole-genome sequencing, genome mining, NRPS, lipopepetide. 
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 Introduction 
The rise in drug-resistant pathogens is currently an alarming global health concern 
(Spellberg et al., 2008). In the United States alone, approximately 100,000 individuals 
die annually from infections caused by antibiotic resistant bacteria (Wong et al., 2012). 
For example, methicillin-resistant S. aureus (MRSA) infections are responsible for more 
deaths than those from both AIDS and tuberculosis (Wong et al., 2012). In developing 
communities where sanitation is frequently inadequate, outbreaks of cholera (caused by 
V. cholera O1 and O139 strains) are a major public health concern particularly due to 
the occurrence of drug resistant strains during epidemics (Akoachere et al., 2013). 
Furthermore, in South Africa there is currently an increase in tuberculosis resistance as 
a result of the high prevalence of HIV infected individuals (O’Donnell et al., 2010).  
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Table 1.1:  Frequently encountered drug-resistant bacteria (Levy, 2002) 
Hospital  
    
Community 
     
 
Gram-negative 
    
 
Acinetobacter sp. 
    
E. coli 
Citrobacter sp. 
    
Neisseria gonorrhoeae 
Enterobacter sp. 
    
S. typhi 
Klebsiella sp. 
    
Salmonella typhimurium 
P. aeruginosa 
     Serratia marcescens 
    
      Gram-positive 
     Enterococcus sp.: vancomycin-resistant enterococci (VRE) Enterococcus sp.: VRE 
coagulase-negative Staphylococcus 
  
Mycobacterium tuberculosis 
MRSA 
    
MRSA 
MRSA heterogeneously resistant to vancomycin 
 
Streptococcus  pneumoniae 
     
Streptococcus  pyogenes 
 
 
A major contributing factor to the spread of drug-resistant pathogenic strains is antibiotic 
misuse. A classic example on the misuse of antibiotics was demonstrated by Amidi and 
colleagues (1975) investigating the prescription of antibiotics among 40 doctors in 
Shiraz (Iran). The study involved a healthy individual claiming to have classical 
symptoms of viral urinary tract infection. Out of 40 doctors visited, 37 (92.5%) still 
prescribed antibiotics following the diagnosis of a viral infection and the majority of the 
drugs were prescribed at inadequate doses. More recent studies have shown antibiotic 
misuse to still be a major problem in health care facilities (Thriemer et al., 2013; Means 
et al., 2014). In addition to misuse, an increase in immuno-compromised patients and 
antibiotic treated food are major contributing factors in the spread of drug resistance 
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(Levy, 2002). Therefore, without strict measures in place to control the use of 
antibiotics, the spread of resistant pathogens will persist and compromise public health. 
In light of these, there is an urgent, but also continuous need for the discovery and 
development of new drug candidates to combat drug resistance. 
 
 Natural products and drug discovery 
Natural products (NPs) are compounds produced by living organisms such as fungi, 
bacteria and plants (Ji et al., 2009). NPs are usually produced as a result of secondary 
metabolism and although not essential for growth, improve the survival of the producing 
organism (Williams et al., 1989). NPs have been exploited for many years in the 
treatment of a myriad of ailments and diseases due to the broad range of biological 
activities they possess. Clay tablets from Mesopotamia 2600 B.C (modern day Iraq) are 
amongst the oldest records depicting the use of NPs (oils from Cypress and Myrrh) as 
medicine which are still being used today as remedies against coughs and inflammation 
(Dias et al., 2012). In fact, the isolation of chemicals with useful properties from 
preparations of ‘ethno-medicinal’ sources was the foundation of the modern 
pharmaceutical industry (Pomponi, 2001). Today, NPs remain a major resource for drug 
discovery and during the past 30 years, 70% of anti-microbials and 60% of 
chemotherapeutics have been developed or analogously synthesized from NPs 
(Pomponi, 2001; Grüschow et al., 2011). In comparison to synthetic compounds, NPs 
offer various advantages over synthetic compounds. For example, NPs exhibit greater 
structural diversity than synthetic compounds and are naturally designed by nature to 
interact with biological targets such as proteins (Zhang and Demain, 2005).  
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Initially, plants represented a major source of medicinal compounds exemplified by taxol 
an anti-cancer drug from Taxus brevifolia and etoposide from Podophyllum peltatum 
(Proksch et al., 2003). However, microbes were recognised as a useful source of NPs 
following the discovery of penicillin in 1928 and its later use as an antibiotic (Davies and 
Davies, 2010; Berdy, 2005). The field of microbial NP discovery was later expanded by 
Selman Waksman whose work involved screening of soil microbes for antagonistic 
compounds (Woodruff, 2014; Reilly et al., 1945; Waksman and Woodruff, 1941). His 
work led to the discovery of numerous antibiotics commonly used today, a period 
referred to as the ‘Golden era of antibiotics’ and is depicted in figure 1.1 (Stallforth and 
Clardy, 2014).  
 
 
Figure 1.1: Timeline depicting the discovery of new antibiotic classes. The discovery of penicillin (β-
lactams) pioneered the discovery of pharmaceutically relevant microbial antibiotics that peaked in 1950’s.  
The period between the 1940’s and 1960’s saw the discovery of a large number of antibiotics and is a 
period referred to as the ‘Golden era’ of antibiotics. However, the period after the 1960’s severely lacked 
any notable drug discoveries with the lipopeptides emerging as the only new class 20 years later 
(Adapted from Lewis, 2012). 
Golden era of antibiotics 
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 Natural product classes of pharmaceutical relevance 
Pharmaceutically relevant NPs belong to different chemical classes that differ not only 
in structure, but also in the mechanisms by which they are synthesized. Important 
classes of NPs include; terpenoids, alkaloids and various ribosomal peptides with a 
wide range of bioactive properties (Graça et al., 2013). However, for the purpose of this 
study, NPs belonging to the polyketide and non-ribosomal peptide classes are of 
particular importance.  
 
1.3.1 Polyketides 
Polyketides are a large class of NPs with important biological activities that include; 
immuno-suppression, anti-cancer and anti-microbial (Chen et al., 2006). As a result of 
polyketide structural and functional diversity (figure 1.2), compounds in this family are 
an attractive source of novel drug candidates.  
Assembly of the polyketide backbone is orchestrated by the polyketide synthase (PKS) 
enzyme family (Kealey et al., 1998). These enzymes are categorized into three different 
types (type I, type II and type III) based on their products as well as biochemical 
features (Gao et al., 2010).  
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Figure 1.2: Structural and functional diversity of the polyketide compounds. Examples shown include: 
rapamycin (immuno-suppressant), actinorhodin (aromatic antibiotic), erythromycin A (macrolide 
antibiotic), 6-Methylsalicylic acid (aromatic antibiotic), aflatoxin (mycotoxin carcinogen), rifamycin S 
(ansamycin antibiotic) and lovastatin (anti-cholesterol) (Taken from Staunton and Weissman, 2001). 
 
1.3.1.1 Type I polyketide synthases 
Type I PKSs are a group of large multi-functional enzymes exhibiting modular 
architecture (Cheng et al., 2003). A module is a catalytic unit (figure 1.3) consisting of 
domains (in varying combinations) needed for the successful incorporation of 
monomers and modification of the growing chain (Ruan et al., 1997; Bergendahl et al., 
2002). Three compulsory domains are required for successful biosynthesis of type I 
polyketides and include; acyl-transferase (AT), acyl-carrier protein (ACP) and a 
ketosynthase (KS) (Schirmer et al., 2005). Additional domains may be present that play 
rapamycin 
 
actinorhodin 
 
erythromycin A 
 
6-Methylsalicylic acid 
 
aflatoxin B1 
 
rifamycin S 
 
 
lovastatin 
 
immuno-suppressant 
 
aromatic antibiotic 
 
mycotoxin carcinogen 
 
anti-cholesterol 
 
ansamycin antibiotic 
 
aromatic antibiotic 
 
macrolide antibiotic 
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a role in modification of the polyketide chain. Domains that are involved in chain 
modification include; ketoreductases (KR), enoylreductases (ER) and dehydratases 
(DH) (Gao et al., 2010). The KR-domain plays a role in reducing the β-keto group 
(formed after each condensation reaction) to a hydroxyl group that is subsequently 
reduced by the DH-domain to form a double bond that can be further reduced by the 
ER-domain (Keatinge-Clay and Stroud, 2006).  
Type I polyketide biosynthesis is initiated following the activation of a starter unit 
(usually a molecule with an acyl group, such as malonate or acetate) by the AT-domain 
and its subsequent transfer to the ACP-domain (Lim et al., 2012). The ACP-domain in 
turn is responsible for shuttling the acyl units onto the KS-domain which carries out a 
decarboxylative claisen condensation reaction between the starter and extender units 
(Crawford and Townsend, 2010). Activation of the ACP-domain requires the addition of 
a 4’-phosphopantetheine group as a post-translational modification by the 
phosphopantetheine transferase enzyme (PPTase) (Walsh et al., 1997). Once chain 
elongation is complete, the final product is released by the catalytic action of a 
thioesterase domain (TE) usually located at the C-terminal of the last module (Cane and 
Walsh, 1999). 
A characteristic feature of type I PKSs is the single use of each domain involved and 
their role in synthesizing macrolide compounds (Novakova et al., 2002). However, in 
contrast to bacterial type I PKS, fungal type I PKSs make use of each active site 
iteratively and are responsible for the production of aromatic compounds (Crawford and 
Townsend, 2010). Examples of bacterial type I PKS compounds include; rifamycin, 
rapamycin, epothilone and erythromycin (Khosla et al., 1999; Ginolhac et al., 2004). 
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Figure 1.3: Modular organisation of the erythromycin gene cluster, a type I PKS. The PKS involved in the 
production erythromycin, is encoded by three genes eryAI, eryAII and eryAIII. The erythromycin genes 
code for the proteins DEBS 1, DEBS 2 and DEBS 3 respectively. Each module is uniquely colour coded 
and contains the compulsory domains KS, AT and ACP. Optional domains (KR and DH) involved in 
backbone modification, are present in all modules except module 3. A thioesterase (TE) domain is 
located downstream (C-terminal) of the final module (module 6) and functions as a chain terminator 
releasing the final product (Adapted from Staunton and Weissman, 2001). 
 
1.3.1.2 Type II polyketide synthases 
In contrast to the type I PKS family of enzymes, bacterial type II PKSs are mono-
functional enzymes whose active sites are distributed among individual protein subunits 
(figure 1.4)  that congregate to form complexes (Khosla et al., 1999). Each active site in 
type II PKSs is used iteratively producing compounds with aromatic rings, the aromatic 
polyketides (Staunton and Weissman, 2001; Seow et al., 1997). The core set of 
domains required for the successful synthesis of aromatic polyketides include an acyl 
carrier protein (ACP) and two ketosynthase (KS) genes KSα and KSβ (King et al., 2009). 
.         eryAI
 
         DEBS 1 
        eryAII         eryAIII
 
         DEBS 1 
  
         DEBS 1         DEBS 2         DEBS 3 
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The KSβ domain, also referred to as the chain length factor, plays a role in determining 
the length of the polyketide chain (Tang et al., 2003). Conversely, the KSα domain 
condenses the acyl substrates whereas the ACP-domain serves as an anchor for the 
growing polyketide chain and is responsible for receiving the malonyl substrates (Revill 
et al., 1995). Although AT-domains are not present within type II PKS gene clusters, 
ACP-domains have been shown to exhibit self malonyl-transfer activity (Arthur et al., 
2006). Important aromatic polyketides include doxorubicin, tetracenomycin and 
actinorhodin (Khosla et al., 1999; Summers et al., 1993). 
 
 
                                    
                          
 
 
Figure 1.4: Illustration of type II PKS genetic organisation exemplified by the tetracenomycin gene cluster 
from Streptomyces glaucescens. Each domain, KSα, KSβ and ACP (encoded by tcmK, tcmL and tcmM 
respectively), is located on an individual gene. This is in sharp contrast to the modular type I PKSs where 
domains are located on large proteins encoded by a single gene. The individual domains of type II PKS 
subsequently form dissociable protein complexes that are iteratively (repetitively) used during 
biosynthesis (Adapted from Seow et al., 1997). 
tcmJ tcmK tcmM tcmL tcmN 
KSα KSβ ACP 
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1.3.1.3 Type III polyketide synthases 
Type III PKSs make up a family of enzymes predominantly found in higher plants, 
however, bacterial type III PKSs were first discovered in Streptomyces griseus (Funa et 
al., 1999). In comparison to type I and II PKSs, this class of PKSs is relatively simple 
with a homodimeric structure where each monomer is responsible for the iterative 
loading of substrates, extension and carrying out cyclization reactions (Yu et al., 2012). 
In addition, type III PKSs, unlike the type I and type II PKS enzymes use free coA 
substrates as opposed to 4’-phosphopantetheine bound substrates (Saxena et al., 
2003). Although relatively simple in comparison to other PKS classes, type III PKS 
produce diverse compounds such as chalcones, pyrones and stilbenes (Yu et al., 
2012).  
 
1.3.2 Non-ribosomal peptides 
Non-ribosomal peptides (NRPs) constitute a large group of microbial NPs which exhibit 
useful biological activities including anti-inflammatory, anti-viral, biosurfactants, anti-
microbial and anti-tumour (Stachelhaus et al., 1998; Caboche et al., 2010). They are 
small polypeptides usually consisting of fewer than 50 amino acids, whose synthesis is 
engineered by a family of enzymes known as the non-ribosomal peptide synthases 
(NRPSs) (Neilan et al., 1999; Walsh, 2008).  
NRPs are built from proteinogenic amino acids in the ‘L’ form, although unusual 
components including hydroxyl acids, non-proteinogenic amino acids and amino acids 
in the ‘D’ form are often observed (Lee et al., 2005; Marahiel et al., 1997). NRPs 
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currently in clinical use include; penicillin, cephalosporins and vancomycin that is an 
antibiotic used as a last line of defence against MRSA infections (Micek, 2007). In 
addition, polymyxin E is extensively used to combat lung infections caused by P. 
aeruginosa (Hancock and Chapple, 1999). Members of the gram-positive 
Actinomycetes and the genus Bacilli are major producers of NRPs (Finking and 
Marahiel, 2004). 
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Figure 1.5: Examples of non-ribosomal peptides and their structural diversity. Vancomycin, a last line of 
defence antibiotic against MRSA, cyclosporin is a potent immune-suppressant (Borel et al., 1976) and 
enterobactin is an iron-chelating agent (siderophore) facilitating iron assimilation from the environment  
(Gehring et al., 1998). (Taken from Challis and Naismith, 2004). 
 
 
 
 
cyclosporin A 
vancomycin 
enterobactin 
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1.3.2.1 Biosynthesis of non-ribosomal peptides 
The ribosome-independent synthesis of NRPs (Neilan et al., 1999) was first 
hypothesized in the 1960’s when cell free extracts of peptide antibiotic producing 
organisms were studied. These studies demonstrated the restoration of antibiotic 
production even in the presence of RNAses and ribosome inhibitors (Gevers et al., 
1968; Mach et al., 1963).  
NRPSs exhibit a modular organization whereby each module (figure 1.6) is a catalytic 
unit responsible for the incorporation of one amino acid into the backbone of the 
resulting product (Challis and Naismith, 2004). For successful biosynthesis of the 
peptide product, each NRPS module requires a set of core domains that include; a 
condensation (C), adenylation (A) and thiolation (T) or peptidyl carrier protein (PCP) 
(Felnagle et al., 2008). In addition, NRPSs may contain secondary domains responsible 
for the modification of the peptide chain and include; an epimerization (E) domain 
involved in altering the chirality of the amino acid, a methylation (M) domain involved in 
addition of methylation groups and a heterocyclization (Cy) domain (Lautru and Challis, 
2004). Once chain elongation is complete, the final product is released by the catalytic 
action of the thioesterase domain (TE) (Ehrenreich et al., 2005).  
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During NRP biosynthesis, the A-domain is responsible for substrate specificity (Weber 
et al., 2000) and activating the cognate amino acid to an aminoacyl adenylate using 
ATP (Stachelhaus et al., 1999). This mechanism is analogous to the aa-tRNA 
synthetase in ribosome-dependent protein synthesis (May et al., 2002). The activated 
amino acid is subsequently transferred and covalently bound to the PCP-domain where 
it can undergo modifications by additional domains (Weber et al., 2000). The final step 
during NRP biosynthesis is catalysed by the C-domain responsible for peptide-bond 
formation between activated amino acids bound to the PCP-domains of adjacent 
modules (Weber et al., 2000). 
 
 
C A T A T C A T E A T C A T E C A T C A M T C AT TE 
aptA1 aptA2 aptB aptC aptD aptE aptF 
Figure 1.6: Modular organization of NRPSs exemplified by the anabaenopeptin gene cluster. Genes 
involved in NRP biosynthesis frequently form clusters and are further organized into modules containing the 
condensation, adenylation and thiolation domains respectively (C-A-T). Domains variably present within 
each module can include a methylation (M) and epimerization (E). The thioesterase domain (TE) plays a 
role in cyclisation and release of the final peptide chain (Adapted from Rouhiainen et al., 2010). 
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1.3.3 Polyketide and non-ribosomal peptide hybrid compounds 
This is an interesting class of NPs that consists of compounds assembled from both 
NRP and polyketide elements (Weinig et al., 2003). Although NRPs and polyketides 
differ structurally and in their building blocks, the respective biosynthetic enzymes 
exhibit structural and catalytic similarities that enable the synthesis of these hybrid 
products (Du et al., 2001). Important examples of hybrid compounds include epothilone 
an anti-tumour agent (Chen et al., 2001), yersiniabactin a siderophore (Haag et al., 
1993), barbamide an anti-mollusc compound (Chang et al., 2001) as well as rapamycin 
an immuno-suppressant (Law, 2005).  
 
 Natural products from the sea 
Spanning approximately 70% of the earth’s surface, oceans hold the largest share of 
the ecosystem (Glöckner and Joint, 2010). The rich biodiversity contained within the 
oceans (15 animal phyla exclusive to the oceans) makes them a unique and rich drug 
discovery reservoir (Leal et al., 2012). 
Marine NP discovery initially was focused on the easily accessible macro-organisms 
(such as algae, soft corals and sponges) from which a range of bioactive NPs were 
isolated. For example, the discovery of unusual nucleosides from the sponge 
Cryptotethia crypta in the early 1950s led to the development of the potent anti-cancer 
and anti-viral analogues, Ara-C and Ara-A respectively (Bergmann and Feeney, 1951; 
Hu et al., 2011).  Ziconotide, also of marine origin, is a peptide isolated from a marine 
mollusc (Conus magus) and is used as a non-addictive drug for the treatment of chronic 
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pain (McGivern, 2007). With marine invertebrates making up 60% of the marine animal 
diversity (Leal et al., 2012), there is numerous potential for the discovery of novel drug 
leads in the oceans.  
However, marine NP discovery efforts gradually turned to the smaller life forms such as 
bacteria and fungi (Gerwick and Moore, 2012) that constitute a large portion of the 
marine biomass (Sogin et al., 2006). Of particular interest are the micro-organisms 
associated with eukaryotic hosts. These invertebrate-associated microbes are 
postulated to play a number of roles for their hosts such as chemical defence against 
predators and competitors (Haygood et al., 1999).  
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Figure 1.7: Natural products isolated from marine animals. Examples shown include conotoxin MVIIA 
(Ziconotide) from a cone snail (Conus magus), squalamine isolated from a dogfish shark (Squalus 
acanthias), halichondrin B of marine sponge origin (Lissodendoryx sp.) and bryostatin isolated from a 
bryozoan (Bugula neritina) (Taken from Proksch et al., 2003). 
 
 
conotoxin MVIA 
Conus magus (cone snail) 
squalamine 
 
Squalus acanthias (dogfish shark) 
halichondrin B 
Lissodendoryx sp. (sponge) 
bryostatin 1 
Bugula neritina (bryozoan)  
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 Marine invertebrates  
Although marine NPs have been isolated from a range of marine organisms, for the 
purpose of this study, the phylum Porifera and subphylum Tunicata are of particular 
interest.  
 
1.5.1 Sponges 
Sponges are the oldest animals in the phylum Porifera dating back nearly 580 million 
years (Fieseler et al., 2004). They are sessile filter-feeders making up a dominant 
benthic community in the ocean (Leys and Eerkes-Medrano, 2006). Although the 
majority of sponges inhabit the marine environment, approximately 1% of these 
invertebrates are found in fresh water bodies (Belarbi et al., 2003).  
Sponges have an aquiferous body through which they continuously filter large volumes 
of sea-water for nutrient acquisition (Kennedy et al., 2007). As water flows through 
specialised canals within the sponge, bacteria (among other micro-organisms) are 
transferred to the mesohyl tissue (figure 1.8) where they are able to establish a 
symbiotic relationship with the host (Kennedy et al., 2007). In high microbial abundance 
sponges (HMA), micro-organisms may constitute as much as 40% of the sponge 
biomass estimated to be 108 to 1010 bacteria per gram of tissue (Selvin et al., 2009). 
These high bacterial densities in HMAs are in contrast to low microbial abundance 
sponges (LMA) that exhibit microbial densities ranging between 105 to 106 bacteria per 
gram of tissue (Hentschel et al., 2006).  
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Sponges were established as a source of potent biologically active compounds (NPs) 
following the discovery of the uncommon nucleosides spongouridin and spongothymidin 
from the sponge Cryptotethia crypta (Bergmann and Feeney, 1951; Hu et al., 2011; 
Kijjoa and Sawangwong, 2004). Following their discovery, numerous bioactive 
compounds have been isolated from marine sponges, and these animals contribute the 
largest number of novel marine invertebrate NPs (Mehbub et al., 2014). 
 
 
Figure 1.8: Simplified illustration of the sponge anatomy. The pinacoderm functions as a barrier between 
the outer and inner environment. The region between the inner and outer layer is the mesohyl layer. As 
the sea-water flows in through the incurrent pore, bacteria are transferred to the mesohyl tissue and 
subsequently ingested or form symbiotic associations with the sponge. Waste is released through the 
excurrent pore (Taken from Kennedy et al., 2007). 
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The phylum Porifera is comprised of three major taxonomic classes that include; 
Hexactinellida, Calcarea and the Demospongiae (Abdelmohsen et al., 2014). The class 
Demospongiae is the largest class, consisting of over 80% of all known sponge species 
from which a myriad of novel compounds have been isolated (Thompson et al., 1985; 
Wang and Lavrov, 2008). Looking at the total number of NPs isolated from each order 
in the class Demospongiae (figure 1.9), it is clear that perhaps not all taxonomic groups 
of sponges are equally important sources of NPs. For example, in comparison to the 
orders Halichondria and Dictyoceratida, fewer NPs have been isolated from the orders 
Astrophorida and Hadromerida. Taking these observations into account, designing a 
more targeted sampling strategy might be more appropriate to improve NP discovery 
efforts. However, sampling bias could contribute to the differences in the number of NP 
discovered from different orders within the class Demospongiae.  
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Figure 1.9: Percentage of natural products isolated from sponge-associated microbes represented 
according to the order in the class Demospongiae. The sponge orders Halichondrida, Poecilosclerida and 
Dictyoceratida contribute a total of 29.03%, 15.48% and 14.83% respectively of NPs from microbes 
associated with sponges. In certain sponge orders, fewer microbial NPs have been isolated and include 
the orders Chondrosida (4.51%), Astrophorida (1.29%), Hadromerida (0.64%), Lithistida (4.51%), and 
Spirophorida (0.64%) (Taken from Thomas et al., 2010). 
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1.5.2 Tunicates 
Classified under the phylum Chordata, tunicates make up a diverse group of animals 
whose body is covered in a cellulose-containing tunic (Lemaire, 2011). Tunicates are 
the only animals with the ability to biosynthesise cellulose, a trait hypothesised to have 
been acquired from bacteria through horizontal gene transfer (HGT) (Sasakura et al., 
2005). In a manner similar to sponges, tunicates obtain their food by a filter-feeding 
mechanism (Radford et al., 2000). They are usually sessile when adults and make use 
of an array of toxins for protection (Cooper and Yao, 2012). 
In the context of drug discovery, tunicates are an important group of organisms because 
they are a source of numerous NPs with bioactive properties. For example, Didemnin B 
a strong anti-cancer compound that also possesses anti-viral activity (RNA and DNA 
viruses) was the first marine NP that progressed onto phase I clinical trials (Ankisetty et 
al., 2013).  
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Figure 1.10: Simplified illustration of tunicate anatomy (Ciona intestinalis form Millar 1970). The oral 
siphon serves as an entry point for sea-water from which particulate matter (such as bacteria) is retained 
within the branchial sac and the waste excreted through the atrial siphon (Shenkar et al., 2015). (Taken 
from NOBANIS, 2015). 
 
 
 
 
 
 
 
Literature review 
 
25 
 
1.5.3 Marine invertebrate-associated bacteria 
The filter-feeding nature of sessile marine invertebrates facilitates close contact 
between the hosts and micro-organisms. In addition to being a source of food, providing 
stability to the sponge skeleton and waste management, micro-organisms play a role in 
chemical defence to deter competitors and predators (Hentschel et al., 2002; Haygood 
et al., 1999).  
Due to the striking resemblance of compounds isolated from invertebrates to those 
considered exclusively of microbial origin, micro-organisms are thought to be the true 
producers of marine invertebrate NPs (Piel et al., 2004; Muscholl-Silberhorn et al., 
2008). For example, ET-743 (also known as Trabectedin/Yondelis), is an anti-cancer 
agent isolated from the tunicate Ecteinascidia turbinata. This compound shows 
structural similarity to the prokaryotic derived compounds, saframycin A, saframycin 
Mx1 and safracin B and strongly suggests bacterial origin as opposed to eukaryotic 
(tunicate) production as was initially suggested (Rath et al., 2011). A more recent study 
however, proved the bacterial origin of compounds in the marine sponge Theonella 
swinhoei. The marine sponge T. swinhoei produces an array of compounds of 
ribosomal origin (polytheonamides) as well as polyketides such as 
onnamide/theopederins (Piel et al., 2004; Hamada et al., 2005). Although originally 
thought to be produced by the sponge itself, Wilson and colleagues (2014) proved, 
using single-cell genomics and metagenomics that the polytheonamides and 
onnamides/theopederins are in fact produced by symbiotic bacteria. This symbiotic 
bacterium belongs to a novel and as yet uncultured bacterium of the candidate genus 
Entotheonella.  
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Figure 1.11: Structural similarity between marine compounds of microbial and invertebrate origin. Non-
ribosomal peptides and polyketides were known exclusively to be of microbial origin. Therefore, the 
structural similarity of marine invertebrate compounds to those isolated from their symbiotic bacterial 
counterparts suggests microbes to be the true producers (Taken from Proksch et al., 2003). 
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1.5.3.1 Distribution of marine invertebrate-associated bacteria 
It has been established that filter-feeders associate with micro-organisms within their 
tissues whose cell density frequently outnumbers that of the surrounding sea-water 
(Taylor et al., 2007). Marine invertebrates, in addition to selectively filtering out bacterial 
symbionts from the sea-water, are able to transmit specific microbial populations by 
vertical transmission to their progeny (Sharp et al., 2007). It is therefore expected that 
bacterial communities differ between invertebrates and do not necessarily reflect the 
communities in the surrounding sea-water.  
Several studies have investigated the bacterial community structures and host-
specificity of bacterial populations within marine invertebrate hosts. For example, Erwin 
and colleagues (2011) compared the bacterial communities in sea-water, two marine 
sponges (Hymeniacidon heliophila and Haliclona tubifera) and the tunicate Didemnum 
sp. Evidence of species-specific association between invertebrate hosts and microbes 
was evident in the two sympatric sponges that shared 4 operational taxonomic units 
(OTUs) of which 2 OTUs were shared with the ambient bacterioplankton communities. 
However, a similar study observed differences in the bacterial communities within the 
sponge Cymbastela concentrica harvested from tropical and temperate regions in 
Australia (Taylor et al 2005).  These studies implicate other factors such as temperature 
as playing a role in shaping the bacterial community structures. Similar bacterial 
community studies were done on the tunicate E. turbinata by Peréz-Matos and 
colleagues (2007) that identified a consistent bacterial population between tunicates of 
the same species harvested in the Caribbean and Mediterranean Sea.  
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These studies, in addition to providing evidence of species-specific bacterial 
communities, implicate environmental factors (such as temperature) in shaping the 
bacterial communities.  
In the context of NP discovery, results from bacterial community studies are important in 
formulating an appropriate sampling strategy. For example, novel invertebrate species 
would be considered a preferred source of novel NPs as they likely harbour unique 
microbial communities and hence unique functional diversity. Alternatively, because 
identical invertebrate species harvested from different geographical locations (for 
example temperate vs. tropical) can differ in their microbial communities, then 
previously studied organisms still hold potential to yield unique chemistry on condition 
that they are obtained from different geographical locations.  
 
 Bottlenecks in the discovery and development of natural products 
Although various NPs with promising pharmaceutical relevance are being discovered, 
further study and their progression into clinical trials face various limiting factors. This 
section aims to highlight the major limitations encountered during NP discovery and the 
subsequent development into drugs.  
The progression of NPs into the clinical trial stage requires a considerable amount of 
drug mass (usually kilogram amounts) and the lack of adequate drug mass is a major 
limiting factor (Tsukimoto et al., 2011). In some instances, obtaining sufficient quantities 
of the desired compound can only be achieved by harvesting large amounts of 
invertebrate tissue that is usually impractical and unrealistic. For example, to obtain 
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approximately 1 gram of ET-743 (Yondelis), 1 metric tonne of the tunicate E. turbinate is 
required (Proksch et al., 2003). This complicates the large-scale production of lead 
compounds for clinical development and is obviously environmentally detrimental and 
not a sustainable source of lead compounds.  
It has been established that invertebrate-associated bacteria are possibly the true 
producers of NPs isolated from marine invertebrates. This is of significant importance 
because attempting to improve lead compound titres using large-scale fermentations of 
the producer micro-organism is a viable alternative to harvesting tonnes of invertebrate 
tissue. Unfortunately, only about 1% of bacteria are cultured in vitro and of the 
approximately 61 bacterial phyla, 31 lack cultivable representatives (Vartoukian et al., 
2010). For example, a study investigating the variation of the microbial communities 
within the sponge Aplysina aerophoba, showed that only 0.15% of the bacteria were 
cultivated in vitro when compared to data obtained from microscopic analysis (Friedrich 
et al., 2001). This has led to the use of metagenomics to access the otherwise 
inaccessible genetic material of the uncultivable bacteria (Handelsman, 2004). 
However, although metagenomics is a powerful tool, the poor efficiency in obtaining 
intact fragments and inactivation of promoters in the heterologous hosts limit its 
effectiveness (Xiong et al., 2013). Therefore, isolation and characterisation of whole 
organisms is still an important tool for NP discovery especially with the advancement of 
sequencing tools as will be discussed.  
Traditionally, bacterial isolations were based on physical characteristics such as colony 
morphology and colour. However, the isolation of bacteria based on physical 
characteristics easily contributes to redundancy (in the culture collection and NP library) 
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as organisms from the same genus might share morphological similarities but differ in 
their chemical profile (Ritacco et al., 2003). Alternatively, morphologically different 
strains might be responsible for the production of the same secondary metabolites 
(Macintyre et al., 2014). A high degree of redundancy in the culture collection and NP 
extract library is undesirable because it increases the probability of isolating known or 
similar compounds (Tulp and Bohlin, 2005).  
In attempt to de-replicate compounds at an early stage of the discovery process, 
analytical tools such as nuclear magnetic resonance spectra (NMR), mass 
spectroscopy (MS), high performance liquid chromatography (HPLC) and ultra-violet 
spectra (UV) provide useful structural and chemical information. These tools are 
however not applicable to high-throughput processes and furthermore discriminate 
compounds based on physicochemical properties and not biological properties (Wong 
et al., 2012). This implies that compounds with a similar structure to known compounds 
but which exhibit novel biological activity might be disregarded.  
 
 Developments in the natural product discovery pipeline 
Acknowledging the bottlenecks in NP discovery and development (section 1.6) is 
important in streamlining and maximising the output of the NP drug discovery process. 
This section discusses the strategies currently employed to overcome the various 
limitations associated with NP discovery. These have been divided into culture-
independent and culture-dependent strategies.  
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1.7.1 Culture-independent methods 
 
1.7.1.1 Whole-genome sequencing (WGS)  
Past efforts in NP discovery from bacteria (particularly the genus Streptomyces) largely 
depended on chance, whereby isolates were grown under a range of growth conditions 
with an aim to stimulate secondary metabolite (SM) production (Ziemart et al., 2014; 
Jensen et al., 2014). In recent years, the advancement of high-throughput sequencing 
(HTS) technology (figure 1.12) has drastically increased the number of bacterial 
genomes available to about 3625 genomes by 2013 (Bertelli and Greub, 2013). 
Analysis of this data suggests that culture-based methods are not optimal for the 
activation of SM pathways and therefore NP discovery. For example, analysis of the 
complete S. coelicolor (A3) genome revealed the ability of this organism to produce an 
additional 20 compounds including coelichelin and coelimycin P1 (Aigle et al., 2014).  
Therefore, unlike bioactivity-based screening, WGS is superior as a NP discovery tool 
as it does not depend on the expression of SMs. Secondly, WGS analysis suggests that 
even previously well-studied organisms may still be a rich source of novel NPs (SMs). In 
addition, through WGS a complete snapshot of the SM pathways is available and allows 
for the selection of a particular class of SMs of interest to investigate. This is in contrast 
to chemical analysis where the discovery SMs is limited to those that are actively 
expressed.  
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Figure 1.12: The advancement of DNA sequencing technologies between 1995 and 2012. Sanger 
sequencing techniques were prevalent prior to 2005 and were used to sequence the first bacterial 
genome (H. influenza) and the draft human genome. The development of high-throughput sequencing 
technologies such as pyrosequencing, however, resulted in the significant increase in genome sequence 
data from both draft and completed genomes (Taken from Bertelli and Greub, 2013). 
 
The development of informatics-based tools, specifically designed for the detection and 
analysis of SM pathways from the vast sequence data generated by HTS greatly 
accelerates the NP discovery (table 1.2). For example, the ‘Antibiotics and Secondary 
Metabolite Analysis Shell’ (antiSMASH) software tool can rapidly search genome 
sequences for pathways belonging to a range of different SM classes including PKSs, 
NRPSs, bacteriocins, siderophores and terpenes (Blin et al., 2013). Specific for NRPS 
pathways, the NRPSpredictor2 tool is able to predict the amino acid specificity of NRPS 
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A-domains (Röttig et al., 2011). This is important when predicting possible monomer 
composition of a compound and comparison between a potentially novel pathway and 
known pathways. The NORINE database, dedicated exclusively to peptides of NRPS 
origin provides various computational analysis tools during NRPS characterisation 
(Caboche et al., 2008). For example, predicted amino acid monomers in an NRPS 
pathway of interest can be used to search for compounds of similar monomer 
composition. Additional bioinformatics tools for the computational analysis of SM 
pathways are summarised in table 1.2. 
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Table 1.2: Examples of computational tools for the analysis of secondary metabolite pathways at the genetic 
level 
 
Tool Function/Description URL Reference 
antiSMASH2.0 
Genome mining tool to detect secondary 
metabolite pathways in genome sequence 
data. Provides predicted structures for 
pathways detected. 
http://antismash.secondarymetabolites.or
g/ (Blin et al., 2013) 
 
   
NRPSpredictor2 
Predict the substrate specificity of NRPS 
adenylation domains. 
http://nrps.informatik.uni-
tuebingen.de/Controller?cmd=SubmitJob (Röttig et al., 2011) 
    
NORINE 
A database exclusive to natural products 
of non-ribosomal peptide origin. 
Facilitates structure based searches using 
predicted cognate amino acids recruited 
by the adenylation domain. http://bioinfo.lifl.fr/norine/ (Caboche et al., 2008) 
    
DoBiscuit 
A manually curated database of 
secondary metabolites providing 
integrated information on biosynthetic 
pathways particularly polyketides. http://www.bio.nite.go.jp/pks/top (Ichikawa et al., 2013) 
    
pep2path 
A mass-spectroscopy based approach to 
match tandem MS data to the 
corresponding biosynthetic gene clusters http://pep2path.sourceforge.net/ (Medema et al., 2014) 
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(exclusive to peptide natural products). 
    
NP.searcher 
A genome mining tool for the detection of 
NRPS, PKS, hybrid pathways as well as 
terpenoid genes. http://dna.sherman.lsi.umich.edu/ (Li et al., 2009) 
BAGEL 
A web-based tool for the mining of 
genomes to detect ORFs associated with 
bacteriocin biosynthesis in microbial DNA 
sequences. http://bagel2.molgenrug.nl/ (de Jong et al., 2006) 
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 Culture-based approach 
WGS data suggests that NPs frequently go undetected during conventional bioactivity-
guided screening. Inadequate growth conditions that are unfavourable for the 
expression of SM pathways are considered a major contributing factor. For this reason, 
two major developments to traditional culture-based techniques are discussed here that 
aim at activating silent SM pathways and as a result may diversify NP libraries. 
 
1.8.1 Co-cultivation 
Co-cultivation involves the fermentation of two or more micro-organisms in the same 
vessel (mixed culture) mimicking the natural competition for resources (Marmann et al., 
2014). The aim of co-cultivation is to trigger the expression of silent SM genes by 
creating a competitive environment similar to that of the natural habitat (Ola et al., 
2013). Co-cultivation has successfully been used to activate a cryptic PKS pathway in 
Aspergillus nidulans following the mixed fermentation of this fungus with Streptomyces 
rapamycinicus (Nützmann et al., 2011). In addition, co-cultivation of the fungus 
Emericella sp. (strain CNL-878) and the marine isolate Salinispora arenicola (strain 
CNH-665), resulted in a drastic increase in production of a novel cyclic lipopeptide 
emericellamide A approximately 100-fold (Oh et al., 2007). Co-cultivation therefore 
presents as an ideal method to diversify NP libraries particularly due the low costs 
involved and its application at a large-scale.   
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1.8.2 One strain many compounds (OSMAC) 
One Strain Many Compounds (OSMAC) is a culture-based approach that involves the 
manipulation of easily accessible culturing conditions such as temperature, type of 
culture vessel and media components (Bode et al., 2002). The aim of this approach is to 
induce the expression of silent SM pathways (Bills et al., 2008). A major advantage 
provided by OSMAC is that it eliminates bias during bioactivity-screening because the 
stimuli responsible for the activation of SM pathways differ between organisms. This 
approach therefore has the potential to further diversify NP libraries and improve the hit-
rate.  
 
 An overview of marine biotechnology in South Africa 
South Africa is bordered by a 3650 km linear coastline that extends from the south of 
Namibia in the west to the south of Mozambique in the east (Davies-Coleman and 
Beukes, 2004; Griffiths et al., 2010). Three main bio-geographical zones make up this 
coastline and include a warm temperate southeast coast, a cool temperate west coast 
and the subtropical east coast each harbouring unique biodiversity of endemic marine 
organisms (Davies-Coleman and Beukes, 2004). This provides the South African 
marine research community with rich and abundant sampling resources for NP 
discovery.  
The Tsitsikamma reserve and Algoa bay (South Africa) are habitats to numerous marine 
ascidians. Compounds belonging to acyclic amino alcohols have been isolated from 
these invertebrates exhibiting anti-microbial properties (Davies-Coleman and Beukes, 
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2004). In addition, soft coral distribution along the South African coast is relatively 
abundant with approximately 200 species (60-70% endemic) known and are a major 
component of the benthic community (Hooper and Davies-Coleman, 1995). Soft corals 
such as Capnella thyrsoidea are an important source of potent anti-inflammatory 
xenicane diterpenes such as tsitsixenicin A (Hooper and Davies-Coleman, 1995). 
In addition to the abundant fauna of tunicates and soft corals, molluscs and sponges 
make up a diverse group of marine fauna along the South African coast (Griffiths et al., 
2008). Previously uncharacterised alkaloids, tsitsikammamme A and tsitsikammamine B 
(bispyrroloiminoquinone alkaloids) were isolated from a latrunculid sponge (Hooper et 
al., 1996). Two additional pyrroloiminoquinone alkaloids, 14-bromodiscorhabdin C and 
14-bromodihydrodiscorhabdin C were identified in the same study. Various novel NPs 
have been isolated from marine molluscs (gastropods) and algae from the South African 
coast exhibiting anti-oesophageal cancer activity (van Wyk et al., 2008; Mann et al., 
2007). South African marine sponges have also proved a rich source of bioactive 
compounds exhibiting activity against oesophageal cancer cell lines (Whibley et al., 
2005). Collectively, these studies highlight the potential for the discovery of yet unknown 
NPs from the South African coast.  
It is obvious that the South African NP research has paid minimal attention to micro-
organisms as sources of NPs. This study therefore provides an opportunity to address 
this research gap between micro-organisms and NP discovery in South Africa.  
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 Research objectives 
This study forms part of a broader collaborative project (PharmaSea) with the principal 
aim of isolating and characterising a novel NRPS or PKS pathway from bacteria 
associated with novel marine invertebrate species endemic to the South African coast.  
 
1.10.1 Culture-dependent approach 
Specific objectives include; 
(i) Isolating bacteria associated with novel marine sponge and tunicate species 
endemic to the South African coast. 
(ii) Functional screening of the marine invertebrate-associated bacteria for anti-
microbial activity against a panel of indicator organisms. 
(iii) To select preliminary candidate strains for whole genome sequencing based 
on the anti-microbial profile. 
 
1.10.2 Culture-independent approach 
Specific objectives include; 
(i) Homology screening (specifically for NRPS and PKS genes) of bioactive 
isolates using PCR. 
(ii) Selection of a suitable candidate strain based on anti-microbial profiles and 
PCR screening results. 
(iii) Genome mining of genome sequence data for potentially novel NRPS or PKS 
pathways.  
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(iv) Use of bioinformatics tools to characterise a potentially novel pathway. 
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Chapter 2 Materials and methods 
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 General chemicals and enzymes 
All chemicals used in this study were supplied by Merck Chemicals and laboratory 
supplies (Darmstadt, Germany), Sigma Aldrich Chemical Company (Deissenhofen, 
Germany) and Kimix Chemical and Laboratory Supplies (South Africa). Culture media 
were supplied by Oxoid Ltd and Biolabs. 
Oligonucleotides for use in the polymerase chain reaction (PCR) were synthesized by 
Inqaba Biotech (Johannesburg, South Africa) and Integrated DNA Technologies 
(Coralville, Iowa, USA).  
DNA modifying enzymes (polymerases & restriction endonucleases) were purchased 
from Fermentas Life Sciences Ltd (Vilnius, Lithuania). 
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 Bacterial strains used in this study 
 
Table 2.1: Description of bacterial strains used in this study 
Bacterial strains Genotype Supplier 
E. coli EPI300 F- mcrA Δ(mrr-hsdRMS-mcrBC) Epicentre® an Illumina  
 
Φ80dlacZΔM15 ΔlacX74 recA1 company (USA) 
 
endA1 araD139 Δ(ara, leu)7697 
 
 
galU galK λ- rpsL (StrR) nupG trfA 
 
 
tonA 
  
 
 Plasmids used in this study 
 
Table 2.2: Description of plasmid used in this study 
 
 
 
Plasmid Description/Relevant genotype Supplier 
pUC18 A  high copy number cloning vector   
Contains the bla gene coding for a β-lactamase that confers 
ampicillin resistance.  
LacZ gene present coding for the N-terminal of β-
galactosidase enabling (α)-complementation with the 
defective β-galactosidase ∆ (LacZ) within the host 
facilitating blue/white clone selection 
Thermo scientific 
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 Specimen collection and taxonomic identification 
 
2.4.1 Collection 
Sponge and tunicate specimens were collected using SCUBA by Dr Shirley Parker-
Nance (Just Blue, South Africa) from low profile rocky reefs in Algoa bay White sands 
reef (South Africa) at depths of 23-25 metres (figure 2.1). Sampling was carried out on 
the 23rd January and the 4th of April 2013 respectively. The sponge specimen was 
collected at the geographical coordinates longitude 34°00.366S and latitude 25°43.209E 
whereas the tunicate specimen was collected at longitutde 34000.406S and latitude 
25°43.117E.   
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Figure 2.1: Geographical location of sampling site. Both specimens were collected from Algoa bay 
(demarcated by a red circle), White sands reef at depths ranging between 23-25 metres. The habitats 
consisted of low profile rocky reefs (Adapted from Griffiths et al., 2010). 
 
2.4.2 Taxonomy 
Taxonomic identification of the invertebrate specimens was undertaken by Dr. Shirley 
Parker-Nance (Just Blue, South Africa) and the results are summarised in figure 2.2. 
The specimens are novel species in their respective genera and are classified as 
Spongia (Spongia) sp. 001RSASPN and Pseudodistoma africanum Millar, 1954 (figure 
2.2). 
 
 
 
 
 
 
Materials and methods 
 
46 
 
                    
 
 
 
 
 
 
       
 
Sample ID: PE13 
Phylum: Chordata  
Subphylum: Urochordata-Tunicata 
Class: Ascidiacea 
Order: Aplousobranchia 
Family: Pseudodistomidae 
Genus: Pseudodistoma 
Species: Pseudodistoma africanum Millar, 1954 
Sample ID:  PE8 
Phylum: Porifera 
Class: Demospongiae 
Order: Dictyoceratida 
Family: Spongidae 
Genus: Spongia 
Subgenus: Spongia (Spongia) Linnaeus, 1759 
Species: Spongia (Spongia) sp. 001RSASPN 
Figure 2.2: Taxonomic classification of marine invertebrate specimens used in this study.  
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 Isolation of marine invertebrate-associated bacteria 
Sponge and tunicate tissue was processed within 24 hours of collection by mechanically 
homogenising 1 gram of tissue (including both internal and external tissue) using a 
sterile mortar and pestle. From the resulting mixture, 1 ml was transferred to 9 ml of 
sterile sea-water and a dilution series (10-1-10-6) performed. From each dilution, 100 μl 
was plated onto different media representing different nutrient sources (Appendix B) 
and incubated at 15°C for a period of 6-8 weeks. Growth was monitored regularly and 
colonies picked based on physical characteristics including colour, colony size and 
morphology. Strains were subsequently re-streaked onto the medium from which they 
were isolated.  
 
 Functional screening for anti-bacterial activity 
The agar-overlay assay was used to screen for anti-bacterial activity of invertebrate-
associated bacteria against a panel of indicator organisms consisting of; Escherichia 
coli 1699 (a multi-drug resistant strain, Cubist), Bacillus cereus ATCC 10702, 
Staphylococcus epidermidis ATCC 14990 and Mycobacterium smegmatis LR222. 
Briefly, isolates to be screened were grown on their respective isolation medium for 14 
days at 15°C. Prior to anti-bacterial screening, the indicator organisms were grown up in 
10 ml of LB broth overnight at 37°C shaking at 250 rpm. To ensure an equal amount of 
cells was used for each experiment, the following formulae were used; OD600 x X µl = 4 
(E. coli 1699) and OD600 x X µl = 160 (B. cereus, S. epidermis and M. smegmatis) 
where OD600 refers to optical density measured at 600 nm. The appropriate volume of 
cell culture was added to 6 ml of sloppy agar and gently distributed over the colonies to 
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be screened and incubated at 37°C overnight. Anti-bacterial activity was confirmed by a 
zone of clearance surrounding the colony. 
 
2.6.1 Effect of a change in culture medium on anti-microbial activity 
Selected bioactive isolates were further investigated for anti-bacterial activity on glucose 
yeast malt medium (GYM). Briefly, isolates were grown for 14 days at 15°C on GYM 
agar and the agar-overlay assay performed as described in section 2.6.  
In a collaborative effort with the Medina Foundation (Granada, Spain), the screening 
platform was extended to include clinical strains including Escherichia coli MB2884, 
Staphylococcus aureus MRSA MB5393, Pseudomonas aeruginosa PA01, and 
Pseudomonas aeruginosa PA01 synergy with IMP.  In addition, Aspergillus fumigatus 
ATCC 46645 and Candida albicans MY1055 were included as eukaryotic indicator 
strains. All strains isolated from the specimens described in section 2.4 were grown in 
four different liquid media including GYM, Zobell, Tryptic soy and activated charcoal 
medium (ACM). Extracts (as described in section 2.6.2.5) were subsequently screened 
against the panel of indicator strains listed above. 
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2.6.2 Extraction of anti-microbial compounds 
 
2.6.2.1 Well-diffusion assay 
Prior to the preparation of crude extracts, the well-diffusion assay was used to detect 
anti-microbial compounds in the cell-free culture broth. Briefly, isolates were grown in 25 
ml of medium for 14 days at 15°C while shaking at 250 rpm in a 100 ml conical flask. 
Cells were separated from the broth by centrifugation at 7000 g for 5 minutes at 15°C.  
The broth (20 ml) was concentrated at 46°C to approximately 10 ml. Test strains were 
grown overnight at 37°C in LB broth and adjusted to an OD600 between 0.3-0.4 and 100 
µl of culture spread onto solid LB agar containing wells created using the wide end of a 
yellow pipette tip. The concentrated broth (50 µl) was subsequently loaded into the wells 
and allowed to stand at room temperature for 30-60 minutes and then incubated 
overnight at 37°C. MilliQ water was used as a negative control for anti-microbial activity. 
Once anti-microbial activity was detected in the broth, an equal volume of acetone was 
added to the culture broth and allowed shake for 1 hour at room temperature. The 
mixture was subsequently concentrated at 46°C to half its original volume.   
 
2.6.2.2 Column preparation 
Columns were prepared using 15 ml falcon tubes. Briefly, 3-4 holes were created at the 
bottom of the 15 ml tube and plugged with glass-wool (approximately 1 cm) as 
illustrated in figure 2.3. The resin (2 ml) was allowed to pack on top of the glass-wool.  
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Figure 2.3: Assembly of the ion-exchange columns used in this study. 
 
2.6.2.3 Anionic-exchange resin preparation 
Amberlite IR120 (Na+) resin columns were prepared as described above (figure 2.3). 
The resin was washed once with 10 ml of MilliQ water and allowed to flow through 
completely then with 15% HCl followed by an additional two washes with MilliQ water 
each at a volume of 10 ml. The concentrated acetone extract (section 2.6.2.1) was 
applied to the resin and allowed to drip through the column by gravity flow, followed by a 
single wash with 5 ml of MilliQ water. Bound material was eluted and collected with 5 ml 
of acetone and subsequently dried at 46°C (completely) in the absence or presence of 
vacuum. The dried extract was re-suspended in 500 µl of MilliQ water. Extracts were 
Glass-wool plug 
̴ Approximately 2 ml of resin 
4 holes punctured at the 
bottom of tube 
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tested for anti-microbial activity using the well-diffusion assay as described in section 
2.6.2.1. 
 
2.6.2.4 Cationic-exchange resin preparation 
Amberlite IR 910 (Cl-) resin was packed into the column and allowed to settle above the 
glass-wool plug at a volume of 2 ml (figure 2.3).  Beads were washed with 10 ml of 
MilliQ water and allowed to flow through completely. The beads were washed with 0.1 
M NaOH then two additional washes (10 ml) with MilliQ water. The concentrated 
acetone extract (section 2.6.2.1) was then allowed to flow through the resin followed by 
a wash with 5 ml of MilliQ water.  Bound material was eluted and collected with 5 ml of 
acetone and subsequently dried at 46°C (completely) in the absence or presence of 
vacuum. The dried extract was re-suspended in 500 µl of MilliQ water. Extracts were 
tested for anti-microbial activity using the well-diffusion assay as described in section 
2.6.2.1. 
 
2.6.2.5 Hydrophobic-resin column preparation 
The column was prepared as described above (section 2.6.2.2) and packed with 2 ml of 
Sepabeads® (SP-207). The resin was washed once with 5 ml of acetone followed by a 
single wash with 5 ml of methanol. Once the methanol had run through the resin, the 
column was washed once with 10 ml of MilliQ water. To the cell culture (10 ml), an 
equal volume of acetone was added and shaken for 1 hour at room temperature. This 
mixture was concentrated to half the volume at 46°C and allowed to run through the 
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resin by gravity flow. Once the culture had completely run through the column, the resin 
was washed once with 5 ml MilliQ water. Material bound to the column was eluted using 
5 ml of acetone and collected. The eluent was dried to completion at 46°C and re-
suspended in 200 µl of MilliQ water. 
 
 Construction of growth curves 
A single colony was inoculated into 25 ml of the desired liquid medium in a conical flask 
(150 ml volume) and grown overnight at 15°C whilst shaking at 250 rpm. The overnight 
culture was adjusted to an OD600 of 0.2 and 1 ml transferred to 100 ml of sterile medium 
in a 250 ml conical and grown at room temperature while shaking at 150 rpm. Readings 
(OD600) were taken at appropriate intervals until no further change in the OD600 was 
observed. The OD600 readings were subsequently plotted against time to obtain a 
growth curve. 
 
 DNA extraction 
 
2.8.1 Small-scale genomic DNA extraction 
A single colony was inoculated into sterile medium (10-20 ml) and allowed to grow at 
room temperature until turbid. Cell mass was harvested by centrifugation at 7,000 g for 
5 minutes and the supernatant discarded. The resulting pellet was re-suspended in 500 
µl of lysis buffer and incubated at 37°C overnight. SDS at a final concentration of 1% 
[v/v] and 1 µl of RNAse A (20 mg/ml) were added to the mixture, gently inverted and 
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incubated at 65°C for 30 minutes. An equal volume of phenol/chloroform/isoamyl alcohol 
(PCI) in the ratio of 25:24:1 was added, thoroughly mixed and centrifuged at 10,000 g 
for 10 minutes. The aqueous phase was transferred to a new tube and an equal volume 
of chloroform/isoamyl alcohol (CI) in a ratio of 24:1 added. The tube was gently inverted 
(3-6 times) and centrifuged at 10,000 g for 10 minutes and the aqueous phase (top 
layer) was transferred to a new micro-centrifuge tube. DNA was precipitated using one 
volume of isopropanol and gently inverted to mix thoroughly and centrifuged at 10,000 g 
for 10 minutes. Isopropanol was discarded and the pellet washed with 1 ml of 70% 
ethanol and subsequently air-dried. DNA was re-suspended in 50-100 µl of DNAse-free 
sterile water. 
 
2.8.2 Large-scale genomic DNA extraction 
A single colony was inoculated into 100-400 ml of culture medium at room temperature 
until turbid following which cells were harvested at 10,000 g for 5 minutes. The resulting 
pellet was re-suspended in 9.5 ml of TE buffer (pH 8) to which 0.5 ml of 10% [v/v] SDS, 
100 μl of 20 mg/ml proteinase K and 1U of 10 mg/ml RNAse A was added, thoroughly 
mixed and incubated at 37°C for 1 hour. To this mixture, 1.8 ml of 5 M NaCl and 1.5 ml 
of a 10% [w/v] CTAB/0.7 M NaCl solution was added, thoroughly mixed by inversion 
and incubated at 65°C for 20 minutes. An equal volume of CI (24:1) was added and 
gently but thoroughly mixed followed by centrifugation at 10,000 g for 10 minutes at 4°C. 
The aqueous layer was transferred to a new micro-centrifuge tube to which an equal 
volume of PCI (25:24:1) was added and gently mixed. Following phase separation at 
10,000 g for 10 minutes, DNA was precipitated with a 0.6 volume of isopropanol. The 
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DNA was collected either by centrifugation or spooling and subsequently washed once 
with 1 ml of 70% ethanol for 5 minutes at 10,000 g. The ethanol was discarded following 
which the air-dried DNA pellet was re-suspended in 200-500 µl of TE buffer.  
 
2.8.3 Hard lysis DNA extraction 
DNA from Streptomyces isolates was extracted using a hard lysis method. Briefly, the 
cell mass was harvested by centrifugation at 10,000 g for 5 minutes. The supernatant 
was discarded and cells washed twice with TE buffer (pH 8) by centrifugation at 10,000 
g for 5 minutes at 4°C. The supernatant was discarded and the cell pellet re-suspended 
in 100 µl of breaking buffer following which 0.3-0.4 g of acid-washed glass beads (212-
300 µm, 50-70 U.S sieve) were added and the mixture briefly vortexed at maximum 
speed. To this mixture 100 µl of PCI in the ratio 25:24:1 was added and bead-beating 
performed for 3 minutes. TE buffer (pH 8) was added at a volume of 200 µl gently mixed 
and centrifuged at 10,000 g for 5 minutes at 4°C. The resulting supernatant was 
transferred to a new micro-centrifuge tube to which 1 ml of ice-cold 100% ethanol was 
added and kept on ice for 10 minutes. Centrifugation was performed as above following 
which the DNA pellet was re-suspended in 1 ml of ice-cold 70% ethanol and 10 µl of 4 
M ammonium acetate. This was kept on ice for 10 minutes and centrifuged as above. 
The resulting DNA pellet was air-dried and re-suspended in 50 µl of TE buffer (pH 8). 
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2.8.4 Plasmid extraction using the alkaline lysis method 
A single colony was inoculated into 10 ml of LB supplemented with ampicillin at a final 
concentration of 100 µg/ml and grown overnight at 37°C shaking at 250 rpm. From the 
overnight culture, 2 ml was transferred to a sterile micro-centrifuge tube and cells 
harvested at 16,000 g for 30 seconds. The resulting supernatant was discarded and the 
cell pellet re-suspended in 100 µl of solution 1 (Appendix A) and placed on ice for 5 
minutes. Solution 2 (Appendix A) at a volume of 200 µl, was added and mixed 
thoroughly by inversion and chilled on ice for 5 minutes. This was followed by the 
addition of 150 µl of solution 3 (Appendix A) and the mixture briefly vortexed and kept 
on ice for 5 minutes. Cell debris and chromosomal DNA was subsequently pelleted for 3 
minutes at 16,000 g at room temperature. The supernatant was transferred to a sterile 
micro-centrifuge tube and the plasmid DNA precipitated using 800 µl of 95% ethanol for 
2 minutes at room temperature. Plasmid DNA was collected by centrifugation at 16,000 
g for 1 minute at room temperature and washed with 1ml of 70% ethanol. The plasmid 
DNA was air-dried and re-suspended in 50 µl of TE buffer (pH 8).  
 
2.8.5 Extraction of sequencing grade plasmid DNA 
To ensure good quality plasmid DNA suitable for sequencing, plasmid extractions were 
performed using the Qiaprep® miniprep kit (Qiagen). Briefly, a single colony was 
inoculated into 10 ml of LB supplemented with ampicillin at a final concentration of 100 
µg/ml. Cultures were grown overnight at 37°C while shaking at 250 rpm. Cells were 
harvested by centrifugation at 16,000 g for 30 seconds. Plasmid DNA was extracted 
according to the manufacturers’ instructions.  
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2.8.6 Gel extraction and PCR cleanup 
DNA and PCR amplicons resolved in agarose gel were purified using the NucleoSpin®
 
gel and PCR cleanup kit (Macherey-Nagel) according to the manufacturers’ instructions. 
 
 Total RNA extraction 
A single colony was inoculated into 10 ml of medium and grown overnight at room 
temperature while shaking at 150 rpm. The OD600 of the overnight culture was adjusted 
between 0.1-0.3 and 1 ml transferred to a conical flask (250 ml volume) containing 50 
ml of medium. This culture was grown at room temperature (shaking at 150 rpm) to the 
appropriate growth stage (mid-logarithmic or stationary) and cells immediately 
harvested by centrifugation at 7000 g at room temperature for 5 minutes. The 
supernatant was discarded and cells immediately re-suspended in 1 ml TRIzol reagent. 
Total RNA was subsequently extracted as per the manufacturers’ instructions. 
 
 Nucleic acid analysis 
Nucleic acid purity (based on 260/280 and 260/230 ratios) and the concentration of 
nucleic acid solutions were determined by spectrophotometric analysis using the 
NanoDrop® ND-1000 (NanoDrop technologies, Inc., USA). 
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2.10.1 DNA agarose gel electrophoresis 
DNA was resolved using agarose gel electrophoresis. Agarose gels were prepared in 
1X TAE buffer at a concentration of 0.8-1% [w/v] of agarose. To ensure DNA 
visualisation, the agarose gel was stained with ethidium bromide staining solution at a 
final concentration of 0.5 µg/ml. Prior to loading onto the agarose gel, DNA samples 
were prepared by the addition of 6X DNA loading buffer. Electrophoresis was performed 
in 1X TAE running buffer at 10-12 Volts/cm for 1 hour. DNA size was estimated using 
lambda DNA completely digested with Pst endonuclease as molecular weight marker. 
DNA was visualised under ultra violet (UV) light (302 nm) and images obtained using 
the digital imaging system Alpha Imager® HP 2000 (Alpha Innotech, USA). DNA to be 
excised and subsequently purified for further analysis, was visualised using long 
wavelength UV (365 nm) for no more than 10 seconds. 
 
2.10.2 RNA agarose gel electrophoresis 
RNA was resolved in an agarose gel prepared as described by Aranda and colleagues 
(2012). Briefly, to the 1% [w/v] agarose and 1X TAE buffer mixture, bleach at a final 
concentration of 0.5% [v/v] was added and incubated at room temperature for 5 
minutes. The agarose mixture was subsequently heated and once cooled; ethidium 
bromide staining solution (final concentration 0.5 µg/ml) was added to the gel and 
allowed to set. Electrophoresis was performed in 1X TAE running buffer at 10-12 
Volts/cm for 1 hour. Size estimation was performed using lambda DNA completely 
digested with Pst endonuclease as molecular weight marker. RNA was visualised under 
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UV light (302 nm) and images obtained using the digital imaging system Alpha Imager® 
HP 2000 (Alpha Innotech, USA).  
 
 Cloning of PCR amplicons 
 
2.11.1 Preparation of electrocompetent cells 
A single colony of E. coli EPI300 was inoculated into 10 ml LB and grown overnight at 
37°C while shaking at 250 rpm. Electrocompetent E. coli EPI300 cells were prepared by 
inoculating 400 ml of LB with 4 ml of the overnight culture and grown at 37°C while 
shaking at 250 rpm. Cells were grown to an OD600 between 0.35-0.4 and immediately 
kept on ice for 40 minutes while occasionally swirling. All subsequent steps were 
performed in a cold room (4°C) or on ice. Once cooled, cells were harvested at 7,000 g 
for 20 minutes at 4°C and the resulting supernatant discarded. The cell pellet was re-
suspended in 200 ml of ice-cold sterile demineralised water and harvested at 4°C for 10 
minutes at 7,000 g.  The supernatant was discarded and cell pellet re-suspended in 40 
ml ice-cold sterile distilled water and harvested at 7000 g for 5 minutes at 4°C (repeated 
5-6 times). Once thoroughly washed, the cell pellet was re-suspended in 40 ml of ice-
cold sterile 10% glycerol and harvested at 10,000 g for 20 minutes at 4°C. The 
supernatant was discarded and cell pellet re-suspended in 1 ml of ice-cold 10% 
glycerol. Aliquots (70 µl) were transferred to chilled sterile 1.5 ml micro-centrifuge tubes 
on ice and electrocompetent cells snap frozen in liquid nitrogen and stored at - 80° C 
until further use. 
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2.11.2 Preparation of pUC18 cloning vector 
The cloning vector (pUC18) was prepared for subsequent ligation reactions by digestion 
with 1U of fast-digest SmaI endonuclease per µg of vector DNA in a 20 µl reaction as 
per manufacturers’ recommendations. The digested vector DNA was resolved in 
agarose gel (0.8% [w/v]) and the linearized vector subsequently purified as described in 
section 2.8.6. 
 
2.11.3 Blunt-end DNA ligation 
Linearized pUC18 vector was ligated with insert DNA (blunt-end ligation) in the ratios 
1:5 or 1:3 (vector to insert). The reaction mixture consisted of 1U of T4 DNA ligase, 1X 
T4 DNA ligase buffer and nuclease free water to a final volume of 20 µl. The ligation 
reaction was performed overnight at 16°C. Blunt-ended inserts were created where 
necessary using T4 DNA polymerase as per manufacturers’ protocol. 
 
2.11.4 Transformation by electroporation 
Electrocompetent E. coli EPI300 cells were transformed directly with the ligation 
mixture. Briefly, an aliquot of electrocompetent cells (70 µl) was thawed for 
approximately 1 minute on ice and 5 µl of the ligation mix added to the thawed cells. 
This mixture was kept on ice for 30-60 seconds and subsequently transferred to a 
chilled 0.1 cm sterile electroporation cuvette (Bio-Rad). Cells were electroporated using 
the Bio-Rad MicroPulser™ (USA) with the following parameters; 1 pulse of 1.8 Kv, 25 
µF and 200 Ohms (Ω). Immediately after electroporation, 1 ml of LB was added to the 
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cells and the mixture transferred to a sterile 2 ml micro-centrifuge tube and incubated at 
37°C for 1 hour. Electroporated cells (100 µl) were spread onto LB plates containing 
ampicillin at a final concentration of 100 µg/ml of and 80 µg/ml X-gal and incubated 
overnight at 37°C.  
 
2.11.4.1 Screening of clones  
Based on the principle of blue/white selection, white colonies were picked and plasmid 
DNA extracted as described in section 2.8.4. Using the M13 vector primers, PCR was 
used to screen for clones containing the expected insert size (table 2.3). 
 
 Polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR) was carried out in 25-50 µl reactions. Each 
reaction consisted of 0.25U of a thermo-stable DNA polymerase (DreamTaq DNA 
polymerase), 1X reaction buffer, 0.2 mM dNTP mix (dTTP, dGTP, dCTP and dATP) and 
forward/reverse primers at a final concentration of 1 µM. Nuclease free water was used 
to adjust the reaction volume. All reactions were carried out in an automated thermal 
cycler (T100 thermal cycler, Bio-Rad). Cycling parameters and primer sequences are 
listed in table 2.3. 
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2.12.1 Reverse transcription PCR 
Following total RNA extraction, complementary DNA (cDNA) was synthesised using the 
iScript cDNA synthesis kit (Bio-Rad) according to the manufacturers’ specifications from 
500 ng of RNA (quantified by spectrophotometric analysis). Prior to cDNA synthesis, 
RNA samples were DNAse treated using RNAse-free DNAse I according to the 
manufactures’ instructions. For downstream PCR analysis, the volume of the cDNA did 
not exceed 1/10th of the reaction volume as recommended by the supplier. PCR 
reactions were set-up as described in section 2.12. PCR cycling parameters are listed in 
table 2.3. 
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Table 2.3: Primers and PCR cycling parameters 
Primer Target sequence Sequence (5' - 3') Product size (bp)Thermal cycling parametres Reference
MTF A-domain (NRPS) CCNCGDATYTTNACYTG 900 Initial denaturation at 94°C (Vizcaino et al ., 2005)
MTR GCNGGYGGYGCNTAYGTNCC for 5 min 30 cycles 94° C
for 1 min, 53°C for 30 sec, 72°C 
for 1 min and final extension 
step  at 72°C for 10 min. 
E9F 16S rRNA gene GAGTTTGATCCTGGCTCAG 1500 Initial denaturation at 94°C (Farelly et al ., 1995)
U1510R GGTTACCTTGTTGTTACACTT for 5 mins, 30 cycles of 94°C for (Reysenbach et al ., 1995). 
30 sec, 55°C for 30 sec, 72°C for
1.30 min and final extension  
at 72°C for 10 min.
FAS-F ORF 48 (PE8-15-cluster 4) TCGGTTCCACGAAGGATGAG 856 Initial denaturation at 95° C for This study
FAS-R GCTTTCGTTCCAGTACCGTG 3 min, 30 cycles of 95°C for 30 sec, 
60°C for 30 sec, 72°C for 1 min and
final extension at 72°C for 5 min
NRPS1-F ORF 39  (PE8-15-cluster 4) GGAGGAGTTTACGTTCCGCT 950 Initital denaturation at 95°C for This study
NRPS1-R CCGTCAGGGGAATAACGGAC 5 min, 30 cycles of 95°C for 30 sec,
61°C for 30 sec, 72°C for 1 min and
final extension at 72°C for 5 min.
KS1F1 Type I PKS (KS-domain) ATGGAYCCSCARCARCGBCT 700 Touchdown PCR: Initial denaturation (Hill, unpublished)
KS1R1  (Streptomyces ) GCYTCGATSGGRTCNCCSA at 95°C for 3 min, 10 cycles of 95°C for
30 sec, 77.3°C (-1°C/cycle) for 30 sec, 72°C
for 60 sec. 20 cycles of 95°C for 30 sec
62.3°C for 30 sec, 72°C for 50 sec and 
72°C for 5 min. 
KS2aF1 Type II PKS (KS-domain) TSGCSTGYTTCGAYGCSAT Touchdown PCR: Initial denaturation at 95°C  (Hill, unpublished)
KS2bR1 (Streptomyces) GCRTAGAACCASGCGAWSGAC 1070 for 3 min, 10 cycles of 95°C for 30 sec, 78°C for 30
sec, 72°C for 80 sec. 20 cycles of 95°C for 30 sec,
63°C for 30 sec, 72°C for 80 sec and a final 
extension at 72°C for 5 min.
M13 F Region flanking the pUC18  CCCACTCACGACGTTGTAAAACG Touchdown PCR: Initial denaturation at 94°C  Norrander et al ., 1983
M13 R MCS AGCGGATAACAATTTCACACAGG for 2 mins, 10 cycles of 94°C for 30 sec, 65°C
(-1°C/cycle) for 30 sec and 72°C for 50 sec. 
25 cycles of 94°C for 30 sec, 55°C for 30 sec
and 72°C for 50 sec.
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 Sequence and phylogenetic analysis 
Cloned inserts and PCR amplicons were sequenced at the University of Stellenbosch 
sequencing facility (ABI PRISM 377 automated DNA sequencer) in both the forward and 
reverse direction. Chromatograms were manually edited using the Chromas Lite version 
2.1 software package (Technelysium Pty Ltd, 2012). Curated nucleotide sequences 
(forward and reverse) were assembled using the DNAMAN version 4.13 software 
package (Lynnon Biosoft) to construct a consensus sequence.  
Phylogenetic analysis of assembled 16S rRNA sequences was performed against the 
16S ribosomal RNA sequences (Bacteria and Archaea) database (NCBI) using the 
BLAST tool (Altschul et al., 1990). All other sequence identity analysis was performed 
using the BLASTx tool against the non-redundant protein database (NCBI). Sequence 
alignments were done using MEGA version 6 (Tamura et al., 2013). 
 
 Whole genome sequencing 
Total genomic DNA was extracted (section 2.8.2) and DNA submitted to the University 
of the Western Cape sequencing facility. The sample (1 ng) was prepared using the 
nextera XT kit v2 (500 cycles) and sequencing reactions performed on the Illumina 
MiSeq platform.  
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2.14.1 Genome sequence assembly 
Genome sequence data was curated and analysed using the CLC genomics work 
bench version 6.5 software package. Sequence reads were merged and matched to the 
PHIX174 genome used as positive control for the sequencing run. Prior to the de novo 
assembly, reads were subjected to quality control and adapter trimming using the 
following parameters; quality score_ 0.05, maximum _ 3 ambiguous bases, minimum 
sequence length of 50 nucleotides and removal of adapter sequences (Appendix D) 
Contiguous sequences (contigs) were constructed by de novo assembly using the 
following parameters; mismatch cost _ 2, insertion cost _ 3, deletion cost _ 3, length 
fraction _ 0.95, similarity fraction _ 0.95 and a minimum contig length of 1000bp.  
 
2.14.2 Genome mining for secondary metabolite pathways 
Detection and annotation of SM biosynthetic pathways in genome sequence data 
(contigs) was performed with antiSMASH2.0 (Blin et al., 2013). The antiSMASH 
analysis parameters are shown in figure 2.4.  
 
Figure 2.4: antiSMASH2.0 genome analysis parameters used in this study. 
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2.14.3 Computational characterisation of secondary metabolite pathways 
Further bioinformatics analysis of SM pathways was performed using; NRPSpredictor2 
(Röttig et al., 2011), Natural product domain seeker (NaPDos) (Ziemert et al., 2012), 
and MEGA 6 version 6.0 (Tamura et al., 2013).  
 
2.14.4 Primer Design 
Specific primers were designed using the NCBI primer-BLAST tool (Ye et al., 2012). 
Default settings were used for primer design with the exception of the product length 
(adjusted to minimum 800bp and maximum 1000bp).  
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Chapter 3  Results and discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results and discussion 
 
67 
 
Whole genome sequencing as a tool for the discovery of novel secondary 
metabolite pathways from marine invertebrate-associated bacteria 
 
 Introduction 
Marine invertebrates are an important source of novel NPs from which various 
pharmaceutically relevant compounds have been isolated (Gunasekera et al., 1990; 
Bergmann and Feeney, 1951). NPs isolated from marine invertebrates display high 
similarity those of microbial origin (Velho-Pereira and Furtado, 2012). As a result, it was 
hypothesised that micro-organisms are the true producers of NPs otherwise attributed 
to the invertebrates (Haygood et al., 1999). Evidence for this is presented by Wilson and 
colleagues (2014) discussed in section 1.5.3. The significance of these findings is 
evident from an environmental perspective as bioactive compounds frequently occur at 
such low concentrations within the invertebrate tissue that an unrealistic amount of 
tissue is required (Mendola, 2003). All the economic feasibility of aqua-culture in mass 
production of marine NPs has previously been investigated (Sipkema et al., 2005), this 
approach is hindered by an extensive range factors (Sipkema et al., 2005; Mendola, 
2003). In contrast, micro-organisms are a sustainable source of compounds because 
large-scale microbial fermentation is relatively more practical in comparison to aqua-
farming (Sabdono, 2008). Furthermore, improved compound titres can be achieved 
through heterologous expression of SM pathways in well characterised microbial hosts 
(Ongley et al., 2013).  
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The re-discovery of known microbial NPs is a major bottleneck in NP discovery and has 
sparked interest in novel or previously uncultivated micro-organisms as a source of 
novel compounds (Williams, 2008). With the advancement of HTS, microbial genome 
data currently available has increased substantially (Bertelli and Greub, 2013). Analysis 
of these data shows that micro-organisms with experimentally characterised SM profiles 
contain several pathways with yet unknown products. This implies that the 1% of 
cultivated microbial diversity, thought to contain limited NP novelty still holds the 
potential to yield unknown compounds.  
In this chapter, the isolation of bacteria associated with two novel marine invertebrate 
species harvested from Algoa Bay (South Africa) is described. Invertebrate-associated 
bacteria are subsequently screened for anti-microbial activity with the incorporation of 
the OSMAC strategy described previously (section 1.8.1.2). Bioactive isolates are 
further screened by PCR for NRPS and PKS genes. In addition, the informatics based 
characterisation of a potentially novel NRPS pathway (identified using WGS) is 
described.  
 
 Anti-bacterial activity of marine invertebrate-associated bacteria 
The sponge and tunicate specimens, Spongia sp. 001RSASPN and P. africanum Millar, 
1954 respectively, are new species in their respective genera. To our knowledge, these 
species have previously not been studied in the context of NP discovery. In an attempt 
to diversify the bacteria isolated, several growth media representing a range of 
nutritional components were used (Appendix B). 
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Using the agar-overlay assay (section 2.6), anti-bacterial activity was detected by a 
zone of clearance around a colony (figure 3.1). The inclusion of a multi-drug resistant 
indicator strain (E. coli 1699) is important for the detection of bioactive compounds with 
mechanisms of action different to those of known compounds (Hentschel et al., 2001). 
Therefore, strains exhibiting activity against E. coli 1699 were of particular interest in 
this study. A complete list of antibiotics to which E. coli 1699 exhibits resistance are 
listed in table F.1 (Appendix F).  
 
 
Figure 3.1: Detection of anti-bacterial activity in marine invertebrate-associated bacteria using the agar-
overlay assay. Semi-solid agar (sloppy agar) is inoculated with the indicator strains and subsequently 
spread in a thin layer over the isolates. A zone of clearance surrounding the bacterial colony is indicative 
of the production of an anti-bacterial agent. 
 
Zone of clearance 
Bacterial colony 
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3.2.1 Isolation and anti-bacterial activity of sponge isolates 
Based on colony morphology, a total of 212 bacterial strains associated with Spongia 
sp. 001RSASPN were isolated. Of these isolates, 131 were screened for anti-microbial 
activity and 6.1% (8 isolates) exhibited inhibitory activity against at least one indicator 
strain (table 3.1). Inhibitory activity was frequently observed against B. cereus whereas 
M. smegmatis was less frequently inhibited. A total of 3 isolates were active against the 
multi-drug resistant E. coli 1699 strain.  
 
3.2.2 Isolation and anti-bacterial activity of tunicate isolates 
From the tunicate P. africanum Millar 1954, a total of 184 bacterial strains were isolated 
of which 148 were screened for anti-bacterial activity. Anti-bacterial activity was 
exhibited by 6 isolates (4%) against at least one indicator strain (table 3.1). Inhibitory 
activity was observed against B. cereus, S. epidermidis and E. coli 1699 whereas M. 
smegmatis was not inhibited by any of the isolates.   
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Table 3.1: Anti-bacterial activity exhibited by marine invertebrate-associated 
bacteria  
Strain ID Source M. s S. e E. c   B. c 
PE8-15 Sponge - + - + 
PE8-16 Sponge - + - + 
PE8-17 Sponge - - - + 
PE8-18 Sponge - - - + 
PE8-20 Sponge - - + - 
PE8-149(B) Sponge + - - - 
PE8-152 Sponge - - + - 
PE8-153 Sponge - - + - 
PE13-172 Tunicate - + - + 
PE13-173 Tunicate - - + + 
PE13-88 Tunicate - - - + 
PE13-169 Tunicate - + + - 
PE13-46 Tunicate - + - - 
PE13-181 Tunicate -   - + - 
Total  1 5 6 7 
 
(E.c) = E. coli 1699 (B.c) = B. cereus ATCC 10702 (S.e) = S. epidermidis ATCC 14990 (M.s) = M.      
smegmatis LR222. 
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3.2.3 Effect of growth medium on anti-bacterial activity (secondary screening) 
OSMAC involves the manipulation of growth conditions with the aim of activating silent 
SM pathways (section 1.8.2). This approach was adopted in this study to investigate the 
anti-bacterial activity of the bioactive sponge isolates on solid GYM medium (Note: anti-
bacterial activity of the sponge isolates was previously investigated on solid only 
(ACM)).  
When grown on solid GYM medium, isolates PE8-15, PE-16, PE817, PE18 and PE8-
149(B) all inhibited the multi-drug resistant E .coli 1699 strain. The change in anti-
bacterial profile implicates expression of a different bioactive compound. In contrast, a 
loss of activity against S. epidermidis was observed in isolates PE8-15 and PE8-16 
when grown on solid GYM medium. In addition, a change in medium did not affect the 
anti-bacterial profiles of isolates PE8-20 and PE8-152 (against E. coli 1699) and PE8-
149(B) (against M. smegmatis).  
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Table 3.2: Effect of growth medium on the anti-bacterial activity 
Strain E. c B. c S. e M.s A.f  
 GYM ACM GYM ACM GYM  ACM GYM ACM  Zobell   ACM 
PE8-15 + - + + - + ND ND    +                -
PE8-16 + - + + - + ND ND     - - 
PE8-17 + - + + ND ND ND ND     - - 
PE8-18 + - + + ND ND ND ND     - - 
PE8-20 + + ND ND ND ND ND ND     - - 
PE8-152 + + ND ND ND ND ND ND     - - 
PE8-149 (B) + - ND ND ND ND + +     - - 
 
 
 
 
3.2.3.1 The effect of liquid medium on anti-bacterial activity 
In an attempt to further diversify the bioactivity profile using OSMAC, selected isolates 
were fermented in liquid ACM and GYM media. The concentrated fermentation broth 
was tested for anti-bacterial activity as described in section 2.6.2. Anti-bacterial activity 
was detected against all indicator strains (figure 3.2) including M. smegmatis LR222. 
Inhibition of M. smegmatis was interesting as none of selected strains that were 
(E.c) = E. coli 1699 (B.c) = B. cereus ATCC 10702 (S.e) = S. epidermidis ATCC 14990 (M.s) = M. 
smegmatis LR222 (A.f) = A. fumigatus ATCC 46645. (+) - Denotes a change in the anti-microbial activity as 
a result of a change in growth medium and (ND) - Indicates that anti-microbial activity was ‘Not determined’ 
experimentally 
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screened previously exhibited this activity with the exception of PE8-149(B). The new 
anti-bacterial profiles observed in the liquid medium further demonstrate the production 
of a different bioactive compound(s). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Detection of anti-bacterial activity in the fermentation broth of isolates PE8-15, 16 and 149(B) using 
the well-diffusion assay. Zones of inhibition indicate bacterial growth inhibition against the indicator strain. 
Photographs shown indicate anti-bacterial activity against E. coli 1699 (A), B. cereus ATCC 10702 (B) and S. 
epidermidis ATCC 14990 (C). Activity against M. smegmatis LR222 is not shown in above. Sterile ACM and 
GYM media were used a negative control. 
 
A B 
C 
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3.2.3.2 Isolation of bioactive compounds 
In a collaborative effort with the Medina Foundation (Granada, Spain), extracts were 
prepared from liquid cultures of PE8-15 (using four different media including Zobell, 
TSA, GYM and ACM) and screened against a panel of clinical indicator strains including 
fungi and yeast. These screening efforts identified anti-fungal activity (against A. 
fumigatus ATCC 46645) in extracts prepared from PE8-15 grown in Zobell medium. No 
bioactivity was detected in extracts prepared from TSA, GYM and ACM.  
The above extracts were prepared using a hydrophobic resin (Sepabeads®) and 
therefore the compound isolation procedure was selective for compounds with 
hydrophobic properties. To reduce the bias towards hydrophobic compounds, two 
additional resins (cationic/anionic-exchange resins) were incorporated into the extract 
preparation procedure. ACM fermentation broth extracts prepared using ionic-exchange 
resins did not exhibit any anti-bacterial activity (figure 3.3). In contrast, anti-bacterial 
activity was detected in both ionic-exchange extracts from the GYM fermentation broth 
(figure 3.3). Anti-bacterial activity was however more pronounced in the cationic-
exchange resin derived extracts. These results suggest that the bioactive within the 
ACM broth differed to that of the GYM broth as activity would have been retained in the 
ACM ionic-exchange extracts if similar compound(s) were present. As part of an on-
going collaboration between IMBM and the Medina Foundation (Granada, Spain), 
bioactive extracts are being investigated further to identify the active compounds.  
NPs are known for their diverse biological activities. It is therefore a logical approach to 
diversify the screening platform to incorporate a range of targets as done in this study. 
In addition, a diverse screening platform may facilitate the identification of novel 
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mechanisms of action by even previously characterised compounds (Tulp and Bohlin, 
2005).  
 
     
                
 
Figure 3.3: Anti-bacterial activity exhibited by ionic-exchange extracts prepared from the PE8-15 
fermentation broths. Only extracts obtained from GYM media retained activity against the indicator 
strains. Extracts obtained from the cationic-exchange fraction (lower left quadrant) showed more potent 
activity against test strains in comparison to extracts obtained from the anionic-exchange column (lower 
right quadrant. The well in the centre of the plate represents the negative control (MilliQ water). 
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Antimicrobial activities shown include; (A) – E. coli 1699, (B) – M. smegmatis LR 222, (C) – B. cereus, (D) 
– S. epidermidis. 
 
3.2.4 Phylogenetic Identification of bioactive isolates 
Phylogenetic characterisation of bioactive isolates from Spongia sp. 001RSASPN and 
P. africanum Millar, 1954 was determined by 16S rRNA gene sequencing. Closest 
relatives were determined by a BLASTn analysis against the NCBI 16S rRNA sequence 
database (bacteria/archaea) presented in table 3.3.  
 
3.2.4.1 Spongia sp. 001RSASPN associated bioactive isolates 
Bioactive strains isolated from Spongia sp. 001RSASPN all belonged to the genus 
Bacillus (Phylum-Firmicutes). This genus consists of organisms found ubiquitously in a 
diverse range of environments perhaps due to their spore-forming ability (Nicholson et 
al., 2000). Furthermore, organisms in the genus Bacillus are known for their production 
of various bioactive compounds and possibly play a role in host-defence within Spongia 
(Spongia) sp. 001RSASPN. Bioactive Bacillus isolates have previously been isolated 
from various marine sponges (Zhang et al., 2009; Pabel et al., 2003: Hentschel et al., 
2001). Although the sponge bioactive strains showed a very high sequence identity 
(>99%) to their top BLAST hits, the reference strains were not studied in the context of 
SM production. On this basis, these strains were considered as preliminary candidates 
for further analysis.  
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3.2.4.2 P. africanum Millar, 1954 associated bioactive isolates 
In contrast to the sponge isolates, bioactive bacteria associated with P. africanum Millar 
1954 belonged to three different genera including Pseudovibrio (Phylum-
Proteobacteria), Bacillus (Phylum-Firmicutes) and Streptomyces (Phylum-
Actinobacteria). The dominant bioactive isolates (under the conditions tested) were the 
four Pseudovibrio strains that show 99% sequence identity to Pseudovibrio 
ascidiaceicola.  
An important characteristic of organisms in the genus Pseudovibrio is their production of 
bioactive SMs exemplified by the heptylprodigiosins from P. denitrificans strain Z143-1 
(Sertan-de Guzman et al., 2007) and tropodithietic acid from Pseudovibrio sp. D323 
(Penesyan et al., 2011). A subsequent BLAST analysis against the NCBI nucleotide 
collection (nr/nt) database was performed. This analysis indicated that the Pseudovibrio 
strains in this study shared 99% identity to Pseudovibrio strains isolated from various 
marine invertebrate organisms of which some exhibited anti-microbial activity 
(O’Halloran et al., 2011; Heindl et al., 2010).   
The Streptomyces isolate (PE13-181) was highly similar to Streptomyces flavogriseus 
ATCC 33331 whose genome has previously been sequenced in which a potentially 
novel carbapenem antibiotic was identified (Blanco, 2012). As a result of the high 
similarity to a sequenced organism, PE13-181 was not considered for further analysis.  
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Table 3.3: Identification of bioactive isolates associated with marine invertebrates in this study 
 
Strain ID Closest relative (BLAST) 16S rRNA 
fragment length 
(bp) 
Identity 
(%) 
Source Accession no. 
PE8-15 Bacillus mycoides strain NBRC 101228 1416 99 Spongia sp. 001RSASPN NR_113990.1 
PE8-16 Bacillus mycoides strain NBRC 101228 1421 99 Spongia sp. 001RSASPN NR_113990.1 
PE8-17 Bacillus cereus strain ATCC 14579 1428 99 Spongia sp. 001RSASPN NR_074540.1 
PE8-18 Bacillus anthracis str. Ames strain Ames 669 99 Spongia sp. 001RSASPN NR_074453.1 
PE8-20 Bacillus mycoides strain NBRC 101228 1420 99 Spongia sp. 001RSASPN NR_113990.1 
PE8-149(B) Bacillus mycoides strain NBRC 101228 1427 99 Spongia sp. 001RSASPN NR_113990.1 
PE8-152 Bacillus weihenstephanensis KBAB4 strain 
KBAB4 
699 99 Spongia sp. 001RSASPN NR_074926.1 
PE8-153 Bacillus cereus ATCC 14579 1376 99 Spongia sp. 001RSASPN NR_074540.1 
PE13-172 Pseudovibrio ascidiaceicola strain NBRC 
100514 
1351 99 P. africanum Millar, 1954 NR_113916.1 
PE13-173 Pseudovibrio ascidiaceicola strain NBRC 
100514 
766 99 P. africanum Millar, 1954 NR_113916.1 
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PE13-88 Bacillus aerius strain 24K 803 99 P. africanum Millar, 1954 NR_118439.1 
PE13-169 Pseudovibrio ascidiaceicola strain  NBRC 
100514 
1351 99 P. africanum Millar, 1954 NR_113916.1 
PE13-46 Pseudovibrio ascidiaceicola strain  NBRC 
100514 
1352 99 P. africanum Millar, 1954 NR_113916.1 
PE13-181 Streptomyces flavogriseus strain ATCC 
33331 
1385 99 P. africanum Millar, 1954 NR_074559.1 
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 Sequence-based screening for the discovery of potentially novel 
secondary metabolite genes 
 
3.3.1 Abundance and distribution of secondary metabolite pathways within the 
genus Bacillus 
Bioactive bacteria isolated from Spongia sp. 001RSASPN all belonged to the genus 
Bacillus (section 3.2.4.1). Species within the Bacillus genus are generally known for 
their versatility in SM production. For example, genome analysis of B. amyloliquefaciens 
FZB42 showed that 8.5% of the genome was involved in secondary metabolism (Chen 
et al., 2007). Genomes available on Genbank for species closely related to the bioactive 
strains isolated from the Spongia sp. 001RSASPN were analysed to determine the 
distribution and abundance of SM pathways (figure 3.4 and 3.5 respectively). A major 
benefit of performing such an analysis prior to PCR screening is that it facilitates 
prioritisation for SM genes likely to be present within an organism(s).  
NRPS and bacteriocin pathways were the most abundant class of SMs and were 
present in all genomes analysed. In comparison, terpene and siderophore biosynthetic 
genes were moderately distributed in all species with the exception of B. mycoides 
which lacked a siderophore biosynthetic pathway. Hybrid pathways (NRPS/transAT-
PKS and NRPS/bacteriocin) were only detected in B. subtilis strains whereas the 
lantipeptide class of SMs was only present in B. cereus, B. thuringiensis and B. subtilis 
strains.  The least abundant class, the phosphonates, were only present in B. subtilis 
strains. Although it would be ideal to represent each genome equally for such an 
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analysis, B. mycoides and B. weihenstephanensis lacked multiple strains with 
sequenced genomes and were therefore under-represented. 
 
 
Figure 3.4: Distribution of secondary metabolite classes in selected Bacillus strains. Bacillus strains for 
this analysis were selected based on their relatedness to the bioactive Bacillus isolates in this study 
determined by 16S rRNA sequencing and analysis (section 3.2.4.1). Genome mining was done using the 
antiSMASH2.0 software. The number of strains analysed for each Bacillus species were as follows; B. 
thuringiensis; n = 10, B. cereus; n = 13, B. subtilis; n = 11, B. anthracis; n = 6, B. weihenstephanensis; n = 
1, B. mycoides; n = 1. Accession numbers for each strain analysed are listed in the Appendix. 
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Figure 3.5: The average abundance of SM pathways in selected Bacillus strains. Bacillus strains for this 
analysis were selected based on their relatedness to the bioactive Bacillus isolates in this study 
determined by 16S rRNA sequencing and analysis (section 3.2.4.1). In silico analysis of these genomes 
was done using antiSMASH2.0. The number of strains analysed for each Bacillus species were as 
follows; B. thuringiensis; n = 10, B. cereus; n = 13, B. subtilis; n = 11, B. anthracis; n = 6, B. 
weihenstephanensis; n = 1, B. mycoides; n = 1. NRPS (shaded black) and bacteriocins (shaded blue) 
genes were present in all genomes analysed and represented the majority of SM classes (28% and 32% 
respectively). 
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3.3.2 PCR screening for NRPS genes 
Due to a relatively high abundance of NRPS genes in Bacillus species (figure 3.5), the 
bioactive Bacillus strains were screened by PCR for NRPS genes using degenerate 
primers targeting the A-domain (Vizcaino et al., 2005). The use of degenerate primers is 
significant as the amplification is not limited to known gene sequences. NRPS genes 
were detected in all isolates screened (figure 3.6). A BLAST analysis (Altchul et al., 
1990) confirmed the correct amplification of the NRPS A-domain in each isolate. These 
data are summarised in table 3.4.  
All NRPS amplicons exhibited high sequence identity (> 90%) to their top two BLAST 
hits with the exception of clone 1 from PE8-15. Clone 1 (PE8-15) shared 65% and 50% 
sequence identity respectively to the top two BLAST hits. The high sequence identity 
(>90%) of A-domain sequences suggests that they possibly originate from previously 
characterised pathways or from organisms whose genomes are sequenced (Gontang et 
al., 2010). Furthermore, all BLAST hits originated from sequences in B. cereus and B. 
weihenstephanensis NBRC 101238 = DSM 11821 with the exception of clone 1 of PE8-
15, whose sequences were more identical to those originating from B. oceanisediminis 
2691 and Cyanothece sp. PCC 7424.  
A variation in the nucleotide identity between clones from the same organism was 
observed in isolates PE8-149(B), PE8-20 and PE8-15 (table 3.4). Although this could be 
due to PCR errors introduced by the non-proof reading DNA polymerase (DreamTaq), it 
could also suggest amplification of multiple A-domains within the same organism.  
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Figure 3.6: PCR amplification of NRPS genes (specifically the A-domain) in bioactive isolates associated 
with Spongia sp. 001RSASPN. The expected amplicon size was approximately 900bp. Lanes 1 and 8: 
DNA molecular marker (lambda DNA digested with PstI). Lane 2: Negative control (Milli-Q water as a 
template). Lane 3-7: Isolates PE8-15, 16, 17, 149(B), 152 respectively. PCR amplicons were resolved in 
a 1% [w/v] TAE agarose gel.  
        λPst        ( - )         15         16           17       149(B)     152         λPst 
11501bp 
805bp 
1093bp 
4749bp 
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Table 3.4: Sequence identity of NRPS amplicons 
Isolate Clone  Top BLAST  hits (top 2 hits) Identity (%) Query cover Accession no. 
PE8_152 Clone 3 AMP binding protein B. cereus 
 
99 95% WP_002032315.1 
  Putative non-ribosomal peptide synthetase [Bacillus 99 95% GAE38254.1 
  weihenstephanensis NBRC 101238 = DSM 11821].    
      
PE8_152 Clone 2 AMP binding protein B. cereus 
 
99 93% WP_002032315.1 
  Amino acid adenylation domain-containing protein 99 93% WP_016120260.1 
  B. cereus    
      
PE8_152 Clone 1 AMP binding protein B. cereus 
 
99 93% WP_002032315.1 
  Putative non-ribosomal peptide synthetase [Bacillus 99 93% GAE38254.1 
  Weihenstephane9nsis NBRC 101238 = DSM 11821].    
      
PE8_149 (B) Clone 3 AMP binding protein B. cereus 
 
99 96% WP_002032315.1 
  Putative non-ribosomal peptide synthetase [Bacillus 99 96% GAE38254.1 
  weihenstephanensis NBRC 101238 = DSM 11821].    
      
PE8_149 (B) Clone 4 Amino acid adenylation domain-containing protein 91 95% WP_016127041.1 
  B. cereus 
 
   
  Amino acid adenylation domain-containing protein 91 95% WP_016101927.1 
  B. cereus    
      
PE8_149 (B) Clone 5 AMP binding protein B. cereus 93 96% WP_002032315.1 
  Putative non-ribosomal peptide synthetase [Bacillus 93 96% GAE38254.1 
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  weihenstephanensis NBRC 101238 = DSM 11821].    
      
PE8_20 Clone 3 AMP binding protein B. cereus 
 
98 99% WP_002032315.1 
  Putative non-ribosomal peptide synthetase [Bacillus 98 99% GAE38254.1 
  weihenstephanensis NBRC 101238 = DSM 11821].    
      
PE8_20 Clone 4 AMP binding protein B. cereus 
 
98 99% WP_002032315.1 
  Putative non-ribosomal peptide synthetase [Bacillus 98 99% GAE38254.1 
  weihenstephanensis NBRC 101238 = DSM 11821].    
      
PE8_20 Clone 5 MULTISPECIES: hypothetical protein (Bacillus cereus 
group) 
 
99 51% WP_002086912.1 
  Hypothetical protein C174 15052 Bacillus 
weihenstephanensis 
99 51% ETT76802.1 
  FSL H7-687    
      
PE8_15 Clone 1 Hypothetical protein Bacillus oceanisediminis 
 
65 90% WP_019379468.1 
  Amino acid adenylation protein (Cyanothece sp. PCC 
7424 
50 90% WP_015956918.1 
      
PE8_15 Clone 6 AMP binding protein B. cereus 
 
98 98 % WP_002032315.1 
  Putative non-ribosomal peptide synthetase [Bacillus 98 98 % GAE38254.1 
  weihenstephanensis NBRC 101238 = DSM 11821].    
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3.3.3 PCR screening for PKS genes 
Organisms in the genus Streptomyces are a well-known source of bioactive compounds 
particularly from the polyketide class (Berdy, 2005). Three isolates associated with P. 
africanum Millar, 1954 were identified as Streptomyces strains. Of these three isolates, 
only PE13-181 exhibited anti-bacterial activity against at least one indicator organism 
(E. coli 1699) whereas PE13-182 and PE13-175 did not exhibit any activity under the 
conditions tested.  
Nevertheless, because Streptomyces species are an important source of polyketides 
and due to the well-known “cryptic pathways” phenomena in this genus, all three strains 
were screened with degenerate primers for type I and type II PKS genes. As depicted in 
figure 3.7, type I PKS genes were detected in isolates PE13-181 and PE13-182. Type II 
PKS genes were only detected in isolate PE13-181 (figure 3.8). Although PKS genes 
were detected in isolate PE13-182, this strain previously did not exhibit any anti-
bacterial activity under the conditions tested. These results therefore highlight the 
importance of integrating bioactivity-guided screening with sequence-based screening. 
The absence of amplification in isolate PE13-175 can be explained by PCR bias as well 
as undetectable levels of product amplification. However, complete absence of PKS 
pathways in this organism cannot be ruled out.   
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Figure 3.7: Amplification of type I PKS genes in Streptomyces isolates associated with P. africanum 
Millar, 1954. The expected amplicon size was approximately 700bp. Lane 1: DNA molecular marker 
(lambda DNA digested with PstI). Lane 3: isolate PE13-181. Lane 5: isolate PE13-182. Lane 7: isolate 
PE13-175. Amplicons were resolved in a 1% [w/v] TAE agarose gel.  
 
 
 
 
  λPst                      181                         182                       175 
805bp 
11501bp 
1093bp 
4749bp 
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Figure 3.8: Amplification of type II PKS genes in the Streptomyces isolates associated with P. africanum 
Millar, 1954. The expected product size was approximately 1070bp. Lane 1: DNA molecular marker 
(lambda DNA digested with PstI). Lane 2-4: Isolates PE13-175, 181 and 182 respectively. PCR products 
were resolved in a 1% [w/v] TAE agarose gel. 
 
 
 
 
 
 λpst           175          181          182 
805bp 
11501bp 
1093bp 
4749bp 
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Table 3.5: Sequence analysis of PKS (KS) sequences 
Isolate PKS 
type 
Clone Top BLAST  hits Identity (%) Query 
cover 
Accession no. 
PE13-181 Type I Clone 2 Polyketide synthase, partial [Streptomyces sp. ID05-A0431] 94 98% BAH68103.1 
   Polyketide synthase, partial [Streptomyces sp. ID05-A0096] 94 98% BAH67688.1 
       
PE13-181 Type I Clone 5 Polyketide synthase, partial [Streptomyces sp. ID05-A0431] 94 96% BAH68103.1 
   Polyketide synthase, partial [Streptomyces sp. ID05-A0096] 94 96% BAH67688.1 
       
PE13-182 Type I Clone 1 Polyketide synthase, partial [Streptomyces sp. ID05-A0096] 99 99% BAH67686.1 
   Type I polyketide synthase, partial [Streptomyces sp. CNR-
885 
98 95% ACZ54341.1 
   PL04]    
       
PE13-182 Type I Clone 3 Polyketide synthase, partial [Streptomyces sp. ID05-A0096] 98 99% BAH67686.1 
   Type I polyketide synthase, partial [Streptomyces sp. CNR-
885 
97 95% ACZ54341.1 
   PL04]    
       
PE13-182 Type I Clone 4 Polyketide synthase, partial [Streptomyces sp. ID05-A0431] 99 100% BAH68102.1 
   Type I polyketide synthase, partial [Streptomyces sp. CNR-
885 
98 95% ACZ54340.1 
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PE13-181 Type II  Polyketide beta-ketoacyl synthase WhiE-KS [Streptomyces 
sp. PAMC26508] 
100 78% WP_015575864.1 
   MULTISPECIES: beta-ACP synthase [Streptomyces] 100 78% WP_014158007.1 
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In summary, isolates were considered unsuitable for further analysis (WGS) 
based on the following criteria: 
(I) Isolates that were closely related to an organism(s) whose genome has been 
sequenced and studied for the purpose of SM discovery (for example PE13-
181). 
(II) Isolates exhibiting a limited range of anti-microbial activity  
(III) Isolates with NRPS and PKS amplicons exhibiting sequence identity greater 
than 75%.  
(IV) Isolates closely related to strains previously isolated from marine 
invertebrates (PE13-172, PE13-173, PE13-169 and PE13-46). 
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Table 3.6: Summary of PCR screening results 
Isolate Genus Type I PKS Type II PKS NRPS 
PE8-15 Bacillus ND ND + 
PE8-16 Bacillus ND ND + 
PE8-17 Bacillus ND ND + 
PE8-149(B) Bacillus ND ND + 
PE8-152 Bacillus ND ND + 
PE13-181 Streptomyces + + ND 
PE13-182 Streptomyces + - ND 
PE13-175 Streptomyces - - ND 
 
 
 Whole genome sequencing (WGS) 
Among all the bioactive isolates, PE8-15 was selected based on the selection criteria 
outlined above. This isolate exhibited the most diverse bioactivity profile with inhibition 
against gram-positive, gram-negative as well as eukaryotic organisms (fungi). In 
addition, the low sequence identity of the NRPS amplicon from clone 1 (PE8-15) 
predicts the presence of a potentially novel NRPS pathway.  
Following quality trimming, a total of 4,625,328 reads averaging 193.7bp in length were 
retrieved. De novo assembly resulted in 101 contigs and a total genome size of 
5,911,306bp with an average GC-content of 36%. This genome size was slightly larger 
(ND) - Indicates genes whose presence was not determined experimentally.   
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in comparison to the genome from the B. mycoides strain 219298 (the closest relative to 
PE8-15 based on 16S rRNA sequence analysis) with a genome size of 5.6753Mbp. 
 
3.4.1 Genome mining of isolate PE8-15 
Using antiSMASH2.0, the genome of PE8-15 was mined for SM specific pathways. A 
total of 10 pathways were identified (figure 3.9) belonging to four different classes. The 
genome predominantly contained bacteriocin (5) and NRPS (3) pathways. In contrast, 
siderophore and terpene pathways were the least abundant with one pathway of each 
detected. These results are consistent with the in silico analysis of SM abundance in 
selected Bacillus strains (section 3.3.1). 
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Cluster 
  
Type 
    Cluster 1 
  
Bacteriocin 
    Cluster 2 
  
Bacteriocin 
    Cluster 3 
  
Bacteriocin 
    
Cluster 4 * 
 
NRPS 
    Cluster 5 
  
Siderophore 
    Cluster 6 
  
Bacteriocin 
    Cluster 7 
  
Bacteriocin 
    Cluster 8 
  
NRPS 
    Cluster 9 
  
NRPS 
    Cluster 10 
  
Terpene 
 
Figure 3.9: Secondary metabolite pathways identified in the genome of isolate PE8-15 using the 
antiSMASH2.0 software. A total of 10 SM pathways were detected of which the bacteriocin and NRPS 
classes were the most abundant with a total of 5 and 3 pathways respectively. Siderophore and terpene 
pathways were the least abundant with only one of each detected. The NRPS amplicon from clone 1 
(PE8-15) originated from Cluster 4 (highlighted by a red asterisk). 
 
3.4.2 Identification of an NRPS pathway in isolate PE8-15 
Using clone 1 from PE8-15 as a query sequence, contig_18 was identified to contain 
Cluster 4 highlighted in figure 3.9. Cluster 4 consists of 4 NRPS genes (ORF36, 39, 41 
and 43) all oriented in the same direction (figure 3.10). Located downstream of the 
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NRPS gene cluster are 4 adjacent PKS or fatty acid synthase (FAS) related genes 
(ORF46, 47, 48 and 49) separated from the NRPS genes by two ORFs (44 and 45). 
The PKS/FAS genes exhibited type II architecture in which each domain is located on 
discrete ORFs. The presence of both NRPS and PKS/FAS components suggest a 
hybrid NRPS-PKS/FAS pathway.  
A PPTase and TE are located upstream of the NRPS genes in ORF30 and 29 
respectively. SM pathways frequently contain two TE-domains of which one is 
integrated into the final module also known as TEI, whereas the additional TE (TE II) is 
discretely situated within the gene cluster (Claxton et al., 2009). TEI is involved in the 
catalytic release of the final peptide product (Hutchinson, 2003). In contrast, TEII is 
known to play various roles that among others, includes the removal of atypical acyl 
units from the carrier proteins (Claxton et al., 2009).  
Analysis of Cluster 4 identified the presence of a discrete TE (TEII) in ORF29 although 
a typical C-terminal (final module) TEI is absent. Despite product release often carried 
out by a TEI, the discrete TE (TEII) is capable of this activity. For example, the TEII 
LovG situated in the lovastatin biosynthetic gene cluster, was shown to release 
dihydromonacolin L acid in addition to removal of anomalous intermediate products (Xu 
et al., 2013). Therefore, due to the lack of an integrated TE (TEI) within Cluster 4, it is 
possible that the discrete TE (ORF29) is involved in product release.  
An MbtH-like protein (ORF45) is situated in the region between the NRPS and 
PKS/FAS gene clusters. These proteins are commonly associated with NRPS and 
siderophore biosynthetic gene clusters (Baltz, 2011). Although the specific role played 
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by MbtH-like proteins is still unclear, they have been implicated in forming complexes 
with A-domains and playing a role in the adenylation reactions (Herbst et al., 2013).  
The presence of two transposase genes flanking Cluster 4, suggest that this cluster is a 
mobile genetic element. Mizuno and colleagues (2013) previously identified a hybrid 
NRPS/PKS related to the bleomycin family of antibiotics flanked by transposase genes. 
This was subsequently hypothesized to have been acquired by HGT. Comparison of the 
GC-content of the hybrid gene cluster and the plasmid in which the hybrid cluster was 
identified, indicated a higher GC-content in the hybrid gene cluster. It was therefore 
suggested that the bleomycin-like gene cluster was acquired through HGT.  
To determine the possibility of HGT in the acquisition of Cluster 4, a GC-content 
analysis between Cluster 4 and the PE8-15 genome was conducted. This analysis 
showed a relatively small difference in GC-content between Cluster 4 (35%) and the 
PE8-15 genome (36%) therefore suggesting that HGT did not play a role in acquisition 
of Cluster 4. It is however possible that Cluster 4 was acquired from a closely related 
organism (as opposed to a distantly related organism) and hence the minimal difference 
in GC-content. Alternatively, if Cluster 4 was acquired a long time ago from a distantly 
related organism, the GC-content could ameliorate to that of its receiving host 
(Lawrence and Ochman, 1997). The latter possibly explains why the A-domain amplified 
from PE8-15 (clone 1) showed significant sequence similarity (50%) to a sequence 
originating from Cyanothece (a genus in the phylum Cyanobacteria). It is also possible 
that Cluster 4 is mobile specifically between specific Bacillus species as opposed to 
distantly related organisms. Additional genes associated with Cluster 4 are summarised 
in table 3.7  
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Figure 3.10: Prediction of ORFs on contig_18 using antiSMASH2.0. Each ORF is assigned a number and colour coded according to their role as 
described in the key. ORFs coding for putative transposase genes are identified with a red arrow and are seen to flank either side of Cluster 4. 
Transcriptional regulatory genes are identified with a green arrow. 
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Table 3.7: Predicted ORFs within Cluster 4 and their putative functions 
ORF Gene Top BLAST hit Proposed function I / S (%) Accession no. 
8 Transposase Transposase [Bacillus cereus] DNA repair, replication and   
recombination 
    82/83 WP_002191895.1 
21 ArsR family transcriptional  
regulator 
Transcriptional repressor [Bacillus cereus] Arsenical resistance operon 
repressor 
    
99/100 
WP_016095069.1 
29   Thioesterase Hypothetical protein [Bacillus 
oceanisediminis] 
Predicted thioesterase involved in 
NRPS biosynthesis 
    68/81 WP_019379475.1 
30 Phosphopantetheinyl 
transferase 
Hypothetical protein [Bacillus 
oceanisediminis] 
Transfers the 4'-
phosphopantetheine group from 
coenzyme A (CoA) to the 
invariant serine resulting in a 
holo-ACP 
   46/69 WP_026041532.1 
34   Dehydrogenase Hypothetical protein [Laceyella sacchari] -    43/64 WP_022737585.1 
36   NRPS Hypothetical protein [Bacillus 
oceanisediminis] 
NRP biosynthesis    56/72 WP_019379472.1 
39  N  NRPS Hypothetical protein [Bacillus 
oceanisediminis] 
NRP biosynthesis    54/71 WP_019379471.1 
40 Dioxygenase TauD/TfdA Hypothetical protein [Bacillus Taurine catabolism                70/85 WP_019379470.1 
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oceanisediminis] 
41             NRPS Hypothetical protein [Bacillus 
oceanisediminis] 
NRP biosynthesis    53/74 WP_019379469.1 
43 NRPS Hypothetical protein [Bacillus 
oceanisediminis] 
NRP biosynthesis    62/77 WP_019379468.1 
44 ABC transporter ATP- 
binding protein 
Hypothetical protein [Bacillus 
oceanisediminis] 
Multi-drug resistance    75/86 WP_019379467.1 
45 MbtH-like protein Hypothetical protein [Bacillus 
oceanisediminis] 
Synthesis of antibiotics, 
siderophores and 
glycopeptidolipids 
   75/82 WP_019379466.1 
46 Short-chain-
dehydrogenase 
(reductase/SDR) (KR) 
3-oxoacyl-ACP synthase [Paenibacillus 
mucilaginosus]  
FabG, 3-ketoacyl-acyl carrier 
protein reductase. NADH 
dependent reduction of ACP in de 
novo fatty acid synthesis 
   54/74 WP_014651400.1 
47 Acyl carrier protein Hypothetical protein ER50_05790 [Bacillus 
safensis] 
Phosphopantetheine attachment 
site 
   43/74 KEP30945.1 
48 Beta-ketoacyl synthase Beta-ketoacyl-ACP synthase [Bacillus 
gaemokensis] 
FabF-elongation during fatty acid 
synthesis 
   56/72 KEK21730.1 
49 Beta-ketoacyl synthase Hypothetical protein BAGA_26265 [Bacillus 
gaemokensis] 
FabB-catalyse a claissen-like 
condensation in addition to fatty 
   37/58 KEK21729.1 
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acid synthesis and degradation, 
polyketide synthesis 
50 [3-hydroxymyristoyl]   -
acetylglucosamine 
Beta-hydroxyacyl-(acyl-carrier-protein) 
Dehydratase [Planctomycete KSU-1] 
FabZ- responsible for the 
dehydration of beta-hydroxyacyl-
ACP to trans-2-acyl-ACP. This is 
the third step of bacterial or 
plastid type II fatty acid 
biosynthesis 
   49/70 WP_007222374.1 
51 Amino transferase class-
III              
4-aminobutyrate aminotransferase, [Bacillus 
oceanisediminis]. 
 Members of this family act on 
basic amino acids and the 
subsequent intermediates are 
involved in transamination and 
decarboxylation 
    86/92 WP_033196446.1 
52 Aldehyde dehydrogenase               Hypothetical protein [Bacillus 
oceanisediminis] 
Involved in the oxidation of a 
wide range of 
endogenous/exogenous aliphatic 
and aromatic aldehydes to their 
corresponding carboxylic acids 
and are also involved in 
detoxification 
    76/73 WP_019379464.1 
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54 padR family 
transcriptional      
regulator      
 Hypothetical protein [Bacillus 
oceanisediminis]                 
Transcription regulator      81/77 WP_019379462.1 
56 AcrB/AcrD/AcrF family        
protein             
 Hypothetical protein [Bacillus 
oceanisediminis]                 
Cation/multidrug efflux pump      74/89 WP_019379461.1 
64 Transposase                                 Transposase [Bacillus cereus] DNA repair, replication and   
recombination 
      95/99 WP_002090249.1 
67 Beta-lactamase                             Penicillin-binding protein [Bacillus sp. FJAT-
13831] 
       74/86 WP_017151866.1 
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3.4.3 Modular organisation of Cluster 4: a putative hybrid NRPS-PKS/FAS 
pathway 
NRPSs are organised into modules where each module is responsible for the 
incorporation of one amino acid into the growing chain (section 1.3.2.1). Cluster 4 
consists of 5 NRPS modules (figure 3.11) each containing the classic set of compulsory 
domains i.e. C, A and T-domain. Additional modification domains present in modules 1 
and 2 include an epimerization domain. An odd observation was the presence of two C-
domains in module 2. The presence of a carboxy-terminal located C-domain has 
previously been identified in the microcystin synthase gene cluster where it is involved 
in peptide-bond formation (Tillett et al., 2000). However, as there 5 A-domains and 
therefore amino acid substrates, the function of the additional C-domain in Cluster 4 
requires further investigation. The presence of a C-domain in the first module, is 
reminiscent of lipopeptide pathways such as iturin A (Tsuge et al., 2001), surfactin 
(Bruner et al., 2002) and lichenysin A (Konz et al., 1999). The C-domain in the first 
module is suggested to link the first amino acid to a fatty acid moiety (Miao et al., 2006).  
As previously discussed, PKS/FAS genes in close proximity to the NRPS cluster are 
suggestive of a hybrid pathway between the NRPS and PKS/FAS. The domains 
associated with PKS/FAS biosynthesis (2 KS, ACP and KR) are situated on individual 
ORFs consistent with the type II class of PKS and FAS enzymes. A major difference 
between polyketide and fatty acid biosynthesis is the complete and sequential reduction 
of fatty acids by the KR, DH and ER-domains (Crawford and Townsend, 2010). The 
presence of both a KR and DH-domain (ORF34) and the absence of an ER-domain 
suggest that a polyketide is incorporated instead. The role of the ER-domain can 
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however be provided by a trans-acting ER as seen in the type I PKS (PpsD) involved in 
the production of surface-exposed lipids in Mycobacterium tuberculosis (Siméone et al., 
2007).  
Immediately downstream of the PKS/FAS gene cluster, an ORF predicted to encode an 
unusual aminotransferase class-III gene (AMT) was observed. The presence of an 
AMT-domain is rather interesting as it has previously only been identified in the iturins, 
hepatotoxins (microcystin and nodularin) and prodigiosins (Aron et al., 2005; Moffitt and 
Neilan, 2004). The proposed role of this domain is the conversion of an activated fatty 
acid moiety into a β-amino fatty acid as observed in the biosynthesis of mycosubtilin. 
Mycosubtilin is a lipopeptide in the iturin family whose peptide moiety is modified by the 
addition of a β-amino fatty acid (Duitman et al., 1999).  
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Figure 3.11: Modular organisation of Cluster 4, a putative hybrid NRPS-PKS/FAS pathway. The NRPS genes contained a total of 5 modules with 
each of the three core domains C-A-T present. Modules 1 and 2 each have an epimerization domain and module 2 contains an additional C-
domain. The PKS/FAS like domains exhibited typical type II architecture with each core domain (KSα-KSβ-ACP) located on a discrete ORF. In 
addition to the core domains, the PKS/FAS cluster has a ketoreductase (KR) and an aminotransferase (AMT) domain present. Thioesterase (TE) 
and phosphopantetheine transferase (PPTase) genes were situated upstream of module 1. 
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3.4.4 Prediction of A-domain specificity in Cluster 4 
The A-domain constitutes part of the compulsory domains (C-A-T) required for the 
successful incorporation of the cognate amino acid into the growing chain. Following the 
co-crystallisation of the gramicidin S A-domain with its phenylalanine substrate (Conti et 
al., 1997), amino acids involved in substrate interaction were identified. Amino acids at 
specific positions lining the active site were used as a predictor of the A-domain 
substrate specificity (Stachelhaus et al., 1999; Challis et al., 2000). This forms the basis 
of the NRPSpredictor2 algorithm used to predict substrate specificity of the A-domain 
using the specific signature of amino acids lining the active site (Röttig et al., 2011).  
The predicted cognate amino acids for the 5 different modules in Cluster 4 are listed in 
table 3.8. These included; non-proteinogenic amino acids (ornithine) in modules 2 and 3 
and proteinogenic amino acids (asparagine, threonine and leucine) modules 1, 4 and 5 
respectively. The incorporation of non-proteinogenic amino acids (for example ornithine) 
is characteristic of NRPS enzymes (Hubbard et al., 2000).  
A-domains within module 3 (ornithine) and module 4 (threonine) exhibited the highest 
sequence identity (70% and 100% respectively) to their closest active site signature 
sequence. Lowest sequence identity was observed in A-domains from module 2 
(ornithine) and 5 (leucine) both exhibiting 50% identity to the closest active site 
signature sequence. The low identity to known active site sequence signatures could be 
indicative of A-domains with specificity to yet unknown substrates not represented in 
NRPSpredictor2 reference database. However, the degeneracy of the amino acid 
specificity signature could account for the low identity. For example, 4 different amino 
acid selectivity signatures are known for A-domains specific for leucine whereas 
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tyrosine and cysteine specific A-domains have 3 and 2 selectivity signatures 
respectively (Stachelhaus et al., 1999). Therefore, amino acid specificity signatures are 
not expected to be identical to the signatures of previously characterised A-domains, 
and could explain the low sequence identity observed in the ornithine and leucine 
selective A-domains.  
Amino acid positions in the A-domain specificity signature sequence exhibit variable 
degrees of conservation. For example, amino acids at positions 235 and 517 in the 
active site are strictly conserved as observed in table 3.8. Asparagine (235) and Lysine 
(517) are invariantly conserved and play a role in stabilising the α-amino and α-
carboxylate groups of the cognate amino acid respectively (Stachelhaus et al., 1999). 
Consistent with the observation that the residues Asp235 and Lys517 are invariantly 
conserved, all the A-domains in Cluster 4 had conserved residues at these positions as 
shown in table 3.8. All other residue positions in the active site (236, 239, 278, 299, 301, 
322, 330 and 331) are either moderately or highly variant (Stachelhaus et al., 1999) and 
could further account for the low sequence identities observed by the A-domains 
particularly in modules 2 and 5 both at 50%.  
 
 
 
 
 
 
Results and discussion 
 
109 
 
Table 3.8: Prediction of A-domain amino acid specificity using NRPSpredictor2 
Module 
Amino 
acid  
specificity Identity (%) A-domain active site amino acids  
   
235 236 239 278 299 301 322 330 331 517 
Module 1 Asparagine 60 D S V L I G E V W K 
Module 2 Ornithine 50 D P E N A G F T T K 
Module 3 Ornithine 70 D A K N L G L S N K 
Module 4 Threonine 100 D F W N I G M V H K 
Module 5 Leucine 50 D Y F Y M S Q V E K 
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3.4.5 C-domain classification 
The C-domain plays a role in peptide-bond formation between amino acids during NRP 
biosynthesis (Samel et al., 2007). Classification of C-domains is based on the 
stereochemistry of the amino acids between which they catalyse peptide-bond 
formation. C-domain subtypes include the LcL and DcL C-domains where; LcL domains 
catalyse the peptide-bond formation between L-amino acids and the DcL domains 
catalyse peptide-bond formation between a D and L-amino acid (Rausch et al., 2007). 
In addition, classification of C-domains can be based on functional subtypes and 
include; the heterocyclization (Cyc) and dual E/C domains. Cyc-domains, in addition to 
catalysing peptide-bond formation, play a role in cyclization of the peptide product 
(Rausch et al., 2007). The dual E/C domains however, are involved in both 
epimerization and peptide-bond formation (Balibar et al., 2005). Lastly, the starter C-
domains are involved in the acylation of the first amino acid with a fatty acid or 
polyketide moiety (Miao et al., 2006). The Natural Product Domain Seeker (NaPDos) 
server was used to classify the C-domains in Cluster 4 into their respective sub-types as 
summarised in table 3.9. The C-domains in module 1, 3 and 4 were classified as LcL 
whereas the C-domain in module 2 classified as DcL.  
Although the first module of an NRPS usually lacks a C-domain, the first module of 
Cluster 4 contained a C-domain. It is therefore possible that the C-domain in the first 
module of Cluster 4 belongs to the starter C-domain class. The false clustering of the C-
domain in module 1 as an LcL subtype is not unlikely as starter and LcL C-domains 
share a close evolutionary relationship (Rausch et al., 2007). Interestingly, the C-
domain in module 5 clustered with a recently discovered C-domain subtype, the 
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modified amino acid (modAA) domain. The ‘modified AA’ C-domain subtype (previously 
identified in bleomycin and microcystin pathways), although not experimentally 
characterised, is hypothesised to play a role in amino acid modification (Ziemert et al., 
2012). For example, the dehydration of serine to dehydroalanine is a proposed 
modification of the modAA C-domain subtype although further investigation is required 
(Tillett et al., 2000). 
In addition to functional classification, the NaPDos server is able to identify potential 
pathways from which the C-domain originates. C-domains in Cluster 4 were predicted to 
originate from three different pathways namely; microcystin (module 1, 2 and 5), 
actinomycin (module 3) and syringomycin (module 4). KS or C-domains with amino acid 
identity greater than 85% are likely to belong to pathways that produce similar or 
identical compounds to those of the reference pathway (Gontang et al., 2010). All 
domains showed less than 40% identity at the amino acid level (table 3.9) to their 
respective reference pathways. Therefore, C-domains in Cluster 4 are likely to be 
involved in the biosynthesis of a novel compound.  Alternatively, the low identity could 
be as a result of limited sequence data available within the NaPDos reference 
database. 
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Table 3.9: C-domain subtypes as determined by the NaPDos server 
Module C-domain Class Pathway Identity (%) 
Module 1 1 LCL Microcystin 32 
Module 2 1 DCL Microcystin 33 
Module 2 1 DCL Microcystin 35 
Module 3 1 LCL Actinomycin 23 
Module 4 1 LCL Syringomycin 32 
Module 5   1 ModAA Microcystin 39 
 
 
3.4.5.1 Conserved C-domain motifs 
The conserved C-domain conserved sequence motif HHxxxDGxS/C (referred to as the 
His-motif) is implicated in the catalytic reaction of peptide-bond formation (Bergendahl 
et al., 2002). Alignment of the C-domain amino acid sequences from Cluster 4, resulted 
in the identification of an intact His-motif in all C-domains with the exception of module 3 
and 5 (table 3.10). The C-domain in module 3 contained a ‘Phe’ residue in the place of 
the ‘Gly’ and the first and second ‘His’ residues were replaced by ‘Leu’ and ‘Ser’ 
respectively. In contrast, the C-domain His-motif in module 5 consisted of a ‘Cys’ 
residue in place of the first ‘His’ residue.  
Mutational analysis by Stachelhaus and colleagues (1998), saw the abolition of the 
condensation reaction between the Pro-CAT (proline specific module) and Phe-ATE 
(phenylalanine specific domain) modules following the exchange of the second ‘His’ 
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(HHxxxDG) with a ‘Val’ residue. Deviation from the conserved His-motif has been 
observed in a number of NRPS pathways including pAMDE1 gene cluster (Mizuno et 
al., 2013) as well as the bleomycin, tallysomycin and the zorbamycin gene clusters 
(Galm et al., 2011). The C-domains that show deviation from this motif are thought to be 
inactive or play alternative roles during biosynthesis (Galm et al., 2011). 
 
Table 3.10: Conserved amino acid motifs in each C-domain 
Module C-domain motif 
H H x x x D G     x     S/C 
Module 1 H H L A I D G    W     S 
Module 2 H H   L L M D G    W     S 
Module 2 H H L L L D G    W     S 
Module 3 L S L N T D F      I       S 
Module 4 H H I I F D G    W     S 
Module 5 C H L I F D G    W     S 
 
 
3.4.6  Conserved PCP-domain motifs 
The conserved sequence motif “LGG H/D S L/I” is required for the attachment of the 4’-
phosphopanteitheine co-factor that facilitates activation of the PCP-domain 
(Vollenbroich et al., 1993) was present in all PCP-domains from Cluster 4. The serine 
residue in this conserved motif is necessary for the attachment of the co-factor and was 
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conserved in all PCP-domains and is indicative of functional PCP-domains. Slight 
deviation from the conserved PCP-domain motif was observed in module 1, where a 
‘Met’ residue replaced the ‘Leu’ residue. The core of the conserved motif (H/D S L/I) is 
considered as the binding site of the 4’-phosphopanteitheine co-factor and the effect of 
the observed substitutions (Met in place of Leucine) that lie outside of the core motif are 
yet unknown. 
 
Table 3.11: Conserved 4’-phosphopantetheine binding site in PCP-domains 
Module PCP motif 
L G G H/D S L/I 
Module 1 (PCP1) M    G G D S I 
Module 2 (PCP1) L G G D S I 
Module 3 (PCP1) L G G H S L 
Module 4 (PCP1) L G G D S I 
Module 5 (PCP2) L G G D S L 
 
 
3.4.7 Cluster 4 summary:  a putative lipopeptide pathway 
Cluster 4 consists of 4 NRPS genes with a combined total of 5 modules. Located in 
close proximity, are PKS/FAS associated genes situated on an individual ORFs 
consistent with the type II class of these enzyme families. The presence of both NRPS 
and PKS/FAS genes suggests a possible hybrid pathway. In addition to consisting of 
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both NRPS and PKS/FAS, various characteristics of Cluster 4 are consistent with 
lipopeptide pathways described below.   
Although usually absent, the first module in Cluster 4 contains a C-domain (Lautru and 
Challis, 2004). This unusual C-domain has previously been proposed to play a role in 
the coupling of a fatty acid group to an amino acid group (Miao et al., 2006). 
Furthermore, Cluster 4 contains an AMT-domain that is known to play a role in the 
conversion of fatty acids into β-amino fatty acid groups (Duitman et al., 1999). The 
AMT-domain has been found in only a few pathways as mentioned previously including 
cyanobacterial hepatotoxins, prodigiosins and lipopeptides (iturin family). Prodigiosin 
production is a characteristic feature of organisms in the genus Serratia and are also 
produced by a few other organisms for example those in the order Actinomycetales 
(Khanafari et al., 2006; Williams, 1973). Therefore, Cluster 4 is likely to encode a 
lipopeptide because these compounds are frequently produced by organisms in the 
genus Bacillus (Raaijmakers et al., 2010). Three lipopeptide families commonly found in 
the genus Bacillus include; iturins, surfactins and fengycins (Raaijmakers et al., 2010). 
A distinguishing characteristic of the different lipopeptide families is the modification of 
their fatty acid moiety, where surfactins and fengycins both incorporate a β-hydroxy fatty 
acid whereas the iturins incorporate a β-amino fatty acid (Raaijmakers et al., 2010). 
Therefore, the presence of an AMT-domain, associated with the conversion of fatty 
acids into β-amino fatty acid groups likely suggests the production of an iturin type 
lipopeptide.  
ORF44 was annotated as a transporter protein by antiSMASH2.0. A BLAST analysis of 
this ORF identified a hypothetical protein sharing 75% identity as the closest related 
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sequence originating from (B. oceanisediminis). This hypothetical protein contains a 
PvdE region that functions as an ABC-type siderophore export system. A TransportDB 
analysis (Ren et al., 2004) yielded similar results although the closest related sequence 
was a pyoverdin export ABC transporter from Thermosynechococcus elongatus BP-1 at 
42% identity. This discrepancy is likely due to insufficient reference sequence data 
within the database. These two analyses however both implicate a siderophore type 
export system related to pyoverdin. Pyoverdin is a siderophore produced by 
Pseudomonas aeruginosa (Cox and Adams, 1985).  
Siderophores are low molecular weight chelating compounds specific for ferric iron 
secreted by micro-organisms under iron-limiting conditions (Neilands, 1995). Their 
biosynthesis follows either an NRPS-dependent or NRPS-independent mechanism 
(Miethke and Marahiel, 2007). AntiSMASH2.0 is able to discriminate between NRPS-
dependent/independent siderophore pathways, although the software classifies NRPS-
dependent siderophores as NRPS. The presence of a transporter associated with 
siderophore export could therefore be suggestive of Cluster 4 being involved in the 
production of an iron-chelating compound. Lipopeptides have previously been identified 
that exhibit siderophore activity such as the serobactins (Rosconi et al., 2013), 
marinobactins and aquachelins (Martinez and Butler, 2007). Further experimentation 
using a siderophore specific activity assay is however necessary to confirm this 
hypothesis.  
The second transport associated ORF; ORF56 was classified into the AcrB/AcrD/AcrF 
family of proteins sharing 74% sequence identity (antiSMASH2.0). This family of 
proteins among other substrates is associated with acriflavine resistance (Visalli et al., 
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2003). A further TransportDB analysis of this ORF shows a close relationship to the 
acriflavine resistance protein corresponding to the previous analysis. The AcrB and 
AcrD homologs are also involved in the efflux of hydrophobic inhibitors such as fatty 
acids and bile salts in E. coli (Ma et al., 1995). Therefore, because the ORF56 
transporter in Cluster 4 shows homology towards AcrA/AcrB, it is likely that the 
compound encoded by Cluster 4 is hydrophobic in nature. This is consistent with the 
hypothesis that a lipopeptide type of compound is produced by Cluster 4.   
 
3.4.8 Gene cluster comparison 
BLASTn analysis consistently indicated that the Cluster 4 NRPS genes shared highest 
sequence identity to NRPS genes from B. oceanisediminis 2691 (table 3.7). The B. 
oceanisediminis 2691 genome, publicly available, was subsequently submitted to 
antiSMASH2.0 to determine whether a pathway similar to Cluster 4 was present. This 
analysis led to the identification of a NRPS pathway in B. oceanisediminis 2691 
exhibiting a similar genetic organisation and composition to Cluster 4 although several 
differences were evident (figure 3.12). 
The absence of the PKS/FAS genes in B. oceanisediminis 2691 was a notable 
difference because the resulting product possibly lacks the hybrid properties as seen in 
Cluster 4. Both gene clusters contain a padR and asnC transcriptional regulator genes, 
however, an additional padR transcriptional regulator is present in B. oceanisediminis 
2691. This suggests that although these two clusters possibly utilise similar regulatory 
mechanisms, they could require different activation triggers. Additional genes 
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associated with biosynthesis present in B. oceanisediminis 2691 but absent from 
Cluster 4 include; methyltransferase, isochorismatase, oxidoreductase, 2 additional 
ABC transporters and an ABC-2 type transporter. The presence of tailoring enzymes 
such as methyltransferase, isochorismatase and oxidoreductase are indicative of 
different product modifications that provide further support to the notion that two 
different products are encoded by the NRPS pathway in B. oceanisediminis 2691. 
 
3.4.8.1 Comparison of A-domain specificities 
Comparison of the A-domain specificity between the two pathways is summarised in 
(table 3.12). Several differences in A-domain specificity were evident. For example, 
module 1 in Cluster 4 is specific for asparagine whereas the A-domain in ORF266 
(corresponding to module 1 in the B. oceanisediminis 2691) was specific for histidine. 
The fifth module in Cluster 4 and B. oceanisediminis 2691 is specific for leucine and 
isoleucine respectively and all other modules share the same substrate specificities. 
This provides further evidence that these two gene clusters unlikely encode the same 
compound.  
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B. oceanisediminis 2691 
Cluster 4 
Regulation Biosynthesis associated Transport associated 
Other 
Key: 
Figure 3.12: Comparison of Cluster 4 and an NRPS gene cluster identified in B. oceanisediminis 2691. 
Genes present in both clusters are highlighted with an arrow.  One major difference is the absence of the 
PKS/FAS genes from B. oceanisediminis 2691. Secondly, the ORFs predicted to encode the thioesterase 
and phosphopantetheinyl transferase are oriented in opposite directions between the two clusters and are 
highlighted with red arrows.   
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Table 3.12: Comparison of A-domain substrate specificities 
Cluster 4 B. oceanisediminis 2691 
Module 
Amino acid 
substrate Identity (%) 
Active site 
signature ORF 
Amino acid 
substrate Identity (%) 
Active site 
signature 
Module 1 Asparagine  60 DSVLIGEVWK ORF266 Histidine 70 DSVLIAEVWK   
Module 2 Ornithine  50 DPENAGFTTK ORF263 Ornithine 50 DPENAGFTTK 
Module 3 Ornithine 70 DAKNLGLSNK ORF261 Ornithine 70 DAKNLGLSNK 
Module 4 Threonine 100 DFWNIGMVHK ORF259 (1) Threonine 100 DFWNIGMVHK 
Module 5 Leucine 50 DYFYMSQVEK ORF259 (2) Isoleucine 50 DYFFMSQVEK 
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3.4.9 Expression analysis of Cluster 4 
As discussed above, Cluster 4 shows characteristics typical of a hybrid gene cluster due 
to the presence of both NRPS and PKS/FAS genes in close proximity. This section 
focuses on the experimental approach taken to determine whether Cluster 4 is 
expressed in any of the culture conditions under which biological activity was detected. 
Of particular interest was determining the expression of Cluster 4 in Zobell medium as 
extracts from this medium exhibited anti-fungal activity. Cluster 4 is hypothesised to 
encode a lipopeptide, a group compounds that typically exhibit anti-fungal activity 
(Pathak and Keharia, 2014). Therefore, if Cluster 4 is expressed in Zobell medium this 
could provide strong evidence for the production of a lipopeptide.  Specific primers were 
subsequently designed for ORF39 (NRPS) and ORF48 (KS) as representative genes of 
Cluster 4 (figure 3.13). 
 
 
Figure 3.13: Specific primers were designed to ORF39 (NRPS) and ORF48 (FAS/PKS) that are 
demarcated in green above.   
 
Total RNA was extracted from PE8-15 cultures grown to mid-logarithmic and stationary 
phase in ACM and Zobell media. Although SMs are frequently produced during the 
stationary phase of microbial growth (Sánchez et al., 2010), exceptions have been 
observed (Nieselt et al., 2010). Therefore, in order to avoid bias, expression of 
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representative genes from Cluster 4 was investigated in both logarithmic and stationary 
phase cultures of PE8-15. Following amplification of cDNA, ORF39 and ORF48 genes 
were detected in Zobell medium during mid-logarithmic growth stage (figure 3.14). This 
is contrast to ORF39 and ORF48 that were not detected in ACM medium (figure 3.15). 
The observation that Cluster 4, a putative iturin lipopeptide pathway, is expressed 
during the mid-logarithmic stage is surprising because the iturin lipopeptides are known 
to be expressed during late stationary phase (Raaijmakers et al., 2010). However, 
depending on the growth conditions, changes in expression patterns may be observed.   
These results unfortunately are not sufficient to associate the anti-fungal activity with 
Cluster 4. This is because the anti-fungal activity of PE8-15 was detected in a 2 week 
old culture grown in McCartney vials whereas transcription of Cluster 4 genes was 
detected in mid-log cultures grown in a conical flask. The difference in culture vessels 
used could affect the growth kinetics and subsequently the expression of SM pathways. 
Therefore, subsequent experimentation is required to screen for anti-fungal activity in 
both mid-log and stationary-phase cultures and provide more concrete correlation 
between Cluster 4 and the observed biological activity. 
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Figure 3.14: Reverse transcription PCR to detect the expression of ORF39 (NRPS) in isolate PE8-15. 
Lane 1: 1kb DNA ladder. Lane 2: Positive control (PE8-15 genomic DNA). Lane 3: Amplification of cDNA 
prepared from an ACM mid-log culture (A/M). Lane 5: Amplification of cDNA prepared from an ACM 
stationary-phase culture (A/S). Lane 7: Amplification of cDNA prepared from a Zobell mid-log culture 
(Z/M). Lane 9: Amplification of cDNA prepared from a Zobell stationary culture (Z/S). Lane 4, 6, 8, 10: 
Represent negative controls for each reaction. Expected PCR product size is 950b. Amplicons were 
resolved in a 1% [w/v] TAE agarose gel. 
 
 
 
 
 
 
  λPst        +          A/M          -        A/S         -       Z/M          -       Z/S           -     
10000bp 
1000bp 
750bp 
1500bp 
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Figure 3.15: Reverse transcription PCR to detect the expression of ORF48 (PKS/FAS gene). Lane 1 and 
12: DNA molecular marker (lambda DNA digested with PstI). Lane 2: Positive control (PE8-15 genomic 
DNA). Lane 3: Negative control (water as a template). Lane 4: Amplification of cDNA prepared from an 
ACM mid-log culture. Lane 6: Amplification of cDNA prepared from an ACM stationary phase culture. 
Lane 8: Amplification of cDNA prepared from a Zobell mid-log culture. Lane 10: Amplification of cDNA 
prepared from a Zobell stationary culture. Lane 5, 7, 9, 11: Represent negative controls for each reaction. 
Expected product size is 856bp. Amplicons were resolved in a 1% [w/v] TAE agarose gel. 
 
 
                 λPst    +      (n)     A/M    -     A/S    -    Z/M      -   Z/S      -    λPst  
11501bp 
1700bp 
1093bp 
805bp 
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 Conclusion 
We report here a potentially novel hybrid NRPS-PKS/FAS gene cluster hypothesised to 
be involved in the biosynthesis of a lipopeptide. In addition, 10 additional SM pathways 
were identified by genome mining and represent an untapped reservoir of potentially 
novel bioactive compounds. We demonstrate the significance of sequence-based 
methods (PCR and WGS) in NP discovery as they are able to identify the full 
complement of an organisms SM repertoire in a more efficient and cost-effective 
manner circumventing costly and time-consuming analytical methods such as NMR and 
MS. Furthermore, although well-known for their ability to produce an array of SMs,  
these results show that the genus Bacillus is still a promising source of novel chemistry 
in NP discovery.  
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Chapter 4  General discussion and final 
conclusion 
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 General discussion and final conclusion 
Drug-resistance among clinically relevant micro-organisms is currently a major health 
crisis globally (Walsh and Amyes, 2004). Drug-resistant pathogens have serious 
negative implications on patient health care. For example, infections caused by drug-
resistant pathogens result in extended hospital stays (increased medical costs) and are 
associated with higher mortality rates among patients in comparison to drug susceptible 
infections (Cosgrove, 2006). Furthermore, treatment options for drug-resistant infections 
are significantly limited as the available drugs are rendered ineffective (Falagas and 
Bliziotis, 2007). The lack of treatment options and a drastic decline in the discovery of 
novel drugs, underpins the urgent and continuous need for new drug candidates.  
NPs are compounds produced by living organisms including bacteria, fungi and plants 
(Ji et al., 2009) usually as a result of secondary metabolism (Williams et al., 1989). They 
are important for drug discovery as they exhibit diverse biological activities that include 
anti-microbial, anti-cancer and anti-inflammatory properties. The “Golden era of 
antibiotics”, a period when the majority of antibiotics in use today were discovered, 
highlights the importance of micro-organisms as producers of bioactive NPs relevant to 
drug discovery (Lewis, 2012). The drugs discovered during this period were 
predominantly isolated from soil-dwelling bacteria and fungi. Unfortunately, discovery of 
novel compounds in these environments diminished over time (Daniel, 2004), and this 
has led to increased interest in alternative sources such as marine-dwelling organisms. 
 Invertebrates such as sponges, tunicates, soft-corals and bryozoans constitute the 
largest portion of the marine animal diversity (Leal et al., 2012). These animals are 
known for their production of bioactive NPs and hence important for drug discovery 
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(Perdicaris et al., 2013; Ankisetty et al., 2013) However, a major bottleneck in marine 
drug development is that these compounds often occur at very low concentrations 
within the invertebrate tissue, thus requiring large amounts (tonnes) of invertebrate 
biomass to obtain sufficient bioproduct (Proksch et al., 2002; Proksch et al., 2003). 
Therefore, marine invertebrates are not a sustainable and environmentally friendly 
source of NPs.  
Marine invertebrates often form symbiotic relationships with a diverse consortium of 
micro-organisms. Interestingly, NPs originally isolated from marine invertebrates, show 
high similarity to those exclusively of microbial origin (Piel et al., 2004). This 
subsequently led to the hypothesis that marine invertebrate-associated bacteria are the 
true producers of these compounds. Experimental evidence for this hypothesis was 
presented by Wilson and colleagues (2014) described in section 1.5.3. In comparison to 
invertebrates, micro-organisms represent an alternative and most importantly a 
sustainable source of marine NPs.   
The current study was aimed at identifying novel NPs from micro-organisms associated 
with novel marine invertebrate species endemic to the South African coast. The 
methodology consisted of two components; a culture-dependent and a culture-
independent strategy.  
The culture-based approach involved the isolation of bacteria associated with the 
invertebrate specimens (section 2.4.2) using conventional microbiology methods. A 
wide range of media were used to access as much of the microbial and chemical 
diversity as possible. Furthermore, the bacterial isolates were screened for anti-
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microbial activity against a panel of indicator strains including the multi-drug resistant E. 
coli 1699 strain. The significance of inhibitory activity against this strain is that because 
it is resistant to the majority of standard antibiotics (Appendix F), the compounds 
produced by the bacteria likely have a novel mechanism of action (Hentschel et al., 
2001). This study addresses two major bottlenecks in drug discovery (section 1.6); (i) 
NP discovery from a sustainable source (ii) NP discovery from underexplored 
environments less likely to result in the re-discovery of known compounds.  
The primary screening process involved screening isolates on the medium on which 
they were isolated. This was a major limitation in this study as laboratory conditions are 
often not conducive for SM expression. This theory stems from the analysis of microbial 
genome data that has revealed the presence of numerous silent SM pathways in even 
well-studied micro-organisms (Aigle et al., 2014; Ikeda et al., 2003). Silent SM pathways 
encode potentially novel compounds and are therefore of great importance to NP 
discovery. OSMAC (section 1.8.2) is aimed at stimulating the expression of these silent 
SM pathways and formed an integral part of the secondary screening process. Among 
the Bacillus bioactive isolates, the number of strains active against the multi-drug 
resistant E. coli strain doubled from 3 to 6 strains following the use of OSMAC (section 
3.2.3). However, this only represented a very small number of different combinations 
which could have been tested and there is much wider range of media and treatments 
that could be used to maximise SM production (Bertrand et al., 2013; Doull et al., 1994; 
Rateb et al., 2011). Therefore, these findings indicate that laboratory conditions may 
indeed be sub-optimal for microbial SM production. As shown in this study, OSMAC is 
necessary to improve discovery of bioactive compounds from micro-organisms.  
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The second strategy employed was a culture-independent approach that involved 
screening of bioactive bacteria for SM genes by PCR and WGS of a suitable strain. 
PCR played an important role in the de-replication and identification of bacterial isolates 
likely to produce novel SMs.  
PCR as a de-replication tool works on the principle of the degree of sequence similarity 
that SM genes exhibit (usually conserved domains such as the A-domain or KS) 
towards characterised pathways (Gontang et al., 2010). A high sequence similarity to 
known pathways usually suggests that the pathway from which the query sequence 
originates is involved in the production of a similar compound. In this study, the need for 
de-replication arose from the identification of isolates that shared very high 16S rRNA 
sequence similarity (>98%) to reference sequences in the database. Furthermore, the 
majority of the bioactive isolates (Bacillus) shared the same closest relative according to 
the BLAST analysis yet displayed different anti-microbial profiles. An NRPS amplicon 
amplified from the Bacillus strain PE8-15 exhibited low sequence similarity (65% and 
50% respectively) to its reference sequences in the database. Based on the principle of 
PCR de-replication, this revealed a potentially novel NRPS pathway within PE8-15. The 
rest of the NRPS amplicons derived from the other Bacillus isolates showed a high 
sequence similarity (>90%) to their reference sequences. It is not conclusive evidence 
that NRPS amplicons with a high sequence similarity to their reference sequences 
originate from previously characterised pathways. Nonetheless, the pathways of origin 
are publicly available and could be under investigation.  
Traditionally, de-replication, involves the rapid identification of known compounds 
present in a mixture by chromatography (HPLC), MS and NMR analyses. These 
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techniques however, require significant amounts of the compound being analysed and 
are therefore severely limited by the levels of expression of a compound by the 
organism (Lin et al., 2008). Although recent advancements have improved the 
sensitivity of analytical equipment, for example the use of microcoil and microtube 
probes for NMR (Dalisay and Molinski, 2009) these tools may not be readily available to 
research groups. In addition, most analytical methods (NMR, LC-MS and UV spectra) 
are not high-throughput  and thus make the initial de-replication process rather time and 
labour intensive (Wong et al., 2012). Lastly, these analytical methods de-replicate 
compounds based on patterns (physicochemical properties) and do not account for 
novel biological properties (Wong et al., 2012). This could result in compounds 
belonging to well characterised classes but still exhibiting novel mechanisms of action 
being undetected (Wong et al., 2012). 
In comparison, PCR offers various advantages as a de-replication tool over the use of 
more conventional chemical analysis; (i) it facilitates selective screening for NPs genes 
(ii) detects SM associated genes independent of their expression and therefore not 
limited by repressed pathways (silent pathways) (iii) does not require the need for costly 
and time-consuming extract preparation and chemical analysis for the initial de-
replication process (iv) it de-replicates isolates based on the SM genes. Therefore, 
bacterial strains are selected based on their potential to produce novel SMs as opposed 
to their phylogenetic affiliation.  Furthermore, PCR facilitates the prioritisation of strains 
for further investigation thus likely to reduce the number of strains to be analysed (Liu et 
al., 2012). 
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Exhibiting the most diverse anti-microbial profile and containing a potentially novel 
NRPS pathway, the genome of isolate PE8-15 was sequenced (WGS). Genome mining 
identified a potentially novel NRPS pathway. Informatics-based characterisation of 
Cluster 4 predicted the possible production of a lipopeptide compound (chapter 3).  
The discovery of a potentially novel lipopeptide is significant as these compounds have 
numerous industrial applications that extend beyond therapeutic use. For example, in 
the cosmetic industry, lipopeptides are used as dermatological products due to their low 
skin irritation properties (Mandal et al., 2013). In the food industry, lipopeptides are used 
as emulsifiers (Meena and Kanwa, 2015). Lipopeptides have also been shown to have 
important application in the agriculture sector due their antagonistic properties against 
phytopathogens (Cawoy et al., 2015). This group of compounds can also act as 
biosurfactants (microbial-derived surfactants) and are an environmentally friendly 
alternative for environmental clean-ups compared to their synthetic counterparts 
(Varadavenkatesan and Murty, 2013).  
This study demonstrates that WGS is a superior tool in the discovery of SM pathways 
compared to alternative methods such as DNA library screening. DNA library 
preparation requires the use of vectors into which DNA fragments are cloned. Currently 
available vectors such as fosmids, although suitable for longer inserts, are limited to an 
insert size of less than 40kb (Williams et al., 2012). However, complete SM pathways 
can reach up to lengths upwards of 90kb in size (Ichikawa et al., 2013).  In the context 
of the current study, fosmid vectors would not be appropriate as Cluster 4 spans a total 
length of approximately 59kb. Alternative vector systems such as the bacterial artificial 
chromosomes (BAC) are able to carry inserts up to 300kb in size (Shizuya et al., 1992). 
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However, BAC vectors require the need to trim unwanted sequences from the inserts 
and because the DNA is randomly fragmented, genes from the same cluster are 
frequently situated on different clones (Kouprina and Larionov, 2006). Furthermore, in 
terms of preparation time and labour intensity, WGS uses next generation sequencing 
platforms that are fast and negate the need for tedious and time consuming DNA library 
preparation.  
As previously discussed, SMs (or NPs) are often produced at low concentrations by the 
host organism. Improving compound titres can be achieved by large-scale fermentation 
of the native producer (Ongley et al., 2013). However, the native host may exhibit poor 
growth properties inappropriate for large-scale fermentation (Lopanik, 2014). 
Alternatively, large-scale fermentation can be achieved by heterologous expression of 
the genes of interest in a non-native host (Chen et al., 2010). This requires the cloning 
of the complete gene cluster into a suitable vector and subsequent transfer to a non-
native host. We propose transformation-associated recombination (TAR) as a suitable 
approach to completely clone Cluster 4. A major advantage of TAR cloning is that it 
facilitates selective isolation of the complete pathway of interest from the genome and is 
not limited by the size of the insert DNA (Noskov et al., 2003). This system has been 
successfully used to clone the complete taromycin A gene cluster (Yamanaka et al., 
2014).  
A major advantage of heterologous expression (as opposed to large-scale fermentation 
of the native host), is that well-studied expression hosts are readily available and may 
not require extensive optimisation for large-scale fermentation. Furthermore, 
environmental isolates of interest are usually not fully characterised and detailed 
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information for example on their potential pathogenicity is often lacking. Therefore, the 
use of a well-studied heterologous host is an advantage due to the strict safety 
regulations in place for the industrial production of pharmaceuticals (Zobel et al., 2015). 
For example, an appropriate host for the expression of Cluster 4 (NRPS pathway 
predicted to encode a lipopeptide) would be B. subtilis that has previously been used as 
a heterologous host for NRPS pathways (Eppelmann et al., 2001). 
Future work would entail the expression of Cluster 4 by heterologous expression using 
the previously described TAR cloning system. Once successfully expressed, the purified 
product encoded by Cluster 4 will be screened for a range of biological activities with 
clinical relevance. Most importantly however, structural-elucidation of the compound 
biosynthesised by Cluster 4 will be performed and analysed for novelty. Furthermore, 
gene-knockout studies may be necessary to confirm which genes within Cluster 4 that 
are actively involved in biosynthesis. In addition to complete characterisation of Cluster 
4, it would be important to investigate the other SM pathways in PE8-15 for novel 
compounds/bioactivity. Furthermore, it would be worthwhile to re-screen isolates that 
previously did not exhibit any bioactivity. This will however involve the use of OSMAC 
as this was not incorporated into the initial screening process. Lastly, the non-bioactive 
strains will be screened by PCR using a range of primers targeting different classes of 
SM pathways.  
The current study highlights the importance of the South African coastline and endemic 
marine invertebrate species as a source of bioactive micro-organisms potentially 
producing clinically relevant biomolecules. This is in contrast to previous studies where 
the marine invertebrates were the sole focus for marine bio prospecting (section 1.9). 
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Currently, there is only one established academic drug discovery and development 
platform in Africa, the H3-D Drug Discovery & Discovery Centre at the University of 
Cape Town (South Africa) (H3-D, 2015). A major focus of this organisation is to link 
basic and clinical studies. These initiatives are particularly important for developing 
communities such as those in Sub-Saharan Africa where the increase of drug-resistant 
pathogens (e.g. the multi-drug resistant TB strain), high prevalence of HIV/AIDS, wide-
spread poverty and high medical costs are major challenges in the healthcare sector. 
Therefore, as micro-organisms are considered a sustainable source of NPs, this readily 
accessible resource in South Africa should be further exploited for the expansion of the 
drug discovery platform in South Africa. 
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Appendix A  
 
Buffers and stock solutions 
Buffers and stock solutions used in this study are listed below. Solutions marked with an 
asterisk (*) were autoclaved at 121°C for 20 minutes at 15 psi. Alternatively, 
solutions/buffers not amenable to autoclaving were sterilized using 0.22 µm filters.  
 
Table A.1: Buffers and stock solutions used in this study 
Buffers and stock solutions 
50 X TAE buffer (*) NaCl solution (5 M) (*) 
242 g Tris base 146.1 g 
18.6 g EDTA 500 ml of sterile dH2O 
57.1 ml glacial acetic acid 
 sterile dH2O to a final volume of 1 L NaOH/SDS (solution 2)* 
 
0.2 M NaOH 
Ampicillin stock  1% [w/v] SDS 
100 mg/ml ampicillin in sterile dH2O 
 Stored at -20° C Potassium acetate pH 4.8 (solution 3) 
 
29.5 ml glacial acetic acid  
Ammonium acetate (4 M) KOH pellets to pH 4.8 
15.42 g  100 ml of sterile dH2O 
50 ml of sterile dH2O 
 
 
TE buffer  pH 8 (10 mM Tris-HCl; 1 mM) (*) 
Breaking buffer 10 mM Tris-HCL  
2% Triton X100 1 mM EDTA 
1% [w/v] SDS 
 100 mM NaCl Wolfe’s mineral solution 
10 mM Tris-HCl pH 8 Nitrilotriacetic acid – 1.5 g 
1 mM EDTA MgSO4-7H2O – 3 g 
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CTAB/NaCl solution (*) MnSO4-H2O – 0.5 g 
10% [w/v] CTAB NaCl – 1 g 
0.7 M NaCl FeSO4-7H2O – 0.1 g 
 CaCl2 – 0.1 g 
DEPC treated water (*) CoCl2 – 6H2O – 0.1 g 
0.1% diethyl pyrocarbonate ZnSO4-7H2O – 0.1 g 
Final volume of 1L dH2O CuSO4-5H2O – 0.01 g 
 AIK(SO)4-12H2O – 0.01 g 
DNA loading buffer Boric acid – 0.01 g 
20% [v/v] glycerol 
 0.1 M EDTA Wolfe’s vitamin solution 
1% [w/v] SDS Pyridoxine hydrochloride – 10 mg 
0.25% bromophenol blue Thiamine-HCl  - 5 mg                            
 Riboflavin – 5 mg 
Ethidium bromide staining solution Nicotinic acid – 5 mg 
200 mg ethidium bromide powder Calcium D-(+)-pantothenate – 5 mg 
20 ml of sterile dH2O  p-Aminobenzoic acid – 5 mg 
 Thioctic  acid – 5 mg 
GTE (solution 1) (*) Biotin – 2 mg 
50 mM glucose Folic acid – 2 mg 
25 mM Tris-HCl Vitamin B12 – 0.1 mg 
10 mM EDTA dH2O – 1 L 
 
 Lysis buffer X-gal 
25 mM Tris-HCl pH 8 0.6 g x-gal 
50 mM glucose 30 ml dimethylformamide  
10 mM EDTA Stored at -20° C 
25 mg/ml lysozyme powder 
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Appendix B  
 
Isolation and growth media used in this study 
Culture media used in this study are listed in table B.1 and table C.1 and unless stated 
otherwise, were autoclaved at 121°C for 20 minutes (15 psi).  Agar was added at a 
concentration of 15 g/L for the preparation of solid media and pH adjusted using 32% 
HCl and1 or 10 M NaOH.  
 
Table B.1: List of culture media used for the of isolation marine invertebrate 
associated bacteria  
Media Constituents Quantity/L of dH20 
   
 HEPES 2.38 g 
 Sodium pyruvate 3 g  
 Yeast extract 0.1 g 
 Soybean peptone 3 g  
 NaNO3 0.34 g 
 K2HPO4 0.1 g 
 MgSO4* 7 H2O 0.15 g 
Activated charcoal Media (pH 7.0) Activated charcoal  3 g  
   
 Mannitol 15 g 
 K2HPO4 0.3 g 
 MgSO4* 7 H2O 0.3 g 
 10% Sodium molybdate solution 0.1 g 
 10% FeCl3 0.05 g 
 NaCl 18 g 
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 MgCl2 2 g 
 KCl 0.525 g 
Ashby's nitrogen free media (pH 7.5) CaCl2 0.3 g 
   
 Solution 1 - NaNO3  (15 g/L) 100 ml 
  Solution 2 - K2HPO4 (2 g/L) 10 ml 
 Solution 3 - MgSO4*7 H2O (3.75 
g/L) 
10 ml 
 Solution 4 - CaCl2*2 H2O  (1.8 g/L) 10 ml 
 Solution 5 - Citric acid (0.3 g/L) 10 ml 
 Solution 6 - Ammonium ferric 
citrate (0.3 g/L) 
10 ml 
 Solution 7 - Na2EDTA (0.05 g/L) 10 ml 
 Solution 8 - Na2CO3 (1 g/L) 10 ml 
 Wolfe's mineral solution 1 ml 
 NaCl 18 g 
 MgCl2 2 g 
BG 11 (pH 7.5) KCl 0.525 g 
   
 D-Glucose 4 g 
 Yeast extract  4 g 
 Malt extract 10 g 
 CaCO3 2 g 
 NaCl 24 g 
 MgCl2 5.3 g 
 KCl 0.7 g 
Glucose-Yeast-Malt (GYM) CaCl2 0.1 g 
   
 Glucose 10 g 
 Yeast extract 5 g 
 Starch 10 g 
 Tryptone 5 g 
 MgSO4* 7 H2O 2 g 
 CaSO4 * 2 H2O 2 g 
 NaCl 18 g 
 MgCl2 2 g 
 KCl 0.525 g 
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Modified 172F (pH 7.5) CaCl2 0.075 g 
   
Oatmeal (ISP Media 3) Jungle oats easy (no sugar) 40 g 
   
 Glucose 1 g 
 (NH4)2SO4 0.25 g 
 Peptone 0.15 g 
 Yeast extract 0.15 g 
 NaCl 18 g 
 MgCl2 2 g 
 KCl 0.525 g 
Planctomycetes medium CaCl2 0.075 g 
   
 KNO3 0.2 g 
 (NH4)2 HPO4 0.02 g 
 MgSO4* 7 H2O 0.01 g 
 CaCl2 * 2 H2O 0.005 g 
 FeCl2 0.5 g 
 NaCl 18 g 
 MgCl2 2 g 
 KCl 0.525 g 
Pringsheim's Cyanobacteria 
specific media 
CaCl2 0.075 g 
   
 Casein acid hydrolysate 0.5 g 
 Dextrose 0.5 g 
 K2HPO4 0.3 g 
 MgSO4 anhydrous 0.024 g 
 Proteose peptone 0.5 g 
 Sodium pyruvate 0.3 g 
 Starch soluble 0.5 g 
Reasoners 2 agar (pH 7.2) Yeast extract 0.5 g 
   
 dH2O 250 ml 
 Sea water 750 ml 
 Wolfe's mineral solution  5 ml 
Seawater agar Wolfe's vitamin solution 10 ml 
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 Peptone 5 g 
 Beef extract 3 g 
 NaCl 18 g 
 MgCl2 2 g 
 KCl 0.525 g 
Shivji's nutrient  agar (pH 7.5) CaCl2 0.075 g 
   
 Sponge extract  10 g 
 NaCl 18 g 
 MgCl2 2 g 
 KCl 0.525 g 
Sponge extract media CaCl2 0.075 g 
   
 TSB 3 g 
 NaCl 18 g 
 MgCl2 2 g 
 KCl 0.525 g 
Tryptocase soya agar (pH7.5) CaCl2 0.075 g 
   
 TSB 3 g 
 NaCl 18 g 
 MgCl2 2 g 
 KCl 0.525 g 
Tryptocase soya agar (pH4.5) CaCl2 0.075 g 
   
 Yeast extract 1.25 g 
 Peptone 3.75 g 
 NaCl 18 g 
 MgCl2 2 g 
 KCl 0.525 g 
Zobell 1/4 strength (ZBA) CaCl2 0.075 g 
   
 Yeast extract 1.25 g 
 Peptone 3.75 g 
 NaCl 18 g 
 MgCl2 2 g 
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 KCl 0.525 g 
Zobell + 0.0001% crystal violet CaCl2 0.075 g 
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Appendix C  
 
Table C.1: General purpose culture media used in this study 
 
Media Constituents Quantity/L of dH20 
Lysogeny broth (LB)  
 Tryptone 10 g 
 Yeast 5 g 
 NaCl 10 g 
Sloppy agar (semi-solid LB)   
 Tryptone 10 g 
 Yeast extract 5 g 
 NaCl 10 g 
 Agar 7.5 g 
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Appendix D  
 
Table D.1: Nextera sequencing adapter sequences 
Adapter      Sequence 
N504 internal 
  
AATGATACGGCGACCACCGAGATCTACACAGAGTAGATCGTCGGCAGCGTC 
    
N504 end 
  
AATGATACGGCGACCACCGAGATCTACACAGAGTAGATCGTCGGCAGCGTC 
    
N706 internal 
  
CAAGCAGAAGACGGCATACGAGATCATGCCTAGTCTCGTGGGCTCGG 
    
N706 end 
  
CAAGCAGAAGACGGCATACGAGATCATGCCTAGTCTCGTGGGCTCGG 
    
Transposase 
  
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG 
    
Transposase 
  
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG 
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Appendix E  
 
Table E.1: Accession numbers for Bacillus strains used for the in silico analysis 
of secondary metabolite distribution 
B. anthracis B. thuringiensis B. cereus B. subtilis B. weihenstephanensis B. mycoides 
NC_003997.1 NC_005957.1 NC_004722.1 NC_000964.3 NC_010184.1 NZ_CP007626.1 
NC_005945.1 NC_020376.1 NC_012472.1 NC_020507.1 
  NC_012659.1 NC_014171.1 NC_011658.1 NC_014976.1 
  NC_012581.1 NC_01877.1 NC_011773.1 NC_018520.1 
  NC_007530.2 NC_018500.1 NC_003909.8 NC_020244.1 
  NC_017729.1 NC_018508.1 NC_011725 NC_017196.1 
  
 
NC_008600.1 NC_006274.1 NC_016047.1 
  
 
NC_020238.1 NC_016779.1 NC_014479.1 
  
 
NC_017200.1 NC_018491.1 NC_020832.1 
  
 
NC_017208.1 NC_011772.1 NC_019896.1 
  
  
NC_016771.1 NC_017195.1: 
  
  
NC_011969.1 
   
  
NC_014335.1 
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Appendix F  
 
Table F.1: List of antibiotics to which the multi-drug resistant E. coli 1699 exhibits 
resistance 
 
Compound MIC (μg/mL) Target/MOA Antibiotic classification 
    A54145CB-181234 > 512 membrane 
 Calcimycin (A23187) 64 membrane ionophore 
Daptomycin > 512 membrane lipopeptide 
Gramicidin 128 membrane polypeptide 
Polymyxin B 1 membrane polypeptide (cationic) 
    Ampicillin > 256 cell wall aminopenicillin 
Aztreonam ≤ 0.03 cell wall monocyclic beta-lactam 
Cephalosporin C 64 cell wall cephalosporin 
Penicillin G > 256 cell wall beta-lactam 
Ristocetin > 512 cell wall aminoglycoside 
Teicoplanin > 512 cell wall glycopeptide 
Vancomycin 512 cell wall glycopeptide 
    Aclacinomycin A > 512 DNA interaction anthracycline 
Actinomycin A > 256 DNA interaction polypeptide (toxic) 
Actinomycin D 256 DNA interaction polypeptide (toxic) 
Bleomycin A2 > 64 DNA interaction glycopeptide 
Coumermycin A1 64 DNA interaction aminocoumarin 
Daunorubicin > 256 DNA interaction anthracycline 
Gliotoxin 32 DNA interaction mycotoxin 
Mitomycin C 1 DNA interaction aziridine-containing 
Streptonigrin 2 DNA interaction quinone-containing 
Streptozotocin > 64 DNA interaction glucosamine  
    Chromomycin A3 > 512 gyrase glycoside 
Nalidixic Acid > 256 gyrase naphthyridone 
Novobicin > 256 gyrase aminocoumarin 
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Apramycin 64 protein synthesis aminoglycoside 
Dibekacin > 256 protein synthesis aminoglycoside 
Gentamycin 128 protein synthesis aminoglycoside 
Kanamycin > 256 protein synthesis aminoglycoside 
Kasugamycin   > 64 protein synthesis aminoglycoside 
Neomycin 16 protein synthesis aminoglycoside 
Netilmycin  128 protein synthesis aminoglycoside 
Streptomycin > 256 protein synthesis aminoglycoside 
Streptothricin 256 protein synthesis aminoglycoside 
Tobramycin > 256 protein synthesis aminoglycoside 
Puromycin   > 64 protein synthesis aminonucleoside 
Spectinomycin > 256 protein synthesis aminocyclitol 
Chloramphenicol 
 
protein synthesis acetamide  
Chlortetracycline 
 
protein synthesis tetracyclide 
Erythromycin 64 protein synthesis macrolide 
Lincomycin 512 protein synthesis lincosamide 
Spiramycin 256 protein synthesis macrolide 
Tetracycline > 256 protein synthesis tetracycline 
Thiostrepton > 512 protein synthesis oligopeptide 
Tylosin 512 protein synthesis macrolide 
Virginamycin 64 protein synthesis streptogramin 
    Rifampin > 256 RNA polymerase rifamycin 
Rifamycin SV > 64 RNA polymerase rifamycin 
    Albomycin high iron metabolism cyclic polypeptide 
Trimethoprim > 400 DHFR diaminopyrimidine 
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(2003) ‘Producing drugs from marine sponges’, Biotechnology Advances, vol.21, no.7, 
pp.585-598.  
Berdy, J. (2005) ‘Bioactive microbial metabolites’, The Journal of Antibiotics, vol.58, 
no.1, pp.1-26.  
 
 
 
 
References 
 
151 
 
Bergendahl, V., Linne, U. & Marahiel, M.A. (2002) ‘Mutational analysis of the C‐domain 
in nonribosomal peptide synthesis’, European Journal of Biochemistry, vol.269, no.2, 
pp.620-629.  
Bergmann, W. & Feeney, R.J. (1951) ‘Contributions to the study of marine products. 
XXXII. The nucleosides of sponges. I. 1’, The Journal of Organic Chemistry, vol.16, 
no.6, pp.981-987.  
Bertelli, C. & Greub, G. (2013) ‘Rapid bacterial genome sequencing: methods and 
applications in clinical microbiology’, Clinical Microbiology and Infection, vol.19, no.9, 
pp.803-813.  
Bertrand, S., Schumpp, O., Bohni, N., Monod, M., Gindro, K. & Wolfender, J. (2013) ‘De 
novo production of metabolites by fungal co-culture of Trichophyton rubrum and 
Bionectria ochroleuca’, Journal of Natural Products, vol.76, no.6, pp.1157-1165. 
Bills, G., Platas, G., Fillola, A., Jimenez, M., Collado, J., Vicente, F., Martin, J., 
Gonzalez, A., Bur‐Zimmermann, J. & Tormo, J. (2008) ‘Enhancement of antibiotic and 
secondary metabolite detection from filamentous fungi by growth on nutritional arrays’, 
Journal of Applied Microbiology, vol.104, no.6, pp.1644-1658.  
Blanco, G. (2012) ‘Comparative analysis of a cryptic thienamycin-like gene cluster 
identified in Streptomyces flavogriseus by genome mining’, Archives of Microbiology, 
vol.194, no.6, pp.549-555.  
 
 
 
 
References 
 
152 
 
Blin, K., Medema, M.H., Kazempour, D., Fischbach, M.A., Breitling, R., Takano, E. & 
Weber, T. (2013) ‘antiSMASH 2.0--a versatile platform for genome mining of secondary 
metabolite producers’, Nucleic Acids Research, vol.41, Web server issue, pp.W204-12.  
Bode, H.B., Bethe, B., Höfs, R. & Zeeck, A. (2002) ‘Big effects from small changes: 
possible ways to explore nature's chemical diversity’, ChemBioChem, vol.3, no.7, 
pp.619-627.  
Borel, J.F., Feurer, C., Gubler, H. & Stähelin, H. (1994) ‘Biological effects of cyclosporin 
A: a new antilymphocytic agent’, Agents and Actions, vol.43, no.3-4, pp.179-186.  
Bruner, S.D., Weber, T., Kohli, R.M., Schwarzer, D., Marahiel, M.A., Walsh, C.T. & 
Stubbs, M.T. (2002) ‘Structural basis for the cyclization of the lipopeptide antibiotic 
surfactin by the thioesterase domain SrfTE’, Structure, vol.10, no.3, pp.301-310.  
Caboche, S., Leclere, V., Pupin, M., Kucherov, G. & Jacques, P. (2010) ‘Diversity of 
monomers in nonribosomal peptides: towards the prediction of origin and biological 
activity’, Journal of Bacteriology, vol.192, no.19, pp.5143-5150.  
Caboche, S., Pupin, M., Leclere, V., Fontaine, A., Jacques, P. & Kucherov, G. (2008) 
‘NORINE: a database of nonribosomal peptides’, Nucleic Acids Research, vol.36, 
Database issue, pp.D326-31.  
Cane, D.E. & Walsh, C.T. (1999) ‘The parallel and convergent universes of polyketide 
synthases and nonribosomal peptide synthetases’, Chemistry & Biology, vol.6, no.12, 
pp.R319-R325.  
 
 
 
 
References 
 
153 
 
Cawoy, H., Debois, D., Franzil, L., De Pauw, E., Thonart, P. & Ongena, M. (2015) 
‘Lipopeptides as main ingredients for inhibition of fungal phytopathogens by Bacillus 
subtilis/amyloliquefaciens’, Microbial Biotechnology, vol.8, no.2, pp.281-295. 
Challis, G.L. & Naismith, J.H. (2004) ‘Structural aspects of non-ribosomal peptide 
biosynthesis’, Current Opinion in Structural Biology, vol.14, no.6, pp.748-756.  
Challis, G.L., Ravel, J. & Townsend, C.A. (2000) ‘Predictive, structure-based model of 
amino acid recognition by nonribosomal peptide synthetase adenylation domains’, 
Chemistry & Biology, vol.7, no.3, pp.211-224.  
Chang, Z., Flatt, P., Gerwick, W.H., Nguyen, V., Willis, C.L. & Sherman, D.H. (2001) 
‘The barbamide biosynthetic gene cluster: a novel marine Cyanobacterial system of 
mixed polyketide synthase (PKS)-non-ribosomal peptide synthetase (NRPS) origin 
involving an unusual trichloroleucyl starter unit’, Gene, vol.296, no.1, pp.235-247. 
Chen, H., O’Connor, S., Cane, D.E. & Walsh, C.T. (2001) ‘Epothilone biosynthesis: 
assembly of the methylthiazolylcarboxy starter unit on the EpoB subunit’, Chemistry & 
Biology, vol.8, no.9, pp.899-912.  
Chen, X.H., Koumoutsi, A., Scholz, R., Eisenreich, A., Schneider, K., Heinemeyer, I., 
Morgenstern, B., Voss, B., Hess, W.R. & Reva, O. (2007) ‘Comparative analysis of the 
complete genome sequence of the plant growth–promoting bacterium Bacillus 
amyloliquefaciens FZB42’, Nature Biotechnology, vol.25, no.9, pp.1007-1014.  
Chen, X.H., Vater, J., Piel, J., Franke, P., Scholz, R., Schneider, K., Koumoutsi, A., 
Hitzeroth, G., Grammel, N., Strittmatter, A.W., Gottschalk, G., Sussmuth, R.D. & 
 
 
 
 
References 
 
154 
 
Borriss, R. (2006) ‘Structural and functional characterization of three polyketide 
synthase gene clusters in Bacillus amyloliquefaciens FZB 42’, Journal of Bacteriology, 
vol.188, no.11, pp.4024-4036.  
Chen, Y., Smanski, M.J. & Shen, B. (2010) ‘Improvement of secondary metabolite 
production in Streptomyces by manipulating pathway regulation’, Applied Microbiology 
and Biotechnology, vol.86, no.1, pp.19-25. 
Cheng, Y.Q., Tang, G.L. & Shen, B. (2003) ‘Type I polyketide synthase requiring a 
discrete acyltransferase for polyketide biosynthesis’, Proceedings of the National 
Academy of Sciences of the United States of America, vol.100, no.6, pp.3149-3154.  
Claxton, H.B., Akey, D.L., Silver, M.K., Admiraal, S.J. & Smith, J.L. (2009) ‘Structure 
and functional analysis of RifR, the type II thioesterase from the rifamycin biosynthetic 
pathway’, The Journal of Biological Chemistry, vol.284, no.8, pp.5021-5029.  
Conti, E., Stachelhaus, T., Marahiel, M.A. & Brick, P. (1997) ‘Structural basis for the 
activation of phenylalanine in the non-ribosomal biosynthesis of gramicidin S’, The 
EMBO Journal, vol.16, no.14, pp.4174-4183.  
Cooper, E.L. & Yao, D. (2012) ‘Diving for drugs: tunicate anticancer compounds’, Drug 
Discovery Today, vol.17, no.11, pp.636-648.  
Cosgrove, S.E. (2006) ‘The relationship between antimicrobial resistance and patient 
outcomes: mortality, length of hospital stay, and health care costs’, Clinical Infectious 
Diseases: An official publication of the Infectious Diseases Society of America, vol.42 
Suppl 2, pp.S82-9.  
 
 
 
 
References 
 
155 
 
Cox, C.D. & Adams, P. (1985) ‘Siderophore activity of pyoverdin for Pseudomonas 
aeruginosa’, Infection and Immunity, vol.48, no.1, pp.130-138.  
Crawford, J.M. & Townsend, C.A. (2010) ‘New insights into the formation of fungal 
aromatic polyketides’, Nature Reviews Microbiology, vol.8, no.12, pp.879-889.  
Dalisay, D.S. & Molinski, T.F. (2009) ‘NMR quantitation of natural products at the 
nanomole scale’, Journal of Natural Products, vol.72, no.4, pp.739-744.  
Daniel, R. (2004) ‘The soil metagenome–a rich resource for the discovery of novel 
natural products’, Current Opinion in Biotechnology, vol.15, no.3, pp.199-204. 
Davies, J. & Davies, D. (2010) ‘Origins and evolution of antibiotic resistance’, 
Microbiology and Molecular Biology Reviews, vol.74, no.3, pp.417-433.  
Davies-Coleman, M.T. & Beukes, D.R. (2004) ‘Ten years of marine natural products 
research at Rhodes University’, South African Journal of Science, vol.100, no.11 & 12, 
pp.p.539-544.  
de Jong, A., van Hijum, S.A., Bijlsma, J.J., Kok, J. & Kuipers, O.P. (2006) ‘BAGEL: a 
web-based bacteriocin genome mining tool’, Nucleic Acids Research, vol.34, Web 
server issue, pp.W273-9.  
Demain, A.L. & Zhang, L. (2005) ‘Natural products: drug discovery and therapeutic 
medicine’, New Delhi, Humana Press. 
Dias, D.A., Urban, S. & Roessner, U. (2012) ‘A historical overview of natural products in 
drug discovery’, Metabolites, vol.2, no.2, pp.303-336.  
 
 
 
 
References 
 
156 
 
Doull, J.L., Singh, A.K., Hoare, M. & Ayer, S.W. (1994) ‘Conditions for the production of 
jadomycin B by Streptomyces venezuelae ISP5230: Effects of heat shock, ethanol 
treatment and phage infection’, Journal of Industrial Microbiology, vol.13, no.2, pp.120-
125. 
Du, L., Sánchez, C. & Shen, B. (2001) ‘Hybrid peptide–polyketide natural products: 
biosynthesis and prospects toward engineering novel molecules’, Metabolic 
Engineering, vol.3, no.1, pp.78-95.  
Duitman, E.H., Hamoen, L.W., Rembold, M., Venema, G., Seitz, H., Saenger, W., 
Bernhard, F., Reinhardt, R., Schmidt, M., Ullrich, C., Stein, T., Leenders, F. & Vater, J. 
(1999) ‘The mycosubtilin synthetase of Bacillus subtilis ATCC6633: a multifunctional 
hybrid between a peptide synthetase, an amino transferase, and a fatty acid synthase’, 
Proceedings of the National Academy of Sciences of the United States of America, 
vol.96, no.23, pp.13294-13299.  
Ehrenreich, I.M., Waterbury, J.B. & Webb, E.A. (2005) ‘Distribution and diversity of 
natural product genes in marine and freshwater Cyanobacterial cultures and genomes’, 
Applied and Environmental Microbiology, vol.71, no.11, pp.7401-7413.  
Eppelmann, K., Doekel, S. & Marahiel, M.A. (2001) ‘Engineered biosynthesis of the 
peptide antibiotic bacitracin in the surrogate host Bacillus subtilis’, The Journal of 
Biological Chemistry, vol.276, no.37, pp.34824-34831. 
Erwin, P.M., Olson, J.B. & Thacker, R.W. (2011) ‘Phylogenetic diversity, host-specificity 
and community profiling of sponge-associated bacteria in the northern Gulf of Mexico’, 
PLoS One, vol.6, no.11, pp.e26806.  
 
 
 
 
References 
 
157 
 
Falagas, M.E. & Bliziotis, I.A. (2007) ‘Pandrug-resistant gram-negative bacteria: the 
dawn of the post-antibiotic era?’, International Journal of Antimicrobial Agents, vol.29, 
no.6, pp.630-636.  
Farrelly, V., Rainey, F.A. & Stackebrandt, E. (1995) ‘Effect of genome size and rrn gene 
copy number on PCR amplification of 16S rRNA genes from a mixture of bacterial 
species’, Applied and Environmental Microbiology, vol.61, no.7, pp.2798-2801.  
Felnagle, E.A., Jackson, E.E., Chan, Y.A., Podevels, A.M., Berti, A.D., McMahon, M.D. 
& Thomas, M.G. (2008) ‘Nonribosomal peptide synthetases involved in the production 
of medically relevant natural products’, Molecular Pharmaceutics, vol.5, no.2, pp.191-
211.  
Fieseler, L., Horn, M., Wagner, M. & Hentschel, U. (2004) ‘Discovery of the novel 
candidate phylum ‘Poribacteria in marine sponges’, Applied and Environmental 
Microbiology, vol.70, no.6, pp.3724-3732.  
Finking, R. & Marahiel, M.A. (2004) ‘Biosynthesis of nonribosomal peptides 1’, Annual 
Review of Microbiology., vol.58, pp.453-488.  
Friedrich, A.B., Fischer, I., Proksch, P., Hacker, J. & Hentschel, U. (2001) ‘Temporal 
variation of the microbial community associated with the Mediterranean sponge 
Aplysina aerophoba’, FEMS Microbiology Ecology, vol.38, no.2-3, pp.105-113.  
Funa, N., Ohnishi, Y., Fujii, I., Shibuya, M., Ebizuka, Y. & Horinouchi, S. (1999) ‘A new 
pathway for polyketide synthesis in microorganisms’, Nature, vol.400, no.6747, pp.897-
899.  
 
 
 
 
References 
 
158 
 
Galm, U., Wendt-Pienkowski, E., Wang, L., Huang, S., Unsin, C., Tao, M., Coughlin, 
J.M. & Shen, B. (2011) ‘Comparative analysis of the biosynthetic gene clusters and 
pathways for three structurally related antitumor antibiotics: bleomycin, tallysomycin, 
and zorbamycin’, Journal of Natural Products, vol.74, no.3, pp.526-536.  
Gao, X., Wang, P. & Tang, Y. (2010) ‘Engineered polyketide biosynthesis and 
biocatalysis in Escherichia coli’, Applied Microbiology and Biotechnology, vol.88, no.6, 
pp.1233-1242.  
Gehring, A.M., Mori, I. & Walsh, C.T. (1998) ‘Reconstitution and characterization of the 
Escherichia coli enterobactin synthetase from EntB, EntE, and EntF’, Biochemistry, 
vol.37, no.8, pp.2648-2659.  
Gerwick, W.H. & Moore, B.S. (2012) ‘Lessons from the past and charting the future of 
marine natural products drug discovery and chemical biology’, Chemistry & Biology, 
vol.19, no.1, pp.85-98.  
Gevers, W., Kleinkauf, H. & Lipmann, F. (1968) ‘The activation of amino acids for 
biosynthesis of gramicidin S’, Proceedings of the National Academy of Sciences of the 
United States of America, vol.60, no.1, pp.269-276.  
Ginolhac, A., Jarrin, C., Gillet, B., Robe, P., Pujic, P., Tuphile, K., Bertrand, H., Vogel, 
T.M., Perriere, G., Simonet, P. & Nalin, R. (2004) ‘Phylogenetic analysis of polyketide 
synthase I domains from soil metagenomic libraries allows selection of promising 
clones’, Applied and Environmental Microbiology, vol.70, no.9, pp.5522-5527.  
 
 
 
 
References 
 
159 
 
Glöckner, F.O. & Joint, I. (2010) ‘Marine microbial genomics in Europe: current status 
and perspectives’, Microbial Biotechnology, vol.3, no.5, pp.523-530.  
Gontang, E.A., Gaudencio, S.P., Fenical, W. & Jensen, P.R. (2010) ‘Sequence-based 
analysis of secondary-metabolite biosynthesis in marine Actinobacteria’, Applied and 
Environmental Microbiology, vol.76, no.8, pp.2487-2499.  
Graça, A.P., Bondoso, J., Gaspar, H., Xavier, J.R., Monteiro, M.C., de la Cruz, M., 
Oves-Costales, D., Vicente, F. & Lage, O.M. (2013) ‘Antimicrobial activity of 
heterotrophic bacterial communities from the marine sponge Erylus discophorus 
(Astrophorida, Geodiidae)’, PLoS One, vol.8, no.11, pp.e78992. 
Griffiths, C.L., Robinson, T.B., Lange, L. & Mead, A. (2010) ‘Marine biodiversity in South 
Africa: an evaluation of current states of knowledge’, PLoS One, vol.5, no.8, pp.e12008.  
Grüschow, S., Rackham, E.J. & Goss, R.J. (2011) ‘Diversity in natural product families 
is governed by more than enzyme promiscuity alone: establishing control of the 
pacidamycin portfolio’, Chemical Science, vol.2, no.11, pp.2182-2186.  
Gunasekera, S.P., Gunasekera, M., Longley, R.E. & Schulte, G.K. (1990) 
‘Discodermolide: a new bioactive polyhydroxylated lactone from the marine sponge 
Discodermia dissoluta’, The Journal of Organic Chemistry, vol.55, no.16, pp.4912-4915. 
H3-D — Africa’s first integrated drug discovery and development centre. (2015) 
[ONLINE] Available at: http://h3d.co.za/. [Accessed; 7th May 2015]. 
 
 
 
 
References 
 
160 
 
Haag, H., Hantke, K., Drechsel, H., Stojiljkovic, I., Jung, G. & Zahner, H. (1993) 
‘Purification of yersiniabactin: a siderophore and possible virulence factor of Yersinia 
enterocolitica’, Journal of General Microbiology, vol.139, no.9, pp.2159-2165.  
Hamada, T., Matsunaga, S., Yano, G. & Fusetani, N. (2005) ‘Polytheonamides A and B, 
highly cytotoxic, linear polypeptides with unprecedented structural features, from the 
marine sponge, Theonella swinhoei’, Journal of the American Chemical Society, 
vol.127, no.1, pp.110-118.  
Handelsman, J. (2004) ‘Metagenomics: application of genomics to uncultured 
microorganisms’, Microbiology and Molecular Biology Reviews, vol.68, no.4, pp.669-
685.  
Hancock, R.E. & Chapple, D.S. (1999) ‘Peptide antibiotics’, Antimicrobial Agents and 
Chemotherapy, vol.43, no.6, pp.1317-1323.  
Haygood, M.G., Schmidt, E.W., Davidson, S.K. & Faulkner, D.J. (1999) ‘Microbial 
symbionts of marine invertebrates: opportunities for microbial biotechnology’, Journal of 
Molecular Microbiology and Biotechnology, vol.1, no.1, pp.33-43.  
Heindl, H., Wiese, J., Thiel, V. & Imhoff, J.F. (2010) ‘Phylogenetic diversity and 
antimicrobial activities of bryozoan-associated bacteria isolated from Mediterranean and 
Baltic Sea habitats’, Systematic and Applied Microbiology, vol.33, no.2, pp.94-104. 
Hentschel, U., Hopke, J., Horn, M., Friedrich, A.B., Wagner, M., Hacker, J. & Moore, 
B.S. (2002) ‘Molecular evidence for a uniform microbial community in sponges from 
different oceans’, Applied and Environmental Microbiology, vol.68, no.9, pp.4431-4440.  
 
 
 
 
References 
 
161 
 
 Hentschel, U., Schmid, M., Wagner, M., Fieseler, L., Gernert, C. & Hacker, J. (2001) 
‘Isolation and phylogenetic analysis of bacteria with antimicrobial activities from the 
Mediterranean sponges Aplysina aerophoba and Aplysina cavernicola’, FEMS 
Microbiology Ecology, vol.35, no.3, pp.305-312.  
Hentschel, U., Usher, K.M. & Taylor, M.W. (2006) ‘Marine sponges as microbial 
fermenters’, FEMS Microbiology Ecology, vol.55, no.2, pp.167-177.  
Herbst, D.A., Boll, B., Zocher, G., Stehle, T. & Heide, L. (2013) ‘Structural basis of the 
interaction of MbtH-like proteins, putative regulators of nonribosomal peptide 
biosynthesis, with adenylating enzymes’, The Journal of Biological Chemistry, vol.288, 
no.3, pp.1991-2003.  
Hooper, G.J. & Davies-Coleman, M.T. (1995) ‘New Metabolites from the South African 
soft coral Capnella thyrsoidea’, Tetrahedron, vol.51, no.36, pp.9973-9984.  
Hooper, G.J., Davies-Coleman, M.T., Kelly-Borges, M. & Coetzee, P.S. (1996) ‘New 
alkaloids from a South African latrunculid sponge’, Tetrahedron Letters, vol.37, no.39, 
pp.7135-7138.  
Hu, G., Yuan, J., Sun, L., She, Z., Wu, J., Lan, X., Zhu, X., Lin, Y. & Chen, S. (2011) 
‘Statistical research on marine natural products based on data obtained between 1985 
and 2008’, Marine Drugs, vol.9, no.4, pp.514-525.  
Hubbard, B.K., Thomas, M.G. & Walsh, C.T. (2000) ‘Biosynthesis of L-p-
hydroxyphenylglycine, a non-proteinogenic amino acid constituent of peptide 
antibiotics’, Chemistry & Biology, vol.7, no.12, pp.931-942.  
 
 
 
 
References 
 
162 
 
Hutchinson, C.R. (2003) ‘Polyketide and non-ribosomal peptide synthases: falling 
together by coming apart’, Proceedings of the National Academy of Sciences of the 
United States of America, vol.100, no.6, pp.3010-3012.  
Ichikawa, N., Sasagawa, M., Yamamoto, M., Komaki, H., Yoshida, Y., Yamazaki, S. & 
Fujita, N. (2013) ‘DoBISCUIT: a database of secondary metabolite biosynthetic gene 
clusters’, Nucleic Acids Research, vol.41, Database issue, pp.D408-14. 
Ikeda, H., Ishikawa, J., Hanamoto, A., Shinose, M., Kikuchi, H., Shiba, T., Sakaki, Y., 
Hattori, M. & Ōmura, S. (2003) ‘Complete genome sequence and comparative analysis 
of the industrial microorganism Streptomyces avermitilis’, Nature Biotechnology, vol.21, 
no.5, pp.526-531.  
Jensen, P.R., Chavarria, K.L., Fenical, W., Moore, B.S. & Ziemert, N. (2014) 
‘Challenges and triumphs to genomics-based natural product discovery’, Journal of 
Industrial Microbiology & Biotechnology, vol.41, no.2, pp.203-209.  
Ji, H., Li, X. & Zhang, H. (2009) ‘Natural products and drug discovery’, EMBO Reports, 
vol.10, no.3, pp.194-200.  
Kealey, J.T., Liu, L., Santi, D.V., Betlach, M.C. & Barr, P.J. (1998) ‘Production of a 
polyketide natural product in nonpolyketide-producing prokaryotic and eukaryotic hosts’, 
Proceedings of the National Academy of Sciences of the United States of America, 
vol.95, no.2, pp.505-509.  
 
 
 
 
References 
 
163 
 
Keatinge-Clay, A.T. & Stroud, R.M. (2006) ‘The structure of a ketoreductase determines 
the organization of the β-carbon processing enzymes of modular polyketide synthases’, 
Structure, vol.14, no.4, pp.737-748.  
Kennedy, J., Marchesi, J.R. & Dobson, A.D. (2007) ‘Metagenomic approaches to exploit 
the biotechnological potential of the microbial consortia of marine sponges’, Applied 
Microbiology and Biotechnology, vol.75, no.1, pp.11-20.  
Khanafari, A., Assadi, M.M. & Fakhr, F.A. (2006) ‘Review of prodigiosin, pigmentation in 
Serratia marcescens’, Online Journal of Biological Sciences, vol.6, no.1, pp.1-13.  
Khosla, C., Gokhale, R.S., Jacobsen, J.R. & Cane, D.E. (1999) ‘Tolerance and 
specificity of polyketide synthases’, Annual Review of Biochemistry, vol.68, no.1, 
pp.219-253.  
Kijjoa, A. & Sawangwong, P. (2004) ‘Drugs and cosmetics from the sea’, Marine Drugs, 
vol.2, no.2, pp.73-82.  
King, R.W., Bauer, J.D. & Brady, S.F. (2009) ‘An environmental DNA‐derived type II 
polyketide biosynthetic pathway encodes the biosynthesis of the pentacyclic polyketide 
erdacin’, Angewandte Chemie International Edition, vol.48, no.34, pp.6257-6261.  
Konz, D., Doekel, S. & Marahiel, M.A. (1999) ‘Molecular and biochemical 
characterization of the protein template controlling biosynthesis of the lipopeptide 
lichenysin’, Journal of Bacteriology, vol.181, no.1, pp.133-140.  
 
 
 
 
References 
 
164 
 
Kouprina, N. & Larionov, V. (2006) ‘TAR cloning: insights into gene function, long-range 
haplotypes and genome structure and evolution’, Nature Reviews Genetics, vol.7, 
no.10, pp.805-812.  
Lautru, S. & Challis, G.L. (2004) ‘Substrate recognition by nonribosomal peptide 
synthetase multi-enzymes’, Microbiology (Reading, England), vol.150, no.6, pp.1629-
1636.  
Law, B.K. (2005) ‘Rapamycin: an anti-cancer immunosuppressant?’, Critical Reviews in 
Oncology/Hematology, vol. 56, no.1, pp.47-60.  
Lawrence, J.G. & Ochman, H. (1997) ‘Amelioration of bacterial genomes: rates of 
change and exchange’, Journal of Molecular Evolution, vol.44, no.4, pp.383-397.  
Leal, M.C., Puga, J., Serôdio, J., Gomes, N.C. & Calado, R. (2012) ‘Trends in the 
discovery of new marine natural products from invertebrates over the last two decades–
where and what are we bioprospecting?’, PLoS One, vol.7, no.1, pp.e30580.  
Lee, B.N., Kroken, S., Chou, D.Y., Robbertse, B., Yoder, O.C. & Turgeon, B.G. (2005) 
‘Functional analysis of all nonribosomal peptide synthetases in Cochliobolus 
heterostrophus reveals a factor, NPS6, involved in virulence and resistance to oxidative 
stress’, Eukaryotic Cell, vol.4, no.3, pp.545-555.  
Lemaire, P. (2011) ‘Evolutionary crossroads in developmental biology: the tunicates’, 
Development (Cambridge, England), vol.138, no.11, pp.2143-2152. 
 
 
 
 
References 
 
165 
 
Levy, S.B. (2002) ‘The 2000 Garrod lecture. Factors impacting on the problem of 
antibiotic resistance’, The Journal of Antimicrobial Chemotherapy, vol.49, no.1, pp.25-
30.  
Lewis, K. (2012) ‘Antibiotics: recover the lost art of drug discovery’, Nature, vol.485, 
no.7399, pp.439-440.  
Leys, S.P. & Eerkes-Medrano, D.I. (2006) ‘Feeding in a calcareous sponge: particle 
uptake by pseudopodia’, The Biological Bulletin, vol.211, no.2, pp.157-171.  
Li, M.H., Ung, P.M., Zajkowski, J., Garneau-Tsodikova, S. & Sherman, D.H. (2009) 
‘Automated genome mining for natural products’, BMC Bioinformatics, vol.10, no.1, 
pp.185.  
Lim, J., Sun, H., Fan, J., Hameed, I.F., Lescar, J., Liang, Z. & Yang, D. (2012) 
‘Rigidifying acyl carrier protein domain in Iterative Type I PKS CalE8 does not affect its 
function’, Biophysical Journal, vol.103, no.5, pp.1037-1044.  
Lin, Y., Schiavo, S., Orjala, J., Vouros, P. & Kautz, R. (2008) ‘Microscale LC-MS-NMR 
platform applied to the identification of active Cyanobacterial metabolites’, Analytical 
Chemistry, vol.80, no.21, pp.8045-8054.  
Liu, Q., Liu, C., Yu, J., Yan, J. & Qi, X. (2012) ‘Analysis of the ketosynthase genes in 
Streptomyces and its implications for preventing reinvestigation of polyketides with 
bioactivities’, Journal of Agricultural Science, vol.4, no.7, pp.p262. 
Lopanik, N.B. (2014) ‘Chemical defensive symbioses in the marine environment’, 
Functional Ecology, vol.28, no.2, pp.328-340. 
 
 
 
 
References 
 
166 
 
Ma, D., Cook, D.N., Alberti, M., Pon, N.G., Nikaido, H. & Hearst, J.E. (1995) ‘Genes 
acrA and acrB encode a stress‐induced efflux system of Escherichia coli’, Molecular 
Microbiology, vol.16, no.1, pp.45-55.  
Mach, B., Reich, E. & Tatum, E.L. (1963) ‘Separation of the Biosynthesis of the 
Antibiotic Polypeptide Tyrocidine from Protein Biosynthesis’, Proceedings of the 
National Academy of Sciences of the United States of America, vol.50, no.1, pp.175-
181.  
Macintyre, L., Zhang, T., Viegelmann, C., Martinez, I.J., Cheng, C., Dowdells, C., 
Abdelmohsen, U.R., Gernert, C., Hentschel, U. & Edrada-Ebel, R. (2014) ‘Metabolomic 
Tools for Secondary Metabolite Discovery from Marine Microbial Symbionts’, Marine 
Drugs, vol.12, no.6, pp.3416-3448.  
Mandal, S.M., Barbosa, A.E. & Franco, O.L. (2013) ‘Lipopeptides in microbial infection 
control: scope and reality for industry’, Biotechnology Advances, vol.31, no.2, pp.338-
345.  
Mann, M.G., Mkwananzi, H.B., Antunes, E.M., Whibley, C.E., Hendricks, D.T., Bolton, 
J.J. & Beukes, D.R. (2007) ‘Halogenated monoterpene aldehydes from the South 
African marine alga Plocamium corallorhiza’, Journal of Natural Products, vol.70, no.4, 
pp.596-599.  
Marahiel, M.A., Stachelhaus, T. & Mootz, H.D. (1997) ‘Modular peptide synthetases 
involved in nonribosomal peptide synthesis’, Chemical Reviews, vol.97, no.7, pp.2651-
2674.  
 
 
 
 
References 
 
167 
 
Marmann, A., Aly, A.H., Lin, W., Wang, B. & Proksch, P. (2014) ‘Co-cultivation—A 
powerful emerging tool for enhancing the chemical diversity of microorganisms’, Marine 
Drugs, vol. 12, no.2, pp.1043-1065. 
Martinez, J.S. & Butler, A. (2007) ‘Marine amphiphilic siderophores: marinobactin 
structure, uptake, and microbial partitioning’, Journal of Inorganic Biochemistry, vol.101, 
no.11, pp.1692-1698.  
May, J.J., Kessler, N., Marahiel, M.A. & Stubbs, M.T. (2002) ‘Crystal structure of DhbE, 
an archetype for aryl acid activating domains of modular nonribosomal peptide 
synthetases’, Proceedings of the National Academy of Sciences of the United States of 
America, vol.99, no.19, pp.12120-12125.  
McGivern, J.G. (2007) ‘Ziconotide: a review of its pharmacology and use in the 
treatment of pain’, Neuropsychiatric disease and treatment, vol.3, no.1, pp.69-85.  
Means, A.R., Weaver, M.R., Burnett, S.M., Mbonye, M.K., Naikoba, S. & McClelland, 
R.S. (2014) ‘Correlates of Inappropriate Prescribing of Antibiotics to Patients with 
Malaria in Uganda’, PLoS One, vol.9, no.2, pp.e90179.  
Medema, M.H., Paalvast, Y., Nguyen, D.D., Melnik, A., Dorrestein, P.C., Takano, E. & 
Breitling, R. (2014) ‘Pep2Path: Automated mass spectrometry-guided genome mining of 
peptidic natural products’, PLoS Computational Biology, vol.10, no.9, pp.e1003822.  
Meena, K.R. & Kanwar, S.S. (2015) ‘Lipopeptides as the antifungal and antibacterial 
agents: applications in food safety and therapeutics’, BioMed Research International, 
vol.2015.  
 
 
 
 
References 
 
168 
 
Mehbub, M.F., Lei, J., Franco, C. & Zhang, W. (2014) ‘Marine sponge derived natural 
products between 2001 and 2010: Trends and opportunities for discovery of bioactives’, 
Marine Drugs, vol.12, no.8, pp.4539-4577.  
Mendola, D. (2003) ‘Aquaculture of three phyla of marine invertebrates to yield bioactive 
metabolites: process developments and economics’, Biomolecular Engineering, vol.20, 
no.4, pp.441-458.  
Miao, V., Brost, R., Chapple, J., She, K., Coëffet-Le Gal, M. & Baltz, R.H. (2006) ‘The 
lipopeptide antibiotic A54145 biosynthetic gene cluster from Streptomyces fradiae’, 
Journal of Industrial Microbiology and Biotechnology, vol.33, no.2, pp.129-140. 
Micek, S.T. (2007) ‘Alternatives to vancomycin for the treatment of methicillin-resistant 
Staphylococcus aureus infections’, Clinical infectious diseases: an official publication of 
the Infectious Diseases Society of America, vol.45 Suppl 3, pp.S184-90.  
Miethke, M. & Marahiel, M.A. (2007) ‘Siderophore-based iron acquisition and pathogen 
control’, Microbiology and Molecular Biology Reviews, vol.71, no.3, pp.413-451.  
Mizuno, C.M., Kimes, N.E., López-Pérez, M., Ausó, E., Rodriguez-Valera, F. & Ghai, R. 
(2013) ‘A Hybrid NRPS-PKS gene cluster related to the bleomycin family of Antitumor 
antibiotics in Alteromonas macleodii strains’, PLoS One, vol.8, no.9, pp.e76021.  
Moffitt, M.C. & Neilan, B.A. (2004) ‘Characterization of the nodularin synthetase gene 
cluster and proposed theory of the evolution of cyanobacterial hepatotoxins’, Applied 
and Environmental Microbiology, vol.70, no.11, pp.6353-6362.  
 
 
 
 
References 
 
169 
 
Muscholl-Silberhorn, A., Thiel, V. & Imhoff, J.F. (2008) ‘Abundance and bioactivity of 
cultured sponge-associated bacteria from the Mediterranean Sea’, Microbial Ecology, 
vol.55, no.1, pp.94-106.  
NaPDoS. (2012) ‘Natural product domain seeker’ Available from: 
http://napdos.ucsd.edu/, [Accessed on: 10th January 2015]. 
Neilan, B.A., Dittmann, E., Rouhiainen, L., Bass, R.A., Schaub, V., Sivonen, K. & 
Borner, T. (1999) ‘Nonribosomal peptide synthesis and toxigenicity of Cyanobacteria’, 
Journal of Bacteriology, vol.181, no.13, pp.4089-4097.  
Neilands, J.B. (1995) ‘Siderophores: structure and function of microbial iron transport 
compounds’, The Journal of Biological Chemistry, vol.270, no.45, pp.26723-26726.  
Nicholson, W.L., Munakata, N., Horneck, G., Melosh, H.J. & Setlow, P. (2000) 
‘Resistance of Bacillus endospores to extreme terrestrial and extraterrestrial 
environments’, Microbiology and Molecular Biology Reviews, vol.64, no.3, pp.548-572.  
Nieselt, K., Battke, F., Herbig, A., Bruheim, P., Wentzel, A., Jakobsen, O.M., Sletta, H., 
Alam, M.T., Merlo, M.E., Moore, J., Omara, W.A., Morrissey, E.R., Juarez-Hermosillo, 
M.A., Rodriguez-Garcia, A., Nentwich, M., Thomas, L., Iqbal, M., Legaie, R., Gaze, 
W.H., Challis, G.L., Jansen, R.C., Dijkhuizen, L., Rand, D.A., Wild, D.L., Bonin, M., 
Reuther, J., Wohlleben, W., Smith, M.C., Burroughs, N.J., Martin, J.F., Hodgson, D.A., 
Takano, E., Breitling, R., Ellingsen, T.E. & Wellington, E.M. (2010) ‘The dynamic 
architecture of the metabolic switch in Streptomyces coelicolor’, BMC Genomics, vol.11, 
pp.10-2164-11-10.  
 
 
 
 
References 
 
170 
 
Tunicates - Nobanis. [ONLINE] Available at: http://www.nobanis.org/marine-
identification-key/tunicates. [Accessed 1st May 2015]. 
Norrander, J., Kempe, T. & Messing, J. (1983) ‘Construction of improved M13 vectors 
using oligodeoxynucleotide-directed mutagenesis’, Gene, vol.26, no.1, pp.101-106. 
Noskov, V.N., Kouprina, N., Leem, S.H., Ouspznski, I., Barrett, J.C. & Larionov, V. 
(2003) ‘A general cloning system to selectively isolate any eukaryotic or prokaryotic 
genomic region in yeast’, BMC Genomics, vol.4, no.1, pp.16.  
Novakova, R., Bistakova, J., Homerova, D., Rezuchova, B. & Kormanec, J. (2002) 
‘Cloning and characterization of a polyketide synthase gene cluster involved in 
biosynthesis of a proposed angucycline-like polyketide auricin in Streptomyces 
aureofaciens CCM 3239’, Gene, vol.297, no.1, pp.197-208.  
Nützmann, H.W., Reyes-Dominguez, Y., Scherlach, K., Schroeckh, V., Horn, F., Gacek, 
A., Schumann, J., Hertweck, C., Strauss, J. & Brakhage, A.A. (2011) ‘Bacteria-induced 
natural product formation in the fungus Aspergillus nidulans requires Saga/Ada-
mediated histone acetylation’, Proceedings of the National Academy of Sciences of the 
United States of America, vol.108, no.34, pp.14282-14287.  
O’Halloran, J., Barbosa, T., Morrissey, J., Kennedy, J., O’Gara, F. & Dobson, A. (2011) 
‘Diversity and antimicrobial activity of Pseudovibrio spp. from Irish marine sponges’, 
Journal of Applied Microbiology, vol.110, no.6, pp.1495-1508.  
O'Donnell, M.R., Jarand, J., Loveday, M., Padayatchi, N., Zelnick, J., Werner, L., 
Naidoo, K., Master, I., Osburn, G. & Kvasnovsky, C. (2010) ‘High incidence of hospital 
 
 
 
 
References 
 
171 
 
admissions with multidrug-resistant and extensively drug-resistant tuberculosis among 
South African health care workers’, Annals of Internal Medicine, vol.153, no.8, pp.516-
522.  
Oh, D., Kauffman, C.A., Jensen, P.R. & Fenical, W. (2007) ‘Induced production of 
emericellamides A and B from the marine-derived fungus Emericella sp. in competing 
co-culture’, Journal of Natural Products, vol.70, no.4, pp.515-520. 
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